

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 14/47, 14/52, C12N 15/12, 15/19, 15/63, A61K 38/16, 38/19, 48/00		A1	(11) International Publication Number: WO 99/29728 (43) International Publication Date: 17 June 1999 (17.06.99)
(21) International Application Number: PCT/US98/26291 (22) International Filing Date: 11 December 1998 (11.12.98)		(74) Agent: BARRETT, William, A.; Intellectual Property/Technology Law, P.O. Box 14329, Research Triangle Park, NC 27709 (US).	
(30) Priority Data: 60/069,281 11 December 1997 (11.12.97) US		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/069,281 (CON) Filed on 11 December 1997 (11.12.97)		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE [US/US]; 4321 Hartwick Road, College Park, MD 20740 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): GALLO, Robert, C. [US/US]; 8513 Thornden Terrace, Bethesda, MD 02817 (US). DEVICO, Anthony, L. [US/US]; 4533 Peacock Avenue, Alexandria, VA 22304 (US). GARZINO-DEMO, Alfredo [IT/US]; 601 North Eutaw Street, Baltimore, MD 21201 (US).			

(54) Title: **METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES**

(57) Abstract

The present invention relates to a method to enhance the efficacy of a vaccine in a subject treated with the vaccine comprising administering to the subject in combination with the vaccine a one or more chemokines. The present invention also relates to compositions of vaccines containing chemokines.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING CHEMOKINES

1. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 60/069,281 filed December 11, 1997.

2. BACKGROUND OF THE INVENTION

The present invention relates to a method to enhance the efficacy of a vaccine by administration of a chemokine, such as macrophage derived chemokine (MDC), in conjunction with the vaccine. The present invention also relates to compositions useful in the method.

2.1. GENERATION OF AN IMMUNE RESPONSE

The introduction of a foreign antigen into an individual elicits an immune response consisting of two major components, the cellular and humoral immune responses, mediated by two functionally distinct populations of lymphocytes known as T and B cells, respectively (see generally Coutinho, 1991, *Immune System, Encyclopedia of Human Biology*, Vol. 4, Ed. Dulbecco, Academic Press, Inc.). A subset of T cells responds to antigen stimulation by producing lymphokines which "help" or activate various other cell types in the immune system.

Another T cell subset is capable of developing into antigen-specific cytotoxic effector cells, which can directly kill antigen-positive target cells. On the other hand, the B cell response is primarily carried out by secretory proteins, antibodies, which directly bind and neutralize antigens.

Helper T cells (TH) can be distinguished from classical cytotoxic T lymphocytes (CTL) and B cells by their cell surface expression of the glycoprotein marker CD4. Although the mechanism by which CD4⁺ TH function has not been fully elucidated, the existence of functionally distinct subsets within the CD4⁺ T cell compartment has been reported (Mosmann and Coffman, 1989, *Ann. Rev. Immunol.*

Z:145-173). In the mouse, type 1 helper T cells (TH1) produce interleukin-2 (IL-2) and τ -interferon (τ -IFN) upon activation, while type 2 helper T cells (TH2) produce IL-4 and IL-5. Based on the profile of lymphokine production, TH1 appear to be involved in promoting the activation and proliferation of other T cell subsets including CTL, whereas TH2 specifically regulate B cell proliferation and differentiation, antibody synthesis, and antibody class switching.

A second T cell subpopulation is the classical CTL which express the CD8 surface marker. Unlike most TH, these cells display cytolytic activity upon direct contact with target cells, rather than through the production of lymphokines. *In vivo*, CTL function is particularly important in situations where an antibody response alone is inadequate. Significant experimental evidence indicates that CTL rather than B cells and their antibody products play a principal role in the defense against viral infections and cancer.

A salient feature of both T and B cell responses is their exquisite specificity for the immunizing antigen; however, the mechanisms for antigen recognition differ between these two cell types. B cells recognize antigens by antibodies, either acting as cell surface receptors or as secreted proteins, which bind directly to antigens on a solid surface or in solution, whereas T cells only recognize antigens that have been processed or degraded into small fragments and presented on a solid phase such as the surface of antigen-presenting cells (APC). Additionally, antigenic fragments must be presented to T cells in association with major histocompatibility complex (MHC)-encoded class I or class II molecules. The MHC refers to a cluster of genes that encode proteins with diverse immunological functions. In man, the MHC is known as HLA. Class I gene products are found on all somatic cells, and they were originally discovered as targets of major transplantation rejection responses. Class II gene products are mostly expressed on cells of various hematopoietic lineages, and they are involved in cell-cell interactions in the immune system. Most importantly, MHC-encoded proteins have been shown to function as receptors for processed antigenic fragments on the surface of APC (Bjorkman et al., 1987, *Nature* 329:506-512).

Another level of complexity in the interaction between a T cell and an antigenic fragment is that it occurs only if the MHC molecules involved are the same on the APC and the responding T cells. In other words, a T cell specific for a particular antigenic epitope expresses a receptor having low affinity for self MHC

proteins, which when such MHC proteins on APC are occupied by the epitope, engage the T cell in a stronger interaction leading to antigen-specific T cell activation. The phenomenon of a T cell reacting with a processed antigen only when presented by cells expressing a matching MHC is known as MHC-restriction.

The specificity of T cell immune responses for antigens is a function of the unique receptors expressed by these cells. The T cell receptor (TCR) is structurally homologous to an antibody; it is a heterodimer composed of disulfide-linked glycoproteins. Four TCR polypeptide chains known as α , β , τ , and δ have been identified, although the vast majority of functional T cells express the $\alpha\beta$ heterodimeric TCR. Transfer of α and β genes alone into recipient cells was shown to be both necessary and sufficient to confer antigen specificity and MHC-restriction (Dembic et al., 1986, *Nature* 320:232-238). Thus, the $\alpha\beta$ TCR appears to be responsible for recognizing a combination of antigenic fragment and MHC determinants.

The apparent basis of MHC restriction is that $CD4^+$ T cells express $\alpha\beta$ TCR which recognize antigenic fragments physically associated with MHC class II proteins, while the TCR on $CD8^+$ CTL recognize MHC class I-associated fragments. Thus, $CD4^+$ T cells can recognize only a restricted class of APC that are class II $^+$, whereas $CD8^+$ CTL can interact with virtually any antigen-positive cells, since all cells express class I molecules. $CD4^+$ CTL have been identified, and they are MHC class II restricted, and lyse target cells only if the latter express self-MHC class II determinants associated with specific antigenic fragments. Both CD4 and CD8 molecules also contribute to this interaction by binding to monotypic determinants on the MHC class II and I molecules, respectively.

A second type of TCR composed of $\tau\delta$ heterodimers is expressed by a small percentage of T cells, but the involvement of $\tau\delta$ T cells in antigen-specific recognition is still poorly understood. Some studies have shown that functionally active $\tau\delta$ T cells can be cytolytic in a MHC non-restricted manner.

In summary, the generation of an immune response begins with the sensitization of $CD4^+$ and $CD8^+$ T cell subsets through their interaction with APC that express MHC-class I or class II molecules associated with antigenic fragments. The sensitized or primed $CD4^+$ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized $CD8^+$ T cells increase in numbers in response to lymphokines and are capable of destroying any

cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. For example, in the course of a viral infection, CTL eradicate virally-infected cells, thereby limiting the progression of virus spread and disease development.

2.2. ANTIGEN PRESENTING CELLS

The presentation of antigens to T cells is carried out by specialized cell populations referred to as antigen presenting cells (APC). Typically, APC include macrophages/monocytes, B cells, and bone marrow derived dendritic cells (DC). APC are capable of internalizing exogenous antigens, cleaving them into smaller fragments in enzyme-rich vesicles, and coupling the fragments to MHC-encoded products for expression on the cell surface (Goldberg and Rock, 1992, *Nature* 357:375-379). Since APC express both MHC-encoded class I and class II glycoproteins, they can present antigenic fragments to both CD4⁺ and CD8⁺ T cells for the initiation of an immune response.

By definition, APC not only can present antigens to T cells with antigen-specific receptors, but can provide all the signals necessary for T cell activation. Such signals are incompletely defined, but probably involve a variety of cell surface molecules as well as cytokines or growth factors. Further, the factors necessary for the activation of naive or unprimed T cells may be different from those required for the re-activation of previously primed memory T cells. The ability of APC to both present antigens and deliver signals for T cell activation is commonly referred to as an accessory cell function. Although monocytes and B cells have been shown to be competent APC, their antigen presenting capacities *in vitro* appear to be limited to the re-activation of previously sensitized T cells. Hence, they are not capable of directly activating functionally naive or unprimed T cell populations.

Although it had been known for a long time that APC process and present antigens to T cells, it was not shown until relatively recently that small antigenic peptides could directly bind to MHC-encoded molecules (Babbit et al., 1985, *Nature* 317:359; Townsend et al., 1986, *Cell* 44:959). However, it is believed that, normally, complex antigens are proteolytically processed into fragments inside the APC, and become physically associated with the MHC-encoded proteins intracellularly prior to

trafficking to the cell surface as complexes. Two distinct pathways for antigen presentation have been proposed (Braciale et al., 1987, *Immunol. Rev.* 98:95-114). It was thought that exogenous antigens were taken up by APC, processed and presented by the exogenous pathway to class II restricted CD4⁺ T cells, while the endogenous pathway processed intracellularly synthesized proteins, such as products of viral genes in virally-infected cells, for association with MHC class I proteins and presentation to CD8⁺ CTL. However, although the two pathways in antigen processing and presentation may still be correct in some respects, the distinction is blurred in light of recent findings that exogenously added antigens may also be presented to class I-restricted CTL (Moore et al., 1988, *Cell* 54:777).

The term "dendritic cells" (DC) refers to a diverse population of morphologically similar cell types found in a variety of lymphoid and non-lymphoid tissues (Steinman, 1991, *Ann. Rev. Immunol.* 9:271-296). These cells include lymphoid DC of the spleen, Langerhans cells of the epidermis, and veiled cells in the blood circulation. Although they are collectively classified as a group based on their morphology, high levels of surface MHC-class II expression, and absence of certain other surface markers expressed on T cells, B cells, monocytes, and natural killer cells, it is presently not known whether they derive from a common precursor or can all function as APC in the same manner. Further, since the vast majority of published reports have utilized DC isolated from the mouse spleen, results from these studies may not necessarily correlate with the function of DC obtained from other tissue types. (Inaba et al., 1997, *J. Exp. Med.* 166:182-194; Hengel et al., 1987, *J. Immunol.* 139:4196-4202; Kaut et al., 1988, *J. Immunol.* 140:3186-3193; Romani et al., 1989, *J. Exp. Med.* 169:1169-1178; Macatonia et al., 1989, *J. Exp. Med.* 169:1255-1264; Inaba et al., 1990, *J. Exp. Med.* 172:631-6640). For example, despite high levels of MHC-class II expression, mouse epidermal Langerhans cells, unlike splenic DC, are not active APC in mixed leucocyte reaction (MLR), unless cultured with granulocyte-macrophage colony stimulating factor (GM-CSF) (Witmer-Pock et al., 1987, *J. Exp. Med.* 166:1484-1498; Heusler et al., 1988, *J. Exp. Med.* 167:700-705). Most human Langerhans cells express the CD1 and CD4 markers, while blood DC do not. Additionally, it has not been established the extent to which the functional characteristics observed with mouse DC are applicable to human DC, especially the DC obtained from non-splenic tissues; in part, due to inherent differences between the

human and murine immune systems.

Recently, a few studies have described the isolation of human DC from the peripheral blood, which involves the use of sheep red blood cells and/or fetal calf serum (Young and Steinman, 1990, *J. Exp. Med.* 171:1315-1332; Freudenthal and Steinman, 1990, *Proc. Natl. Acad. Sci. USA* 87:7698-7702; Macatonia et al., 1989 *Immunol.* 67:285-289; Markowicz and Engleman, 1990, *J. Clin. Invest.* 85:955-961). Engleman et al. described a partial purification procedure of DC from human blood, which does not involve the use of sheep red blood cells and/or fetal calf serum, and showed that the partially purified human DC can, in fact, present exogenous antigens to naive T cells (PCT Publication WO 94/02156 dated February 3, 1994 at page 9, lines 5-32).

Recent studies have indicated that DCs are superior APCs as compared to other APCs such as macrophages and monocytes. First, the potent accessory cell function of DCs provides for an antigen presentation system for virtually any antigenic epitopes which T and B cells are capable of recognizing through their specific receptors. For example, Engleman et al. demonstrate that human DCs can present both complex protein antigens and small peptides to CD4⁺ T cells as well as to CD8⁺ CTL (PCT Publication WO 94/02156 dated February 3, 1994, Example 7, from page 29, line 10 to page 34, line 16). Engleman et al. also show that the *in vitro* priming effect of DCs does not require the addition of exogenous lymphokines, indicating that DCs produce all of the necessary signals in antigen presentation leading to the activation of T cells (PCT Publication WO 94/02156 dated February 3, 1994, from page 32, line 36 to page 33, line 2). More importantly, DCs can induce a primary CD4⁺ T cell-mediated proliferative response when similarly prepared monocytes can not induce such a response (PCT Publication WO 94/02156 dated February 3, 1994 at page 31, lines 23-30). Similarly, when DCs and monocytes were compared for their ability to present antigens for re-activating secondary T cell response, it was observed that DCs were capable of stimulating a stronger response than monocytes (PCT Publication WO 94/02156 dated February 3, 1994 at page 32, lines 12-16).

2.3. CHEMOKINES

Chemokines, or chemoattractant cytokines, are a subgroup of immune factors

that have been shown to mediate chemotactic and other pro-inflammatory phenomena (see, Schall, 1991, *Cytokine* 3:165-183). Chemokines are small molecules of approximately 70-80 residues in length and can generally be divided into two subgroups, α which have two N-terminal cysteines separated by a single amino acid (CxC) and β which have two adjacent cysteines at the N terminus (CC). RANTES, MIP-1 α and MIP-1 β are members of the β subgroup (reviewed by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; Murphy, P.M., 1994, *Annu. Rev. Immunol.* 12:593-633; Baggolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

MCP-1 has been shown to attract monocytes but not neutrophils. MCP-1, MCP-2, and MCP-3 share a pyroglutamate proline NH₂-terminal motif and are structurally closely related to each other and to eotaxin (56% to 71% amino acid sequence identity). MCP-1, MCP-2, and MCP-3 attract monocytes, CD4 $^{+}$ and CD8 $^{+}$ T lymphocytes (Loetscher et al. *FAESB J.* 1994, 8:1055-60), as well as basophil leukocytes. MCP-2, MCP-3, and MCP-4 (but not MCP-1) attracts eosinophil leukocytes. All four MCPs attract activated T lymphocytes, natural killer (NK) cells, and dendritic cells (see Baggolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

Eotaxin acts on eosinophils and is inactive on neutrophils and monocytes, but has weak-to-moderate chemotactic activity toward IL-2-conditioned T lymphocytes (see Baggolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705). Due to its preferential, powerful action on eosinophils and its occurrence in different species, eotaxin is considered to be an important chemokine in the pathophysiology of allergic conditions and asthma (See Baggolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

IP10 is a CXC chemokine attracts human monocytes, T lymphocytes, and NK cells, and Mig attracts tumor-infiltrating T lymphocytes. It has been suggested that IP10 and Mig may also be involved in the regulation of lymphocyte recruitment and the formation of the lymphoid infiltrates observed in autoimmune inflammatory lesions, delayed-type hypersensitivity, some viral infections, and certain tumors (Baggolini et al. *Annu. Rev. Immunol.* 1997, 15:675-705).

SDF-1 (stromal cell-derived factor 1), including SDF-1 and SDF-1 β stimulates the proliferation of B cell progenitors, and attracts mature dendritic cells (Finkel et al. *Immunobiology* 1998, 198:490-500). Synthetic human SDF-1 stimulates monocytes, neutrophils, and peripheral blood lymphocytes, as is indicated by [Ca²⁺]_i changes and chemotaxis. SDF-1 is also a powerful HIV-suppressive factor (See Baggolini et al.

Ann. Rev. Immunol. 1997, 15:675-705).

The amino terminus of the β chemokines RANTES, MCP-1, and MCP-3 has been implicated in the mediation of cell migration and inflammation induced by these chemokines. This involvement is suggested by the observation that the deletion of the amino terminal 8 residues of MCP-1, amino terminal 9 residues of MCP-3, and amino terminal 8 residues of RANTES and the addition of a methionine to the amino terminus of RANTES, antagonize the chemotaxis, calcium mobilization and/or enzyme release stimulated by their native counterparts (Gong et al., 1996, *J. Biol. Chem.* 271:10521-10527; Proudfoot et al., 1996 *J. Biol. Chem.* 271:2599-2603). Additionally, α chemokine-like chemotactic activity has been introduced into MCP-1 via a double mutation of Tyr 28 and Arg 30 to leucine and valine, respectively, indicating that internal regions of this protein also play a role in regulating chemotactic activity (Beall et al., 1992, *J. Biol. Chem.* 267:3455-3459).

The monomeric forms of all chemokines characterized thus far share significant structural homology, although the quaternary structures of α and β groups are distinct. While the monomeric structures of the β and α chemokines are very similar, the dimeric structures of the two groups are completely different. An additional chemokine, lymphotactin, which has only one N terminal cysteine has also been identified and may represent an additional subgroup (γ) of chemokines (Yoshida et al., 1995, *FEBS Lett.* 360:155-159; and Kelner et al., 1994, *Science* 266:1395-1399).

Receptors for chemokines belong to the large family of G-protein coupled, 7 transmembrane domain receptors (GCR's) (See, reviews by Horuk, R., 1994, *Trends Pharmacol. Sci.* 15:159-165; and Murphy, P.M., 1994, *Ann. Rev. Immunol.* 12:593-633). Competition binding and cross-desensitization studies have shown that chemokine receptors exhibit considerable promiscuity in ligand binding. Examples demonstrating the promiscuity among β chemokine receptors include: CCR-1, which binds RANTES and MIP-1 α (Neote et al., 1993, *Cell* 72:415-425), CCR-4, which binds RANTES, MIP-1 α , and MCP-1 (Power et al., 1995, *J. Biol. Chem.* 270:19495-19500), and CCR-5, which binds RANTES, MIP-1 α , and MIP-1 β (Alkhatib et al., 1996, *Science* 272:1955-1958 and Dragic et al., 1996, *Nature* 381:667-674). Erythrocytes possess a receptor (known as the Duffy antigen) which binds both α and β chemokines (Horuk et al., 1994, *J. Biol. Chem.* 269:17730-17733; Neote et al., 1994, *Blood* 84:44-52; and Neote et al., 1993, *J. Biol. Chem.* 268:12247-12249). Thus the sequence and

structural homologies evident among chemokines and their receptors allow some overlap in receptor-ligand interactions.

Godiska et al. identified and described the nucleic acid and amino acid sequences of an additional β chemokine designated macrophage derived chemokine (MDC) (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). PCT publication WO 96/40923 further provides materials and methods for the recombinant production of the chemokine, the purified and isolated chemokine protein, and polypeptide analogues thereof. The PCT publication WO 96/40923 does not disclose that the human MDC has chemotactic activity upon DC. While Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604) showed that, in a microchamber migration assay, monocyte-derived DC migrated toward the human MDC, the reference fails to teach that MDC can enhance an immune response to an antigen *in vivo*.

Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237), isolated a stimulated T cell chemotactic protein (STCP-1) from an activated macrophage cDNA library. The nucleotide sequence of the STCP-1 is identical to that of the MDC isolated by Godiska et al. (PCT Publication WO 96/40923 dated December 19, 1996, and 1997, *J. Exp. Med.* 185:1595-1604). However, unlike the results observed by Godiska et al. (1997, *J. Exp. Med.* 185:1595-1604), Chang et al. (1997, *J. Biol. Chem.* 272(40):25229-25237) showed that although the STCP-1 acted as a mild chemoattractant for primary activated T lymphocytes and a potent chemoattractant for chronically activated T lymphocytes, the STCP-1 has no chemoattractant activity for monocytes, neutrophils, eosinophils and resting T lymphocytes. Chang et al. further showed that the STCP-1 does not induce Ca^{2+} mobilization in monocytes, dendritic cells, neutrophils, eosinophils, lipopolysaccharide-activated B lymphocytes, and freshly isolated resting T lymphocytes.

2.4. HIV VACCINES

Human immunodeficiency virus (HIV) induces a persistent and progressive infection leading, in the vast majority of cases, to the development of the acquired immunodeficiency syndrome (AIDS) (Barre-Sinoussi et al., 1983, *Science* 220:868-870; Gallo et al., 1984, *Science* 224:500-503). The HIV envelope surface glycoproteins are

synthesized as a single 160 kilodalton precursor protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane glycoprotein and gp120 is an extracellular glycoprotein which remains non-covalently associated with gp41, possibly in a trimeric or multimeric form (Hammerskjold, M. and Rekosh, D., 1989, *Biochem. Biophys. Acta* 989:269-280). The V3 loop of gp120 is the major determinant of sensitivity to chemokine inhibition of infection or replication (Cocchi et al., 1996, *Nature Medicine* 2:1244-1247; and Oravecz et al., 1996, *J. Immunol.* 157:1329-1332).

Although considerable effort is being put into the design of effective therapeutics, currently no curative anti-retroviral drugs against AIDS exist. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for neutralizing anti-HIV antibodies present in AIDS patients (Barin et al., 1985, *Science* 228:1094-1096). Thus far, therefore, these proteins seem to be the most promising candidates to act as antigens for anti-HIV vaccine development. Several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune system (see, for example, Ivanoff et al., U.S. Pat. No. 5,141,867; Saith et al., PCT publication WO 92/22654; Shafferman, A., PCT publication WO 91/09872; Formoso et al., PCT publication WO 90/07119). Therefore, methods to increase the efficacy of vaccines against HIV, especially vaccines using gp120 as the antigen, are needed.

Additionally a novel vaccine technology, designated genetic vaccination, nucleic acid vaccination or DNA vaccination, has been explored to induce immune responses *in vivo*. Injection of cDNA expression cassettes results in *in vivo* expression of the encoded proteins (Dubensky et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:7529-7533; Raz et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4523; Wolff et al., 1990, *Science* 247:1465-1468), with the concomitant development of specific cellular and humoral immune responses directed against the encoded antigen(s) (Wang et al., 1995, *Hum. Gene Ther.* 6:407-418; Ulmer et al., 1993, *Science* 259:1745-1749; Tang et al., 1992, *Nature* 356:152-154; Michel et al., 1995, *Proc. Natl. Acad. Sci. USA* 92:5307-5311; and Lowrie et al., 1994, *Vaccine* 12:1537-1540). Humoral and cellular responses have been induced to HIV-1 and SIV antigens through various applications of this technology in macaques (Wang et al., 1995, *Virology* 221:102-112; Wang et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:4156-4160; and Boyer et al., 1996, *J. Med.*

Primateol. 25:242-250) as well as mice (Wang et al., 1995, *Virology* 221:102-112; Lu et al., 1995, *Virology* 209:147-154; Haynes et al., 1994, *AIDS Res. Hum. Retroviruses* 10 (Suppl. 2):S43-S45; Okuda et al., 1995, *AIDS Res. Hum. Retroviruses* 11:933-943).

Recently, Lekutis et al. (1997, *J. Immunol.* 158:4471-4477), assessed the TH cell response elicited by an HIV-1 gp120 DNA vaccine in rhesus monkeys by isolation of gp120-specific, MHC class II-restricted CD4⁺ T cell lines from the vaccinated animals. Lekutis et al. showed that the isolated cell lines proliferated in response to APC in the presence of recombinant gp120, as well as to APC expressing HIV encoded env protein. Lekutis et al. further showed that these cell lines responded to env by secreting IFN- Γ and IFN- α without appreciable IL-4 production. These results demonstrate that the animals exhibited a cellular immune response to the DNA vaccine.

Boyer et al. (1997, *Nature Medicine* 3:625-532), inoculated chimpanzees with an HIV-1 DNA vaccine encoding env, rev, and gag/pol, and found that the immunized animals developed specific cellular and humoral immune responses to these proteins. After challenging the immunized animals with a heterologous chimpanzee titered stock of HIV-1 SF2, Boyer et al. further found, using a Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay, that those animals vaccinated with the DNA vaccine were protected against infection whereas the control animals were not so protected.

Kim et al., (1997 *J. Immunol.* 158:816-826), investigated the role of co-delivery of genes for IL-12 and GM-CSF along with DNA vaccine formulation for HIV-1 antigens env and gag/pol in mice. Kim et al. observed a dramatic increase in specific CTL response from the mice immunized with the HIV-1 DNA vaccine and IL-12. Kim et al. also observed that the co-delivery of IL-12 genes resulted in the reduction of specific antibody response, whereas the codelivery of GM-CSF genes resulted in the enhancement of specific antibody response. Kim et al. further observed that co-delivery of IL-12 gene with a HIV DNA vaccine results in splenomegaly (Kim et al. 1997, *J. Immunol.*, 158:816-826), which has been shown in mice to have toxic effects such as weight reduction or even death (Eng et al., 1995, *J. Exp. Med.* 181:1893; Stevenson et al., 1995, *J. Immunol.* 155:2545; and Orange et al., 1995, *J. Exp. Med.* 181:901).

Notwithstanding the recent developments of the HIV DNA vaccine, there still

exists a need for a method to enhance the efficacy of a vaccine, especially an HIV DNA vaccine. For instance, for efficacious vaccine against HIV-1 one preferably induces both cellular and humoral immune responses to control the infection (Boyer et al., 1997, *Nature Medicine* 3:625-532). The induction of both cellular and humoral immune response by the Berjer et al. method is still quite low because only one of the three immunized chimpanzees developed both cellular and humoral responses. Similarly, although co-delivery of an IL-12 encoding gene with a HIV DNA vaccine, as described in Kim et al. (1997, *J. Immun.* 158:816-826), may have enhanced the cellular immune response, this co-delivery also decreased the humoral response.

Citation of a reference hereinabove shall not be construed as an admission that such reference is prior art to the present invention.

3. SUMMARY OF THE INVENTION. SUMMARY OF THE INVENTION. . SUMMARY OF THE INVENTION

The present invention is based upon the ability of chemokines, such as MDC, Rantes, MIP-1 α , MIP-1 β , and I-309, to enhance the immune response to an antigen, particularly a vaccine. Accordingly, in a first aspect, the present invention provides a method for enhancing the efficacy of a vaccine, which method comprises administration to a subject of one or more purified chemokines, or biologically active fragments, analogues or derivatives thereof, either concurrently with one or more purified antigens against which an immune response is desired or within a time period either before or after administration of the antigens such that the immune response against the antigens is enhanced.

In a second aspect, the present invention provides a method to enhance the efficacy of a vaccine, which method comprises administration to a subject of a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments, derivatives, analogues, and/or truncation isoforms thereof, and a second purified nucleic acid comprising a nucleotide sequence encoding one or more antigens against which an immune response is desired, such that, the one or more chemokine(s) and the antigen(s) are expressed in a coordinated manner upon introduction into a suitable cell. Alternatively, the nucleotide sequences encoding one or more chemokines, or

fragments, derivatives, and/or analogues thereof, and the antigens against which an immune response is desired are present on the same nucleic acid.

In a preferred embodiment, the invention provides a method to enhance the efficacy of an HIV vaccine.

In yet another aspect, the present invention provides a composition comprising an immunogenic amount of one or more purified antigens, an amount of one or more purified chemokines, or a fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response to the antigen. In another aspect, the present invention provides a composition comprising a first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, fragments, derivatives analogues and or truncation isoforms thereof, and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens against which an immune response is desired, such that, the chemokine(s) and the antigen are expressed in a coordinated manner upon introduction into a suitable cell. In a preferred embodiment, the antigen is an HIV antigen. In another preferred embodiment, the chemokine is selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha

chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. DESCRIPTION OF FIGURES

Figures 1A and 1B. The nucleotide and amino acid sequences of MDC. 1A depicts the nucleotide sequence of MDC (SEQ ID NO:1), with the coding region indicated by the appearance of the amino acid sequence in the line below; and 1B depicts the amino acid of MDC (SEQ ID NO:2) from GenBank accession no. U83171 (Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604).

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a method for enhancing the efficacy of a vaccine in a subject comprising administering to the subject one or more purified antigens in conjunction with one or more purified chemokines, or more purified fragments, derivatives or analogues and/or truncation isoforms thereof.

While any chemokine may be employed according to the present invention, the chemokine is preferably selected from the following table:

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines	Macrophage-derived chemokine	MDC/STCP-1	u83171; u83239
	Monocyte chemotactic protein 1	MCP-1	x14768
	Monocyte chemotactic protein 2	MCP-2	X99886
	Monocyte chemotactic protein 3	MCP-3	x72308; s57464
	Monocyte chemotactic protein 4	MCP-4	u46767
	activated macrophage specific chemokine 1	AMAC-1	Y13710
	Macrophage inflammatory protein 1 alpha	MIP-1 α	AF043339; X03754; D90144

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Macrophage inflammatory protein 1 beta	MIP-1 β	j04130; d90145
	Macrophage inflammatory protein 1 gamma	MIP-1 γ	
	Macrophage inflammatory protein 1 delta	MIP-1 δ	AF031587
	Macrophage inflammatory protein 2 alpha	MIP-2 α	AF043340
	Macrophage inflammatory protein 3 alpha	MIP-3 α	u77035
	Macrophage inflammatory protein 3 beta	MIP-3 β	u77180
	Regulated upon activation, normal T cell expressed and secreted (and its variants)	RANTES	M21211
	I-309		M57502
	EBI1-ligand chemokine	ELC	AB000887
	Pulmonary and activation-regulated chemokine	PARC/DC-CK-1/MIP4	AB000221
	Liver and activation-regulated chemokine	LARC	D86955
	Thymus and activation regulated chemokine	TARC	D43767
	Eotaxin (and variants)		D49372; Z69291; Z75669; Z75668
	Human chemokine 1	HCC1; NCC2	Z49270; z49269
	Human chemokine 2	HCC2; NCC3, MIP-5, MIP-1 δ	Z70292
	Human chemokine 3	HCC3	Z70293
	IL-10-inducible chemokine	HCC4	U91746
	liver-expressed chemokine.	LEC; HCC4;NCC4	AB007454
	6Ckine		AF001979
	Exodus 1		u64197
	Exodus 2		U88320
	Exodus 3		U88321
	thymus-expressed chemokine	TECK	U86358
	Secondary Lymphoid tissue chemokine	SLC	AB002409

Chemokine Class	Chemokines	Abbreviations	Accession Number
CC Chemokines (continued)	Lymphocyte and Monocyte chemoattractant; Monotactin	LMC	AF055467
	Activation-induced, chemokine-related molecule	ATAC	x86474
	Myeloid progenitor inhibitory factor-1	MPIF-1; MIP-3 or ckbeta8	u85767
	Myeloid progenitor inhibitory factor-2	MPIF-2	u85768
	Stromal cell-derived factor 1 alpha	SDF-1 α ; PBSF	L36034
CXC chemokines	Stromal cell-derived factor 1 beta	SDF-1 β ; PBSF	L36033
	B-cell-attracting chemokine 1	BLC	AJ002211
	HuMIG		x72755 s60728
	H174		AF002985
	Interferon-stimulated T-cell alpha chemoattractant	I-TAC	AF030514
	Interleukin-8	IL-8	m17017; y00787
	IP-10		X02530
	platelet factor 4	PF4	M20901
	growth-regulated gene-alpha	GRO- α	J03561
	growth-regulated gene-beta	GRO- β	M36820
	growth-regulated gene-gamma	GRO- γ	M36821
	Neutrophil-activating protein 2	NAP-2; CTAP-3	M54995; M38441
	ENA-78		L37036
	granulocyte chemotactic protein 2	GCP-2	Y08770
C-CHEMOKINES	LYMPHOTACTIN	SCM-1	D63789 D63790
C \times C-CHEMOKINES	Fractalkine/neurotactin		U91835 U84487

The present invention also relates to the use of fragments, analogues and derivatives of the foregoing chemokines, as well as truncation isoforms of such chemokines which are known in the art.

The present invention also relates to therapeutic compositions comprising one or more chemokines, nucleic acids encoding one or more chemokines, derivatives, analogues, and/or truncation isoforms thereof, and nucleic acids encoding the same, that are effective to enhance the immune response of a subject to a vaccine.

In another preferred embodiment of the invention, nucleic acids comprising

nucleotide sequences encoding one or more chemokines or fragments or derivatives, including truncation isoforms, thereof, and encoding one or more antigens against which an immune response is desired, which coding sequences are operatively linked to gene regulatory sequences capable of directing the expression of the one or more chemokines and the one or more antigens upon introduction into a suitable cell, for example, but not limited to, the cell (of a subject), are administered to a subject such that the one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, and one or more antigens, are expressed in the subject.

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the subsections which follow.

5.1. METHODS AND COMPOSITIONS TO ENHANCE THE EFFICACY OF A VACCINE

The present invention provides methods for enhancing the efficacy of a vaccine in a subject, which methods comprise administering to a subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject in conjunction with an amount of one or more purified chemokines, or fragments, derivatives, analogues and/or truncation isoforms thereof, effective to enhance the immune response against the antigen. In one aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered to the subject concurrently with (e.g., in the same composition with) the purified antigen or antigens against which an immune response is desired. In another, aspect, the purified chemokine(s), or fragment(s), derivative(s), analogue(s) and/or truncation isoforms thereof, are administered either before or after the administration of one or more purified antigens against which immunity is desired in the subject, but is administered within such time that the chemokine(s) enhance the immune response to the one or more antigens. For example, but not by way of limitation, the purified chemokine(s) are administered during the time that the subject mounts an immune response against the administered one or more antigens, or, the purified MDC is administered within, for example, but not limited to, 30 minutes, 1 hour, 5 hours, 10 hours, 1 day, 2 days of (preferably, after) administration of the one or more purified antigens against which immunity is desired.

In a preferred embodiment, the present invention provides compositions comprising an immunogenic amount of one or more purified antigens and an amount of purified MDC, or one or more fragments, derivatives or analogues thereof, effective to enhance the immune response to said antigen and, preferably, the composition further comprises a pharmaceutically acceptable carrier.

A preferred chemokine for use in the methods and compositions of the present invention is any MDC protein, fragment or derivative thereof, that is capable of enhancing the efficacy of a vaccine (for example, but not limited to, as determined by the assays described in Section 5.4, *infra*). In one specific embodiment, the MDC is purified full length MDC, preferably full length MDC having the amino acid sequence of SEQ ID NO: 2 (Figure 1B). In another embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 2-69 of SEQ ID NO: 2 (Figure 1B). In another specific embodiment, the MDC is a purified protein, the amino acid sequence of which consists of amino acid numbers 3-69 of SEQ ID NO: 2 (Figure 1B). In still another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified protein, the N-terminal amino acid sequence of which consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (portion of SEQ ID NO: 2). In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg-Asp-Tyr-Val-Arg-Tyr-Arg-Leu (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine. In yet another specific embodiment, the MDC is a purified derivative of a protein, the N-terminal amino acid sequence of which protein consists of the amino acid sequence Pro-Tyr-Gly-Ala-Asn-Met-Glu-Asp-Ser-Val-Cys-Cys-Arg (SEQ ID NO:2), which derivative has activity to enhance the efficacy of the vaccine.

In yet another specific embodiment, the chemokine is a purified derivative of the protein, which derivative has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. In yet another specific

embodiment, the chemokine is a purified derivative of the protein that has only one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative will enhance the efficacy of the vaccine. The chemokines useful in the present invention may be derived from any suitable source and obtained by any method known in the art, for example but not limited to the methods described in Section 5.2 infra.

Preferably, the chemokine(s) are of the same species as the subject to which the vaccine is administered. In a preferred embodiment, one or more human chemokines are administered to a human subject, e.g., human MDC is administered to a human subject, alone or in combination with another chemokine.

The present invention also provides a method to enhance the efficacy of a vaccine in a subject, which method comprises administering to a subject a purified first nucleic acid comprising a nucleotide sequence encoding an antigen against which an immune response is desired in a subject and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragment(s), derivative(s) or analogue(s) thereof, where the expression of the encoded antigen(s) and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are under control of one or more appropriate gene regulatory elements (which regulatory elements can be any regulatory element known in the art, for example, but not limited to, those regulatory elements described in Section 5.2 supra), such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen and chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are coordinately expressed, i.e., are expressed either at the same time or within an appropriate time period (i.e., sufficient for the chemokine(s) to enhance the immune response against the antigen relative to a corresponding immune response in the absence of the chemokine) and the antigen(s) are expressed in an immunogenic amount and the chemokine(s), or fragment(s), derivative(s) or analogue(s) thereof, are expressed in an amount sufficient to enhance the immune response against the antigen(s). In a specific embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen are present on separate nucleic acids. In another embodiment, the nucleotide sequences encoding the chemokine(s) and the antigen(s) are present on the same nucleic acid.

The present invention also provides compositions to enhance the

efficacy of a vaccine in a subject, which compositions comprise a purified first nucleic acid comprising a nucleotide sequence encoding one or more antigen(s) and a purified second nucleic acid comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives, including truncation isoforms, thereof, wherein the nucleotide sequences encoding the antigens and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified first set of one or more purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens and a purified second set of one or more purified nucleic acids comprising a nucleotide sequence encoding one or more chemokines, or fragments, analogues, derivatives, (including truncation isoforms) thereof, wherein the nucleotide sequence(s) encoding the antigen(s) and the chemokine(s) are operably linked to one or more gene regulatory elements such that, upon introduction of said first and second sets of nucleic acids into a suitable cell (e.g., a cell of the subject), the antigen(s) and chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are expressed in an amount effective to enhance the immune response against the antigen, relative to a corresponding immune response in the absence of such chemokine(s).

The present invention also provides compositions to enhance the efficacy of a vaccine in a subject, which compositions comprise a purified nucleic acid comprising a first set of one or more nucleotide sequences encoding one or more antigens and a second set of one or more nucleotide sequence encoding one or more chemokines, or fragments, derivatives, or analogues thereof (including truncation isoforms), wherein the first and second sets of nucleotide sequences are operably linked to one or more gene regulatory elements such that, upon introduction into a suitable cell, the antigen(s) and the chemokine(s) are expressed in a coordinated manner and the antigen(s) are expressed in an immunogenic amount and the chemokine(s) are

expressed in an amount effective to enhance the immune response against the antigen(s).

Any nucleic acid comprising a nucleotide sequence encoding one or more chemokine proteins, or fragments or derivatives, thereof (including truncation isoforms), that are capable of enhancing the immune response to the antigen (for example, but not limited to, as determined by any of the assays described in Section 5.2., *infra*) can be used in the methods and compositions of the present invention.

In a preferred embodiment, the nucleotide sequence encodes MDC. In another embodiment, the MDC-encoding nucleotide consists of the nucleotide sequence of SEQ ID NO:1 (Figure 1A). In another specific embodiment, the method or composition of the invention uses a nucleic acid encoding an MDC derivative having deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the immune response against an antigen in a subject.

Such compositions of nucleic acids encoding an antigen are often referred to as DNA vaccines.

Such DNA vaccines are produced by any method known in the art for constructing an expression plasmid vector containing the nucleotide sequences of the antigen(s) and/or chemokine(s) to be expressed which vector is suitable for expression of the encoded proteins in the subject or in cells recombinant for the expression vector, which cells are to be provided to the subject. Such expression vectors may contain various promoters, terminators and polyadenylation coding regions to control the expression of the encoded protein.

The DNA vaccine can be administered by any method known in the art for administration of DNA. The DNA vaccine may be delivered either directly, in which case the subject is directly exposed to the DNA vaccine such that the DNA enters and is expressed in cells of the subject, or indirectly, in which case, the DNA vaccine is first introduced into suitable cells by any method known in the art *in vitro*, then the cells containing the DNA vaccine are transplanted into the subject.

In a specific embodiment, the DNA vaccine is directly administered *in vivo*, where it is expressed to produce the encoded antigens and chemokine(s). This can be accomplished by any of numerous methods known in the art, e.g., by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by infection using a defective or attenuated retroviral or

other viral vector (see U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, *J. Biol. Chem.* 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In a preferred embodiment, the nucleic acid of a DNA vaccine is injected into the muscle of the subject to be immunized.

Another approach is to introduce the nucleic acid of the DNA vaccine into a cell prior to administration *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign nucleic acid into cells (see e.g., Loeffler and Behr, *Meth. Enzymol.* 217:599-618 (1993); Cohen et al., *Meth. Enzymol.* 217:618-644 (1993); Cline, *Pharmac. Ther.* 29:69-92 (1985)) and may be used in accordance with the present invention. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene.

Cells into which a DNA vaccine can be introduced for purposes of immunization encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

The resulting recombinant cells can be delivered to a subject by various

methods known in the art. In a preferred embodiment, the recombinant cells are injected, e.g., subcutaneously. In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The cells can also be encapsulated in a suitable vehicle and then implanted in the subject (see, e.g., Dionne et al. PCT Publication WO 92/19195, dated November 12, 1992). The amount of cells envisioned for use depends on the desired effect, subject state, etc., and can be determined by one skilled in the art.

By way of example, and not by way of limitation a DNA vaccine may be generated as described by Lekutis et al. for an HIV DNA vaccine (1997, *J. Immunol.* 158:4471-4477). Briefly, an expression vector is constructed with the promoter, enhancer and intron A of human cytomegalovirus (CMV) and the termination and polyadenylation sequences of bovine growth hormone in a plasmid backbone. Additionally, the nucleotide sequence for signal sequence of tissue plasminogen activator is either substituted for the signal sequence of the antigen, if the antigen has a signal sequence or is added onto the amino-terminus of the antigen, thereby eliminating the dependence on viral proteins for expression (e.g., in the case of gp120 expression, rev and env proteins are required unless the HIV-1 signal sequence is so substituted). The resulting formulation is then injected intra-muscularly.

Further examples of DNA vaccines are set forth in Boyer et al. (1996, *J. Med. Primatol.*, 25:242-250), which describes the construction of a plasmid encoding the HIV-1 gp160 envelope glycoprotein as well as the rev-tax region cloned into pMAMneoBlue vector (Clonetech, Inc., Palo Alto, CA), and a vector encoding the envelope glycoprotein and rev from HIV-1 strain MN under the control of the CMV promoter. Another vector which can be used in the present invention is as described in Boyer et al. (1997, *Nature Medicine* 3:526-532) and contains expression cassettes encoding the envelope and Rev proteins of HIV-1 strain MN, and encoding the Gag/Pol proteins of HIV-1 strain IIIB.

For the practice of the present invention, the nucleotide sequence for the one or more chemokines, or fragments, derivatives, or analogues thereof, can either be incorporated into the same expression vector containing the nucleotide sequence encoding the antigen in such a manner that the chemokine(s) are expressed. Alternatively, the nucleotide sequence encoding the chemokine(s), or fragment(s),

derivative(s) or analogue(s) thereof, can be cloned into a separate expression vector (e.g., as described above for the expression vector containing the sequences coding for antigen) and the expression vector that expresses the antigen(s) mixed with the expression vector that expresses the chemokine(s). The mixture of the two expression vectors can then be administered to the subject.

The methods and compositions of the present invention may be used as a vaccine in a subject in which immunity for the antigen(s) is desired. Such antigens can be any antigen known in the art to be useful in a vaccine formulation. The methods and compositions of the present invention can be used to enhance the efficacy of any vaccine known in the art. The vaccine of the present invention may be used to enhance an immune response to infectious agents and diseased or abnormal cells, such as but not limited to bacteria, parasites, fungi, viruses, tumors and cancers. The compositions of the invention may be used to either treat or prevent a disease or disorder amenable to treatment or prevention by generating an immune response to the antigen provided in the composition. In one preferred embodiment, the antigen(s) are proteins, fragments or derivatives, including truncation isoforms, thereof, encoded by any genes of the HIV genome including the *env*, *gag*, *pol*, *nef*, *vif*, *rev*, and *tat* genes. In a more preferred embodiment, the antigen is an HIV-associated gp120 protein.

The methods and compositions of the present invention may be used to elicit a humoral and/or a cell-mediated response against the antigen(s) of the vaccine in a subject. In one specific embodiment, the methods and compositions elicit a humoral response against the administered antigen in a subject. In another specific embodiment, the methods and compositions elicit a cell-mediated response against the administered antigen in a subject. In a preferred embodiment, the methods and compositions elicit both a humoral and a cell-mediated response.

The subjects to which the present invention is applicable may be any mammalian or vertebrate species, which include, but are not limited to, cows, horses, sheep, pigs, fowl (e.g., chickens), goats, cats, dogs, hamsters, mice and rats, monkeys, rabbits, chimpanzees, and humans. In a preferred embodiment, the subject is a human. The compositions and methods of the invention can be used to either prevent a disease or disorder, or to treat a particular disease or disorder, where an immune response against a particular antigen or antigens is effective to treat or prevent the

disease or disorder. Such diseases and disorders include, but are not limited to, viral infections, such as HIV, CMV, hepatitis, herpes virus, measles, etc, bacterial infections, fungal and parasitic infections, cancers, and any other disease or disorder amenable to treatment or prevention by eliciting an immune response against a particular antigen or antigens. In another preferred embodiment, the subject is infected or at risk of being infected with HIV virus.

In another preferred embodiment the invention provides methods and compositions to enhance the efficacy of an HIV vaccine, such a vaccine can be administered to either prevent or treat HIV.

5.2. CHEMOKINE GENES AND PROTEINS

Chemokine proteins and nucleic acids can be obtained by any method known in the art. Chemokine nucleotide and amino acid sequences are available in public databases such as Genbank and are also published in various references known to those of skill in the art. The gene bank accession numbers for the preferred chemokines of the present invention are provided in Table I, in Section 5 above. The ensuing discussion uses MDC by way of example, but applies equally to other chemokines as well.

The MDC nucleotide and amino acid sequences for, *inter alia*, human, are available in the public databases (e.g. Genbank accession No. U83171) also published in Godiska et al., 1997, *J. Exp. Med.* 185:1595-1604. The nucleotide sequence and the amino acid sequence for the human MDC are provided in Figures 1A and B (SEQ ID NOS:1 and 2, respectively).

Chemokines used herein include, but are not limited to, chemokines from mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, and human. In one preferred embodiment, the chemokine is of human origin.

Any vertebrate cell potentially can serve as the nucleic acid source for the isolation of chemokine nucleic acids. The nucleic acid sequences encoding the chemokine(s) can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (e.g., a

DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (see, for example, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.

In the molecular cloning of the gene from cDNA, cDNA is generated from totally cellular RNA or mRNA by methods that are well known in the art. The gene may also be obtained from genomic DNA, where DNA fragments are generated (e.g. using restriction enzymes or by mechanical shearing), some of which will encode the desired gene. The linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

Once the DNA fragments are generated, identification of the specific DNA fragment containing all or a portion of the chemokine gene may be accomplished in a number of ways.

A preferred method for isolating a chemokine gene is by the polymerase chain reaction (PCR), which can be used to amplify the desired chemokine sequence in a genomic or cDNA library or from genomic DNA or cDNA that has not been incorporated into a library. Oligonucleotide primers which would hybridize to chemokine sequences can be used as primers in PCR.

Additionally, a portion of the chemokine (of any species) gene or its specific RNA, or a fragment thereof, can be purified (or an oligonucleotide synthesized) and labeled, the generated DNA fragments may be screened by nucleic acid hybridization to the labeled probe (Benton, W. and Davis, R., 1977, *Science* 196:180; Grunstein, M. And Hogness, D., 1975, *Proc. Natl. Acad. Sci. U.S.A.* 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. Chemokine nucleic acids can be also identified and isolated by expression cloning using, for example, anti-chemokine antibodies for selection.

Alternatives to obtaining the chemokine DNA by cloning or amplification

include, but are not limited to, chemically synthesizing the gene sequence itself from the known chemokine sequence or making cDNA to the mRNA which encodes the chemokine protein. Other methods are possible and within the scope of the invention. Once a clone has been obtained, its identity can be confirmed by nucleic acid sequencing (by any method well known in the art) and comparison to known chemokine sequences. DNA sequence analysis can be performed by any techniques known in the art, including but not limited to the method of Maxam and Gilbert (1980, *Meth. Enzymol.* 65:499-560), the Sanger dideoxy method (Sanger, F., et al., 1977, *Proc. Natl. Acad. Sci. U.S.A.* 74:5463), the use of T7 DNA polymerase (Tabor and Richardson, U.S. Patent No. 4,795,699), use of an automated DNA sequenator (e.g., Applied Biosystems, Foster City, CA) or the method described in PCT Publication WO 97/ 15690.

Nucleic acids which are hybridizable to a chemokine nucleic acid, or to a nucleic acid encoding a chemokine derivative can be isolated, by nucleic acid hybridization under conditions of low, high, or moderate stringency (see also Shilo and Weinberg, 1981, *Proc. Natl. Acad. Sci. USA* 78:6789-6792). For example, the nucleic acid of SEQ ID No: 1 is hybridizable to an MDC nucleic acid.

Chemokine proteins and derivatives, analogs and fragments of chemokine proteins can be obtained by any method known in the art, including but not limited to recombinant expression methods, purification from natural sources, and chemical synthesis.

For example, chemokines can be obtained by recombinant protein expression techniques. For recombinant expression, the chemokine gene or portion thereof is inserted into an appropriate cloning vector for expression in a particular host cell. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as pBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site

desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and chemokine gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In an alternative method, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a "shot gun" approach. Enrichment for the desired gene, for example, by size fractionation, can be done before insertion into the cloning vector.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated chemokine gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The nucleotide sequence coding for a chemokine protein or a functionally active analog or fragment or other derivative thereof, can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native chemokine gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein

coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding a chemokine protein or peptide fragment may be regulated by a second nucleic acid sequence so that the chemokine protein or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of a chemokine protein may be controlled by any promoter/enhancer element known in the art. Promoters which may be used to control chemokine expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, *Nature* 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, *Nature* 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Kamaroff, et al., 1978, *Proc. Natl. Acad. Sci. U.S.A.* 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, *Proc. Natl. Acad. Sci. U.S.A.* 80:21-25); see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, *Cell* 38:639-646; Ornitz et al., 1986, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409; MacDonald, 1987, *Hepatology* 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, *Nature* 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, *Cell* 38:647-658; Adames et al., 1985, *Nature* 318:533-538; Alexander et al., 1987, *Mol. Cell. Biol.* 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, *Cell* 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, *Genes and Devel.* 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, *Mol. Cell. Biol.* 5:1639-1648; Hammer et al., 1987, *Science* 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, *Genes and Devel.* 1:161-171), beta-globin gene control region

which is active in myeloid cells (Mogram et al., 1985, *Nature* 315:338-340; Kollias et al., 1986, *Cell* 46:89-94), myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, *Cell* 48:703-712), myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, *Nature* 314:283-286), and gonadotropin releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, *Science* 234:1372-1378).

For example, a vector can be used that comprises a promoter operably linked to an chemokine-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning a chemokine coding sequence into the EcoRI restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, *Gene* 7:31-40). This allows for the expression of the chemokine protein product from the subclone in the correct reading frame.

Expression vectors containing chemokine gene inserts can be identified by three general approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of a chemokine gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted chemokine gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of a chemokine gene in the vector. For example, if the chemokine gene is inserted within the marker gene sequence of the vector, recombinants containing the chemokine insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the chemokine protein in *in vitro* assay systems, e.g., binding with anti-chemokine antibody or the chemokine's receptor.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host

System and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered protein may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins. Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may effect processing reactions to different extents.

In other specific embodiments, the chemokine protein(s), fragment(s), analogue(s), or derivative(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, e.g., by use of a peptide synthesizer. In a specific embodiment, a chimeric protein containing all or a portion of the chemokine is joined via a peptide bond to all or a portion of an antigen against which immunity is desired.

Both cDNA and genomic sequences can be cloned and expressed.

The chemokine protein(s) may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and sizing column

chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The functional properties may be evaluated using any suitable assay (see Section 5.5). Alternatively, the protein can be synthesized by standard chemical methods known in the art (e.g., see Hunkapiller, M., et al., 1984, *Nature* 310:105-111). The chemokine-encoding nucleic acid sequence(s) can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions. Any technique for mutagenesis known in the art can be used, including, but not limited to, *in vitro* site-directed mutagenesis (Hutchinson et al., 1978, *J. Biol. Chem.* 253:6551), use of TAB linkers (Pharmacia), mutation-containing PCR primers, etc.

The experimentation involved in mutagenesis consists primarily of site-directed mutagenesis followed by phenotypic testing of the altered gene product. Some of the more commonly employed site-directed mutagenesis protocols take advantage of vectors that can provide single stranded as well as double stranded DNA, as needed. Generally, the mutagenesis protocol with such vectors is as follows. A mutagenic primer, i.e., a primer complementary to the sequence to be changed, but consisting of one or a small number of altered, added, or deleted bases, is synthesized. The primer is extended *in vitro* by a DNA polymerase and, after some additional manipulations, the now double-stranded DNA is transfected into bacterial cells. Next, by a variety of methods, the desired mutated DNA is identified, and the desired protein is purified from clones containing the mutated sequence. For longer sequences, additional cloning steps are often required because long inserts (longer than 2 kilobases) are unstable in those vectors. Protocols are known to those skilled in the art and kits for site-directed mutagenesis are widely available from biotechnology supply companies, for example from Amersham Life Science, Inc. (Arlington Heights, IL) and Stratagene Cloning Systems (La Jolla, CA).

In other specific embodiments, the chemokine derivative(s) or analogue(s) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analogue, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art.

In addition, chemokine proteins, derivatives (including fragments and chimeric proteins), and analogues can be chemically synthesized. See, e.g., Clark-Lewis et al., 1991, *Biochem.* 30:3128-3135 and Merrifield, 1963, *J. Amer. Chem. Soc.* 85:2149-2156. For example, chemokines, derivatives and analogues can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography (e.g., see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 50-60). Chemokines, derivatives and analogues that are proteins can also be synthesized by use of a peptide synthesizer. The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 34-49).

The chemokine proteins, derivatives, or analogues of the invention may be synthesized in their entirety by the sequential addition of amino acid residues or alternatively as fragment subcomponents which may be combined using techniques well known in the art, such as, for example, fragment condensation (Shin et al., 1992, *Biosci. Biotech. Biochem.* 56:404-408; Nyfeler et al., 1992, *Peptides*, Proc. 12th Amer. Pep. Soc., Smith and Rivier (eds), Leiden, pp 661-663); and Nokihara et al., 1990, *Protein Research Foundation*, Yanaihara (ed), Osaka, pp 315-320).

In a less preferred embodiment, chemokine derivatives can be obtained by proteolysis of the protein followed by purification using standard methods such as those described above (e.g., immunoaffinity purification).

In another alternate embodiment, native chemokine proteins can be purified from natural sources, by standard methods such as those described above (e.g., immunoaffinity purification).

5.3. COMPOSITION FORMULATIONS AND METHODS OF ADMINISTRATION

The composition formulations of the invention comprise an effective immunizing amount of an immunologically active ingredient, i.e., one or more antigens, and an amount of one or more chemokine(s), or fragment(s) or derivative thereof, effective to enhance the immune response against the antigen in a subject, and a pharmaceutically acceptable carrier or excipient. In a specific embodiment, the

chemokines are selected from the group consisting of Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

Pharmaceutically acceptable carriers or excipients are well known in the art and include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, sterile isotonic aqueous buffer, and combinations thereof. One example of such an acceptable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as stabilized, hydrolyzed proteins, lactose, etc. The carrier is preferably sterile. The formulation should suit the mode of administration.

In addition, if desired, the vaccine or composition preparation may also include minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the vaccine or composition. Suitable adjuvants may include, but are not limited to: mineral gels,

e.g., aluminum hydroxide; surface active substances such as lysolecithin, pluronic polyols; polyanions; peptides; oil emulsions; alum, MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, and N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine. The effectiveness of an adjuvant may be determined by comparing the induction of antibodies directed against a MDC-containing composition in the presence and in the absence of various adjuvants.

In instances where the recombinant antigen is a hapten, i.e., a molecule that is antigenic in that it can react selectively with cognate antibodies, but not immunogenic in that it cannot elicit an immune response, the hapten may be covalently bound to a carrier or immunogenic molecule; for instance, a large protein such as serum albumin will confer immunogenicity to the hapten coupled to it. The hapten-carrier may be formulated for use as a vaccine.

The composition can be a liquid solution, suspension, emulsion, tablet, pill, capsule, sustained release formulation, or powder. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.

The chemokinè(s), or fragment(s) or derivative(s) thereof, and/or the antigen(s) may be formulated into the composition as neutral or salt forms. Pharmaceutically acceptable salts include the acid addition salts (formed with free amino groups of the peptide) and which are formed with inorganic acids, such as, for example, hydrochloric or phosphoric acids, or organic acids such as acetic, oxalic, tartaric, maleic, and the like. Salts formed with free carboxyl groups may also be derived from inorganic bases, such as, for example, sodium potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

The vaccines of the invention may be multivalent or univalent. Multivalent vaccines are made from recombinant viruses that direct the expression of more than one antigen.

An effective dose (immunizing amount) is that amount sufficient to produce an immune response to the antigen(s) in the host to which the vaccine preparation is administered. The precise dose of the composition to be employed in the formulation will depend on the route of administration, and the nature of the subject to be

immunized, and should be decided by the practitioner according to standard clinical techniques. Effective doses of the vaccines or compositions of the present invention may also be extrapolated from dose-response curves derived from animal model test systems.

The invention also provides a pharmaceutical pack or kit comprising one or more containers comprising one or more of the ingredients of the composition formulations of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is administered by injection, an ampoule of sterile diluent can be provided so that the ingredients may be mixed prior to administration.

In a specific embodiment, a lyophilized immunologically active ingredient and one or more chemokine polypeptide(s) of the invention are provided in a first container; a second container comprises diluent consisting of an aqueous solution of 50% glycerin, 0.25% phenol, and an antiseptic (e.g., 0.005% brilliant green).

Many methods may be used to introduce the composition formulations of the invention; these include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal routes, and via scarification (scratching through the top layers of skin, e.g., using a bifurcated needle).

The DNA vaccines of the invention can be administered by any method known in the art for delivery of DNA to subject (for example, as described in Section 5.3 supra)

5.4. DETERMINATION OF COMPOSITION EFFICACY

The activity of one or more chemokines, or a fragment, derivative or analogue thereof, to enhance immune response to an antigen can be determined by monitoring the immune response in test animals following immunization with a composition containing the chemokine(s) and an antigen and comparing the response to that following immunization with the antigen in the absence of the chemokine(s). Generation of a humoral (antibody) response and/or cell-mediated immunity, may be taken as an indication of an immune response. Test animals may include mice, hamsters, dogs, cats, monkeys, rabbits, chimpanzees, etc., and eventually human subjects. Assays for humoral and cell-mediated immunity are well known in the art.

Methods of introducing the composition may include oral, intracerebral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal or any other standard routes of immunization. The immune response of the test subjects can be analyzed by various approaches well known in the art, such as but not limited to: testing the reactivity of the resultant immune serum to the antigen of the chemokine-containing vaccine, as assayed by known techniques, e.g., immunosorbant assay (ELISA), immunoblots, radioimmunoprecipitations, etc.

As one example of suitable animal testing, a composition of the present invention may be tested in mice for the ability to enhance an antibody response to an antigen (using for example, but not limited to, the method as described in Section 6, *infra*) and the delayed-type hypersensitivity (DTH) response (also described in Section 6 *infra*), measured by an increase in footpad swelling after inoculation in the footpad of the test animal, as compared to the measurements in animals administered the antigen in a composition not containing chemokine. For example, as test animals BALB/c mice may be used. The test group each receives an inoculation with fixed amount of antigen and varying amount of one or more chemokines. The control group receives an inoculation of comparable amount of antigen alone.

Serum samples may be drawn from the mice after the final inoculation (for example every one or two weeks after inoculation), and serum is analyzed for antibodies against the antigen using known methods in the art, e.g., using an ELISA. DTH responses to the antigen may be measured after the final inoculation (e.g. within 1-7 days). An increase in the serum titer of antibodies recognizing the antigen and/or

an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokine(s) as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing the chemokine(s), indicates that the chemokine(s) enhance the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing the chemokines as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing chemokine(s), indicates that the chemokine(s) enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen. An increase in the serum titer of antibodies recognizing the antigen and/or an increase in footpad swelling in the animals receiving the antigen-compositions containing MDC as compared to the serum titer of antibodies against the antigen and/or the footpad swelling in the animals receiving the antigen composition not containing MDC, indicates that the MDC enhances the immune response to antigen.

6. EXAMPLE: IMMUNIZATION WITH MDC-CONTAINING COMPOSITION

The following experiment illustrates the evaluation of whether MDC will act as an adjuvant for a protein antigen and enhance the efficacy of a vaccine. However, it will be appreciated that the description applies equally to other chemokines and combinations of chemokines.

6.1. MATERIALS AND METHODS

6.1.1. ANIMALS AND REAGENTS

BALB/c mice are purchased from Harlan-Sprague-Dawley (Indianapolis, IN).

Human MDC (hMDC) was obtained from CD8⁺ T cell clones immortalized *in vitro* prepared as previously described (Markham et al., 1983 *Int. J. Cancer* 31:413; Markham et al. 1984, *Int. J. Cancer* 33:13). One such immortalized CD8⁺ T cell clone, F3b Clone 19, was adapted to growth in serum-free medium by the following procedure and used for further studies. F3b Clone 19 cells were grown in complete medium containing rIL-2 (16 ng/ml) at 37°C in a CO₂ incubator. After expanding the culture to 200 ml, the cells were pelleted and resuspended in RPMI medium containing HB101 (Irvine Scientific) supplemented with 16 ng/ml of rIL-2, 1% glutamine and 1% penicillin/streptomycin. The cells were grown to full confluence and the medium harvested by centrifugation at 670 x g for 10 minutes.

Human MDC (hMDC) was purified from F3b Clone 19 as described in Pal et al., 1997, *Science* 278:695-698. Briefly, the cell free culture supernatant from F3b Clone 19 was clarified by high speed centrifugation and fractionated by heparin affinity chromatography, taking advantage of the heparin binding characteristics of chemokines (Witt and Lander, 1994, *Current Biology* 4:394; Proost et al., 1996, *Method: A Companion to Methods in Enzymology* 10:82). Culture supernatant (1200 ml) from F3b Clone 19, grown to high cell density in serum-free medium supplemented with rIL-2 was clarified by high speed centrifugation (100,000 x g for 60 minutes at 4°C) and applied to a 5 ml HiTrap heparin affinity FPLC column (Pharmacia) equilibrated in 10 mM Tris-HCl, pH 7.6 containing 0.1 M NaCl (column buffer). The column was then washed extensively with column buffer and the bound proteins eluted from the column with 10 mM Tris-HCl, pH 7.6 containing 2.0 M NaCl at a flow rate of 0.5 to 1 ml/minute. Virtually all of the HIV suppressive activity effective against primary NSI and SI isolates and HIV-1^{IIIb} was recovered in the column eluate (data not shown). The heparin affinity column eluate was brought to pH 2.0 by addition of trifluoroacetic acid (TFA) and subjected to reversed phase HPLC on a PEEK C-18 column (Waters Instruments) equilibrated in H₂O containing 0.1 % TFA. Proteins bound to the column were eluted with a 5 minute linear gradient of aqueous acetonitrile (0 to 35 %) containing 0.1% TFA. After 10 minutes at 35% acetonitrile, the column was further developed with a 60 minute linear gradient of 35-70% aqueous acetonitrile in TFA. The flow rate was maintained at 0.5 to 1 ml/minute. The fractions obtained were then tested for suppressor activity in the acute infectivity assay using HIV-1^{IIIb}. Active fractions were pooled, diluted twofold in H₂O with 0.1 % TFA

and reapplied to the column. The column was then developed with a 30 minute linear aqueous acetonitrile gradient (0-60%) containing 0.1% TFA at a flow rate of 0.5 to 1 ml/minute. The fractions obtained were assayed as above. Active fractions were pooled, diluted with H₂O/0.1 % TFA and fractionated under the same conditions to obtain a single protein peak. The fraction corresponding to the peak and flanking fractions were tested in the infectivity assay to verify that suppressor activity was cofractionated with the protein.

Suppressive activity against HIV-1^{IIIb} in the absence of cytotoxic effects consistently copurified with a single protein peak that appeared as a homogeneous 8 kDa band when analyzed by SDS-polyacrylamide gel electrophoresis. This protein was not reactive in ELISAs for RANTES, MIP-1 α or MIP-1 β (R&D Systems).

Recombinant gp120 protein derived from HIV-1 IIIB isolate is purchased from Intracel (Foster City, CA).

6.1.2 IMMUNIZATION OF MICE

The hMDC and the gp120 is resuspended in a total volume of 50 μ l of phosphate-buffered saline (PBS). Mice are divided into 5 groups with 3-4 mice in each group. Groups 1-4 are inoculated with 10 μ g gp120 and 0.3 μ g, 0.1 μ g, 0.03 μ g, and 0.01 μ g of hMDC, respectively. As a control, group 5 is inoculated with 10 μ g of gp120 in the absence of hMDC. For primary inoculation, each group of mice is inoculated with 10 μ l of the hMDC and gp120 solution via footpad. Two to three weeks after the primary inoculation, each mouse is given the same doses of hMDC/gp120 that is used in primary inoculation.

6.1.3 ELISA ASSAY

Serum samples are collected one week after the second inoculation via tail vein bleed. gp120 serum responses are measured using standard gp120 antibody ELISA assays.

6.1.4 DTH ASSAY

The delayed-type hypersensitivity (DTH) response is measured from 1-7 days after the second inoculation. A caliper is to be used to measure footpad swelling.

6.2. RESULTS

Mice inoculated with hMDC/gp120 are expected to have greater serum antibody and DTH responses than mice inoculated with gp120 alone. The improved responses will be reflected in either increased titers of serum antibody responses or increased footpad swelling. A dose response effect is expected - increasing the dose of hMDC used is expected to cause a corresponding improvement in the serum and DHT gp120-specific responses.

7. EXAMPLE: OTHER CHEMOKINES AND COMBINATIONS OF CHEMOKINES

The foregoing experiments can be repeated using other chemokines and combinations of chemokines. For example, the experiments are preferably repeated using one or more chemokines selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

Various references are cited herein, the disclosures of which are incorporated by reference in their entireties.

THE CLAIMS:

1. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject an immunogenic amount of one or more purified antigens against which an immune response is desired in the subject and an amount of one or more chemokines, or purified fragments or derivatives thereof, effective to enhance the efficacy of said vaccine.
2. The method of claim 1, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
3. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-

regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

4. The method of claim 1, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
5. The method of claim 1 wherein the fragment(s) or derivative(s) are truncation isoforms.
6. The method of claim 1, wherein the one or more chemokines include MDC comprising the amino acid sequence of SEQ ID NO: 2.
7. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
8. The method of claim 1, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2., which derivative has activity to enhance the efficacy of the vaccine.
9. The method of claim 1, wherein the one or more chemokine derivatives has one or more insertions or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
10. The method of claim 1, including a chemokine derivative having one or more conservative substitutions in sequence relative a wildtype MDC, which derivative has activity to enhance the efficacy of the vaccine.
11. The method of claim 1, wherein the one or more chemokines include a human chemokine.

12. The method of claim 1, wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof is/are administered concurrently with the purified antigen(s).
13. The method of claim 1 wherein the purified chemokine(s) or purified fragment(s) or derivative(s) thereof, are administered within a time period before or after administration of the purified antigen, which time period permits the purified MDC or purified fragment or derivative thereof MDC to enhance the efficacy of the vaccine.
14. The method of claim 1, wherein the antigen is an HIV antigen.
15. The method of claim 14, wherein the HIV antigen is HIV-associated gp120 protein.
16. The method of claim 1, wherein the subject is a human.
17. The method of claim 1, wherein the subject is infected or at risk of being infected with HIV virus.
18. The method of claim 1, wherein the vaccine elicits a humoral response against the antigen in the subject.
19. The method of claim 1, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
20. The method of claim 1, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
21. The method of claim 1, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.

22. A method to enhance the efficacy of a vaccine in a subject comprising administering to the subject a first amount of a first set of one or more purified nucleotide sequences encoding one or more antigens against which an immune response is desired in the subject and a second second set of one or more purified nucleic acids, each comprising a nucleotide sequence encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner upon introduction into a suitable cell, said first amount is immunogenic and said second amount is effective in enhancing the efficacy of the vaccine.
23. The method of claim 22, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
24. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine

- 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
25. The method of claim 22, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
26. The method of claim 22 wherein the fragment(s) or derivative(s) are truncation isoforms.
27. The method of claim 22, wherein the nucleotide sequence encoding one or more chemokines comprises the nucleotide sequence of SEQ ID NO:1.
28. The method of claim 22, wherein one or more of the chemokine derivative(s) have deletional, insertional or substitutional mutations and combination thereof, which derivative has activity to enhance the efficacy of the vaccine.
29. The method of claim 22, wherein the vaccine elicits a humoral response against the antigen in the subject.
30. The method of claim 22, wherein the vaccine elicits a cell-mediated response against the antigen in the subject.
31. The method of claim 22, wherein the vaccine elicits both a humoral and a cell-mediated response against the antigen in the subject.
32. The method of claim 22, wherein the vaccine further comprises pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
33. A composition comprising: an immunogenic amount of one or more purified antigens and an amount of one or more purified chemokines, or purified

fragments or derivatives thereof, effective to enhance the immune response to said antigen(s); and a pharmaceutically acceptable carrier.

34. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.

35. The composition of claim 33, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.

36. The composition of claim 33, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine, Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIG, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating

- protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.
- 37. The composition of claim 33, wherein the fragment(s) or derivative(s) are truncation isoforms.
- 38. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2.
- 39. The composition of claim 33, wherein the one or more chemokine fragment includes an MDC fragment selected from the group consisting of amino acid numbers 2-69, 3-69, 5-69, 7-69 and 9-69 of SEQ ID NO: 2, which derivative has activity to enhance the efficacy of the vaccine.
- 40. The composition of claim 33, wherein the one or more chemokine derivatives has one or more insertions of or substitutions with one or more non-classical amino acids relative to a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
- 41. The composition of claim 33, wherein the one or more chemokine derivatives has one or more conservative substitutions in sequence relative a corresponding wildtype chemokine, which derivative has activity to enhance the efficacy of the vaccine.
- 42. The composition of claim 33, wherein the chemokine is a human chemokine.
- 43. The composition of claim 33, wherein the antigen is an HIV antigen.
- 44. The composition of claim 43, wherein the antigen is HIV associated gp120 protein.
- 45. A composition comprising an amount of a first set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more antigens

- and a second set of purified nucleic acids comprising one or more nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s), or fragment(s) or derivative(s) thereof, are expressed from said first set of nucleic acid(s) and second set of nucleic acid(s) in a coordinated manner such that upon introduction into a suitable cell, the amount of said first set of nucleic acid(s) is sufficient to express an immunogenic amount of the antigen and the amount of the said second set of nucleic acid(s) is effective in enhancing the efficacy of the vaccine; and a pharmaceutically acceptable carrier.
- 46. The composition of claim 45, wherein the chemokine is MDC and the nucleic acid encoding the MDC comprises the nucleotide sequence of SEQ ID NO: 1.
- 47. The composition of claim 45, wherein the chemokine derivative(s) have deletional, insertional or substitutional mutations and/or combinations thereof, and the derivative(s) have activity to enhance the efficacy of the vaccine.
- 48. The composition of claim 45, further comprising pharmaceutically acceptable excipient, auxiliary substance, adjuvant, wetting or emulsifying agent, or pH buffering agent.
- 49. A composition comprising a first set of purified nucleotide sequences encoding one or more antigens and a second set of purified nucleotide sequences encoding one or more chemokines, or fragments or derivatives thereof, wherein the antigen(s) and the chemokine(s) are expressed in a coordinated manner such that upon introduction into a suitable cell, the sets produce an amount of said antigen(s) that is immunogenic and an amount of chemokine(s), or fragment(s) or derivative(s) thereof, that is effective in enhancing the efficacy of the vaccine relative to a corresponding vaccine composition without such chemokine(s), fragment(s) or derivative(s) thereof.
- 50. The composition of claim 49, wherein the one or more chemokines are selected from the group consisting of: Macrophage-derived chemokine,

Monocyte chemotactic protein 1, Monocyte chemotactic protein 2, Monocyte chemotactic protein 3, Monocyte chemotactic protein 4, activated macrophage specific chemokine 1, Macrophage inflammatory protein 1 alpha, Macrophage inflammatory protein 1 beta, Macrophage inflammatory protein 1 gamma, Macrophage inflammatory protein 1 delta, Macrophage inflammatory protein 2 alpha, Macrophage inflammatory protein 3 alpha, Macrophage inflammatory protein 3 beta, Regulated upon activation, normal T cell expressed and secreted (and its variants), I-309, EBI1-ligand chemokine, Pulmonary and activation regulated chemokine, Liver and activation-regulated chemokine, Thymus and activation regulated chemokine, Eotaxin (and variants), Human CC chemokine 1, Human CC chemokine 2, Human CC chemokine 3, IL-10-inducible chemokine, liver-expressed chemokine, 6Ckine, Exodus 1, Exodus 2, Exodus 3, thymus-expressed chemokine, Secondary Lymphoid tissue chemokine, Lymphocyte and Monocyte chemoattractant; Monotactin, Activation-induced, chemokine-related molecule, Myeloid progenitor inhibitory factor-1, Myeloid progenitor inhibitory factor-2, Stromal cell-derived factor 1 alpha, Stromal cell-derived factor 1 beta, B-cell-attracting chemokine 1, HuMIC, H174, Interferon-stimulated T-cell alpha chemoattractant, Interleukin-8, IP-10, platelet factor 4, growth-regulated gene-alpha, growth-regulated gene-beta, growth-regulated gene-gamma, Neutrophil-activating protein 2, ENA-78, granulocyte chemotactic protein 2, LYMPHOTACTIN, and Fractalkine/neurotactin.

51. The method of claim 49, wherein the one or more chemokines are selected from a chemokine class selected from the group consisting of: CC, CXC, C-C and CX3C.
52. The method of claim 49, wherein the one or more chemokines are selected from the group consisting of: MDC, SDF-1, BLC, and MCP-1.
53. The composition of claim 49, wherein the fragment(s) or derivative(s) are truncation isoforms.

- 54. The composition of claim 49, wherein the nucleic acid is administered directly to the subject.
- 55. The composition of claim 49, wherein the nucleic acid is introduced into a suitable host cell and said suitable host cell is introduced into the subject.

GAGACATACA	GGACAGAGC	ATG	GCT	CGC	CTA	CAC	ACT	GCA	CTC	CTG	GTT	GTC	52
Met	Ala	Arg	Leu	Gln	Thr	Ala	Leu	Leu	Val	Val			
-24			-20			-10			-5				
CTC	GTC	CTC	CTT	GCT	GTG	GGC	CTT	CAA	GCA	ACT	GAG	GCA	100
Leu	Val	Leu	Ala	Val	Ala	Leu	Gln	Ala	Thr	Glu	Ala	Gly	
GGC	GCC	AAC	ATG	GAA	GAC	AGC	GTC	TGC	CGT	GAT	TAC	CGT	148
Gly	Ala	Asn	Met	Glu	Asp	Ser	Val	Cys	Cys	Arg	Asp	Tyr	
5													
CGT	CTG	CCC	CTG	CGC	GTG	AAA	CAC	TTC	TAC	TGG	ACC	TCA	196
Arg	Leu	Pro	Leu	Arg	Val	Val	Lys	His	Phe	Tyr	Trp	Thr	
20													
TGC	CCG	AGG	CCT	GGC	GTG	TTG	CTA	ACC	TTC	AGG	GAT	AAG	244
Cys	Pro	Arg	Pro	Gly	Val	Val	Leu	Leu	Thr	Phe	Arg	Asp	
40													
TGT	GCC	GAT	CCC	AGA	GTG	CCC	TGG	GTG	AAG	ATG	ATT	CTC	292
Cys	Ala	Asp	Pro	Arg	Val	Pro	Trp	Val	Lys	Met	Ile	Leu	
55													

AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCCTCCA GGAAAGGCTCA	348
Ser Gln	
GGAGGCCCTAC CTCCCTGCCA TTATAGCTGC TCCCCGCCAG AAGCCTGTGC CAACTCTCTG	408
CATTCCCTGA TCTCCATCCC TGTGGCTGTC ACCCTTGTC ACCTCCGTGC TGTCACTGCC	468
ATCTCCCCC TGACCCCTCT AACCCATCT CTGCCCTCCCT CCCTGCAGTC AGAGGGTCCCT	528
GTTCCTCA GCGATTCCCC TGCTTAAACC CTTCATGAC TCCCCACTGC CCTAAGCTGA	588 2/6
GGTCAGTCTC CCAAGCCCTGG CATGGGCC TCTGGATCTG GTTCCATCT CTGTCTCCAG	648
CCTGCCCACT TCCCTTCATG AATGTTGGT TCTAGCTCCC TGTCTCCAA ACCCATACTA	708
CACATCCCAC TTCTGGGTCT TTGCCCTGGGA TTGCTGTC ACTCAGAAAG TCCCACCCACC	768
TGCACATGTG TAGCCCCACC AGCCCTCCAA GGCAATTGCTC GCCCAAGCAG CTGGTAATTG	828
CATTCATGT ATTAGATGTC CCCTGGCCCT CTGTCCCCCT TTAATAACCC TAGTCACAGT	888
CTCCGCAGAT TCTTGGGAT TGGGGTTT CTCCCCCACC TCTCCCACTAG TTGGACCAAG	948

FIG. 1A-2

<u>GTTTCTAGCT</u>	<u>AAGTTACTCT</u>	<u>AGTCTCCAAG</u>	<u>CCTCTAGCAT</u>	<u>AGAGGCACTGCG</u>	<u>AGACAGGGCC</u>	1008
TGGCTCAGAA	TCAGAGCCC	GAAAGTGGCT	GCAGACAAAA	TCAATAAAC	TAATGTCCT	1068
CCCCTCTCCC	TGCCAAAGG	CAGTTACATA	TCAATAACAGA	GACTCAAGGT	CACTAGAAAT	1128
GGGCCAGCTG	GGTCAATGTG	AAGCCCCAA	TTTGCAGA	TTCACCTTTC	TTCCCCCACT	1188
CCCTTTTTT	TTTTTTTTT	TTTGAGATGG	AGTTTCGCTC	TTGTCACCCA	CGCTGGAGTG	1248
CAATGGTGTG	GTCTTGGCTT	ATTGAAGCCT	CTGCCCTCCTG	GGTTCAAGTG	ATTCTCTTGC	1308 3/6
CTCAGCCCTCC	TGAGTAGCTG	GGATTAACAGG	TTCTGTCTAC	CACGCCAGC	TAATTTTTGT	1368
ATTTTTAGTA	GAGACGAGGC	TTCACCATGT	TGGCCAGGCT	GGTCTCGAAC	TCCCTGTCCTC	1428
AGGTAATCCG	CCCACCTCAG	CCTCCAAAG	TGCTGGGATT	ACAGGGTGA	GCCACAGTGC	1488
CTGGCCTCTT	CCCTCTCCCC	ACTGCCCTCC	CCAACTTTT	TTTTTTTT	ATGGCAGGGT	1548
CTCACTCTGT	CGCCCAAGGCT	GGAGTGCAGT	GGCGTGATCT	CGGCTCACTA	CAACCTCGAC	1608
<u>CTCCCTGGGTT</u>	<u>CAAGTGATTCT</u>	<u>TCCCAACCCAA</u>	<u>GCCTCCCAAG</u>	<u>TACAGGGAT</u>	<u>TACAGGGTGTG</u>	<u>1668</u>

FIG. 1A-3

TGCCACTAAC GCTGGCTAAT TTTGTATTT TAGTAGAGA CAGGGTTTCAC CATAATTGGCC 1728
 AGGCTGGTCT TGAACCTCCTG ACCTCAAGTG ATCCACCTTC CTTGTCCTCC CAAAGTGGCTC 1788
 AGATTACAGG CGTGAGCTAT CACACCCAGC CTCCCCCTT TTTCTTAAT AGGAGACTCC 1848
 TGTACCTTTC TCGTTTAC CTATGTCG TGTCGCTTA CATTTCCTTC TCCCCTCAGG 1908
 CTTTTTGG GTGGTCCCTC AACCTCCAA ACCCAGGCCT GGCCTCTTCA GAGTACCCCC 1968
 CATTCCACTT TCCCTGCCTC CTTCCTTAA TAGCTGACAA TCAAATTCA GCTATGGTGT 2028
 GAAAGACTAC CTTTGACTTG GTATTATAAG CTGGAGTTAT ATATGTTATT GAAAACAGAG 2088
 TAAATACTTA AGAGGCCAA TAGATGAATG GAAGAATTG AGGAACCTGTG AGAGGGGAC 2148
 AAGGTGAAGC TTTCCTGGCC CTGGGAGGAA GCTGGCTGTG GTAGCGTAGC GCTCTCTC 2208
 TCTGTCTGTG GCAGGAGCCA AAGAGTAGGG TGTAAATTGAG TGAAGGAATC CTGGGTAGAG 2268
 ACCATTCTCA GGTGGTTGGG CCAGGCTAAA GACTGGGAGT TGGGTCTATC TATGCCTTTC 2328
TGGCTGATT TTGTAGAGAC GGGGTTT.TGC CATGTTACCC AGGCTGGTCT CAAACCTCTG 2388

4/6

FIG. IA-4

GGCTCAAAGCG	ATCCTCTGG	CTCAGGCCCTCC	CAAAGTGTCTG	GGATTACAGG	CGTGAATCAC	2448
TGGGCCCTGGC	TTCCCTCTTCC	TCTTGAGAAA	TATTCTTTTC	ATACAGCAAG	TATGGGACAG	2508
CAGTGTCCCA	GGTAAGGAC	ATAAAATGTTA	CAAGTGTCTG	GTCCTTCTG	AGGGAGGCTG	2568
GTGCCGCTCT	GCAGGGTATT	TGAACCTGTG	GAATTGGAGG	AGGCCATTTC	ACTCCCTGAA	2628
CCCAGCCTGA	CAAATCACAG	TGAGAATGTT	CACCTTATAG	GCTTGCTGTG	GGGCTCAGGT	2688
TGAAAGTGTG	GGGAGGTGACA	CTGCCCTAGGC	ATCCAGCTCA	GTGTCAATCCA	GGGCCCTGTGT	27486
CCCTCCCGAA	CCCAGGGTCA	ACCTGCCCTGC	CACAGGCACT	AGAAGGACGA	ATCTGCCCTAC	2808
TGCCCATGAA	CGGGGCCCTC	AAGGCGTCCCTG	GGATCTCCCT	CTCCCTCCCTG	TCCTGTCCCTT	2868
GCCCCTCAGG	ACTGCTGGAA	AATAAATCCT	TTAAAATAGT	AAAAAA	AAAAA	2923

FIG. IA-5

FIG. IA-1
FIG. IA-2
FIG. IA-3
FIG. IA-4
FIG. IA-5

FIG. IA

6/6

Met Ala Arg Leu Gln Thr Ala Leu Leu Val Val Leu Val Leu Leu Ala
-24 -20 -15 -10
Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr Gly Ala Asn Met Glu
-5 1 5
Asp Ser Val Cys Cys Arg Asp Tyr Val Arg Tyr Arg Leu Pro Leu Arg
10 15 20
Val Lys His Phe Tyr Tyr Trp Thr Ser Asp Ser Cys Pro Arg Pro Gly
25 30 35 40
Val Val Leu Leu Thr Phe Arg Asp Lys Glu Ile Cys Ala Asp Pro Arg
45 50 55
Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu Ser Gln
60 65

FIG. 1B

SEQUENCE LISTING

(1) GENERAL INFORMATION

(i) APPLICANT: Gallo, Robert C.
DeVico, Anthony L.
Garzino, Alfredo

(ii) TITLE OF THE INVENTION: METHOD AND COMPOSITION TO ENHANCE THE EFFICACY OF A VACCINE USING MACROPHAGE DERIVED CHEMOKINE

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Pennie & Edmonds LLP
(B) STREET: 1155 Avenue of the Americas
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: USA
(F) ZIP: 10036/2711

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Diskette
(B) COMPUTER: IBM Compatible
(C) OPERATING SYSTEM: DOS
(D) SOFTWARE: FastSEQ Version 2.0

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER: To be assigned
(B) FILING DATE: Herewith
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Misrock, S. Leslie
(B) REGISTRATION NUMBER: 18,872
(C) REFERENCE/DOCKET NUMBER: 8769-029

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-790-9090
(B) TELEFAX: 212-869-8864
(C) TELEX: 66141 PENNIE

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2923 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: mat_peptide
(B) LOCATION: 92..298

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GAGACATACA GGACAGAGC ATG GCT CGC CTA CAG ACT GCA CTC CTG GTT GTC	52
Met Ala Arg Leu Gln Thr Ala Leu Val	
-24 -20 -15	
CTC GTC CTC CTT GCT GTG GCG CTT CAA GCA ACT GAG GCA GGC CCC TAC	100
Leu Val Leu Ala Val Ala Leu Gln Ala Thr Glu Ala Gly Pro Tyr	
-10 -5 1	
GGC GCC AAC ATG GAA GAC AGC GTC TGC CGT GAT TAC GTC CGT TAC	148
Gly Ala Asn Met Glu Asp Ser Val Cys Arg Asp Tyr Val Arg Tyr	
5 10 15	
CGT CTG CCC CTG CGC GTG AAA CAC TTC TAC TGG ACC TCA GAC TCC	196
Arg Leu Pro Leu Arg Val Lys His Phe Tyr Trp Thr Ser Asp Ser	
20 25 30 35	
TGC CCG AGG CCT GGC GTG TTG CTA ACC TTC AGG GAT AAG GAG ATC	244
Cys Pro Arg Pro Gly Val Leu Thr Phe Arg Asp Lys Glu Ile	
40 45 50	
TGT GCC GAT CCC AGA GTG CCC TGG GTG AAG ATG ATT CTC AAT AAG CTG	292
Cys Ala Asp Pro Arg Val Pro Trp Val Lys Met Ile Leu Asn Lys Leu	
55 60 65	
AGC CAA TGAAGAGCCT ACTCTGATGA CCGTGGCCTT GGCTCCTCCA GGAAGGCTCA	348
Ser Gln	

GGAGCCCTAC	CTCCCTGCCA	TTATAGCTGC	TCCCCGCCAG	AAGCCTGTGC	CAACTCTCTG	408
CATTCCCTGA	TCTCCATCCC	TGTGGCTGTC	ACCCCTGGTC	ACCTCCGTGC	TGTCACTGCC	468
ATCTCCCCC	TGACCCCTCT	AACCCATCCT	CTGCCCTCCCT	CCCTGCAGTC	AGAGGGTCT	528
GTTCCCATCA	GCGATTCCTCC	TGCTTAAACC	CTTCCATGAC	TCCCCACTGC	CCTAAGCTGA	588
GGTCAGTCTC	CCAAGCCTGG	CATGGATCTG	TCTGGATCTG	GGTCCATCT	CTGTCCTCAG	648
CCTGCCACT	TCCCTTCATG	AAATGGGGT	TCTAGCTCCC	TGTTCTCCAA	ACCCATACTA	708
CACATCCCAC	TTCTGGGTCT	TTGCTGGGA	TGTTGCTGAC	ACTCAGAAAG	TCCCACCAAC	768
TGCACTATG	TAGCCCCCACC	AGCCTCCAA	GGCATTGCTC	GCCCAAGCAG	CTGGTAATT	828
CATTTCATGT	ATTAGATGTC	CCCTGGCCCT	CTGTCCTCTC	TTAATAACCC	TAGTCACAGT	888
CTCCGCAGAT	TCTGGGATT	TTGGGTTTT	CTCCCCCACC	TCTCCACTAG	TTGGACCAAG	948
GTTTCTAGCT	AAAGTACTCT	AGTCTCCAA	CCTCTAGCAT	AGAGCACTGC	AGACAGGCC	1008
TGGCTAGAA	TCAGAGCCCA	GAAAGTGGCT	GCAGACAAAA	TCAATAAAAC	TAATGTCCCT	1068
CCCCCTCTCC	TGCAAAAGG	CAGTTACATA	TCAATACAGA	GACTCAAGGT	CACTAGAAAT	1128
GGGCCAGCTG	GGTCAATGTC	AAGGCCCCAAA	TTTGCCAGA	TTCACCTTT	TTCCCCCACT	1188
CCCTTTTTT	TTTTTTTTT	TTTGAGATGG	AGTTTCGCTC	TTGTCACCCA	CCGCTGGAGTG	1248
CAATGGTGTG	GTCTGGCTT	ATTGAAGCT	CTGCCCTCTG	GGTCAAGTG	ATTCTCTTGC	1308
CTCAGCTCTC	TGAGTAGCTG	GGATTACAGG	TTCCCTGCTAC	CACGCCAGC	TAATTTTGT	1368
ATTTTGTAGT	GAGACGAGGC	TTCACCATG	TGGCCAGGCT	GGTCTCGAAC	TCCTGTCCCTC	1428
AGGTAATCCG	CCACCTCAG	CCTCCCAAAG	TGCTGGATT	ACAGCGCTGA	GCCACAGTGC	1488
CTGGCCTCTT	CCCTCTCCCC	ACTGCCCTCC	CCAATT	TTTTTTTTT	ATGGCAGGGT	1548
CTCACTCTGT	CGCCCAGGCT	GGAGTGCAGT	GGCGTGTACT	CGGCTACTA	CAACCTCGAC	1608
CTCCTGGGT	CAAATGATTC	TCCCACCCCA	GCCTCCCAAG	TAGCTGGGAT	TACAGGTGTG	1668
TGCCACTACG	GCTGCTTAAT	TTTGTTATT	TTAGTAGAGA	CAGGTTTCAC	CATATTGGCC	1728
AGGCTGGTCT	TGAACCTCTG	ACCTCAAGTG	ATCCACCTTC	CTTGTGCTCC	CAAAGTGTG	1788
AGATTACAGG	CGTGAGCTAT	CACACCCAGC	CTCCCCCTT	TTTCTCTTAAT	AGGAGACTCC	1848
TGTACCTTTC	TTCGTTTAC	CTATGTGTG	TGTCTGCTTA	CATTCTCTC	TCCCCTCAGG	1908
CTTTTTTGG	GTGGCTCTCC	AACCTCCAAAT	ACCCAGGCT	GGCCTCTTCA	GAGTACCCCC	1968
CATTCACTT	CTCTGCTCTC	CTTCTCTAA	TAGCTGACAA	TCAATTCAT	GCTATGGTGT	2028
GAAAGACTAC	CTTGTACTTG	GTATTATAAG	CTGGAGTTAT	ATATGTTATT	GAAAACAGAG	2088
TAAATACTTA	AGAGGCCAA	TAGATGAATG	GAAGAATT	AGGAACACTG	AGAGGGGAC	2148
AAGGTGAAGC	TTCTCTGGCC	CTGGGAGGAA	GCTGGCTGTG	GTAGGCTAGC	GCTCTCTCTC	2208
TCTGTCTGTG	GCAGGAGCCA	AAGAGTAGGG	TGTAATTGAG	TGAAGGAATC	CTGGGTAGAG	2268
ACCATTCTCA	GGTGGTTGGG	CCAGGCTAA	GACTGGGAGT	TGGGTCTATC	TATGCCCTTC	2328
TGGCTGATT	TTGTAGAGAC	GGGGTTTGC	CATGTTACCC	AGGCTGGTCT	CAAACCTCTG	2388
GGCTCAAGCG	ATCCTCTGG	CTCAGCTCC	CAAAGTGTG	GGATTACAGG	CGTGAATCAC	2448
TGCGCTCTG	TTCTCTTCC	TCTTGAGAAA	TATTCTCTC	ATACAGCAAG	TATGGGACAG	2508
CAGTGTCTCA	GGTAAAGGAC	ATAAAATGTTA	CAAGTGTCTG	GTCCTCTG	AGGGAGGCTG	2568
GTGCCGCTCT	GCAGGGTATT	TGAACCTGTG	GAATTGGAGG	AGGCCATTTC	ACTCCTCTGAA	2628
CCCAGCTGA	CAAATCACAG	TGAGAATGTT	CACCTTATAG	GCTTGTGTG	GGGCTCAGGT	2688
TGAAAGTGTG	GGGAGTGTAC	CTGCCCTAGGC	ATCCAGCTCA	GTGTCTATCA	GGGCCTGTGT	2748
CCCTCCGAA	CCCAGGGTCA	ACCTGCCCTG	CACAGGCACT	AGAAGGACGA	ATCTGCCTAC	2808
TGCCCCATGAA	CGGGGCCCTC	AAGCGTCTG	GGATCTCTT	CTCCCTCTG	TCCCTGTCTT	2868
GCCCTCTAGG	ACTGCTGAA	ATAAAATCCT	TTAAAATAGT	AAAAAAA	AAAAA	2923

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 93 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Ala	Arg	Leu	Gln	Thr	Ala	Leu	Val	Leu	Val	Leu	Ala			
-24				-20				-15				-10			
Val	Ala	Leu	Gln	Ala	Thr	Glu	Ala	Gly	Pro	Tyr	Gly	Ala	Asn	Met	Glu
								-5				5			
Asp	Ser	Val	Cys	Arg	Asp	Tyr	Val	Arg	Tyr	Arg	Leu	Pro	Leu	Arg	
								10				20			
Val	Lys	His	Phe	Tyr	Trp	Thr	Ser	Asp	Ser	Cys	Pro	Arg	Pro	Gly	
								25				35			40
Val	Leu	Thr	Phe	Arg	Asp	Lys	Glu	Ile	Cys	Ala	Asp	Pro	Arg		
								45				50			55
Val	Pro	Trp	Val	Lys	Met	Ile	Leu	Asn	Lys	Leu	Ser	Gln			
								60				65			

C-CHEMOKINES

LYMPHOTACTIN

(SCM-1)

D63789 D63790

CX3C-chemokines
Fractalkine/neurotactin

U91835 U84487

LOCUS HSU83171 2923 bp mRNA
 DEFINITION Human macrophage-derived chemokine precursor (MDC) mRNA,
 complete
 ACCESSION U83171
 NID g1931580
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2923)
 AUTHORS Godiska, R., Chantry, D., Raport, C.J., Sozzani, S., Allavena, P.,
 Leviten, D., Mantovani, A. and Gray, P.W.
 TITLE Human macrophage-derived chemokine (MDC), a novel
 chemoattractant for monocytes, monocyte-derived dendritic cells, and natural
 killer cells
 JOURNAL J. Exp. Med. 185 (9), 1595-1604 (1997)
 MEDLINE 97296313
 REFERENCE 2 (bases 1 to 2923)
 AUTHORS Godiska, R. and Gray, P.W.
 TITLE Direct Submission
 JOURNAL Submitted (23-DEC-1996) ICOS Corporation, 22021 20th Avenue SE,
 Bothell, WA 98021, USA
 FEATURES Location/Qualifiers
 source 1..2923
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="16"
 gene 20..301
 /gene="MDC"
 sig_peptide 20..91
 /gene="MDC"
 CDS 20..301
 /gene="MDC"
 /function="chemotactic for dendritic cells and natural
 killer cells"
 /codon_start=1
 /product="macrophage-derived chemokine precursor"
 /db_xref="PID:g1931581"
 /translation="MARLQTALLVVLVLLAVALQATEAGPYGANMEDSVCCR DYVRYR
 LPLRVVKHFYWTSDSCP RPGVLLTFRDKEICADPRVPWVKMILNKL SQ"
 mat_peptide 92..298
 /gene="MDC"
 repeat_region /product="macrophage-derived chemokine"
 complement(1194..1805)
 repeat_region /rpt_family="ALU"
 complement(2335..2443)
 /rpt_family="ALU"
 BASE COUNT 605 a 861 c 669 g 788 t
 ORIGIN
 1 gagacataca ggacagagca tggctcgctt acagactgca ctccctggttg tccctcgctt
 61 ctttgcgtgt ggcgttcaag caactggggc agggccctac ggcgccaaca tggaaagacag
 121 cgtctgtgc cgtgattacg tccgttaccc tctggccctg cgcgtgggtga aacacttcta
 181 ctggacctca gactcctgcc cgaggcctgg cgtgggtgtt ctaacacctca gggataagga
 241 gatctgtcc gatcccagag tggccctgggt gaagatgatt ctaataaagc tgagccaaatg
 301 aaggacctac tctgtatgcc gtggcccttgg ctccctccagg aaggctcagg agccctactt
 361 ccctgccatt atagctgctc cccggccagaa gcctgtgcca actctctgca ttccctgtatc
 421 tccatccctg tggctgtcac ctttggtcac ctccgtgtc tcaactggccat cttccctgtatc
 481 accccctaa cccatcccttgc gctcccttcc ctgcgttc tcaactggccat cttccctgtatc
 541 gattccctgt cttaaaccctt tccatgactc cccactgccc taagctgagg tcagtcctcc
 601 aaggctggca tggcccttc tggatctgg ttccatcttgc gtctccagcc tgcccaacttc
 661 ctttcatgaa tggcccttc tagctccctg ttctccaaac ccatactaca catcccaactt
 721 ctgggtctt gcctggatg ttgctgacac tcaaaaatgc ccacccatgc cactatgtatc
 781 gccccaccag ccctccaaagg cattgctcgc ccaagcagct ggttattcca tttcatgtatc
 841 tagatgtccc ctggcccttgc tccatgtatc aataacccta gtcacagtct ccgcagattc

901	ttgggatttg	ggggttttct	cccccaccc	tccactagtt	ggaccaagg	ttctagctaa
961	gttactctag	tctccaagcc	tctagcatag	agcactgcag	acaggccctg	gtcagaatc
1021	agagcccca	aagtggctgc	agacaaaatc	aataaaacta	atgtccctcc	ccctcccttg
1081	ccaaaaggca	gttacatatac	aatacagaga	ctcaagggtca	ctagaaaatgg	gcagctggg
1141	tcaatgtgaa	gcccccaatt	tggccagatt	cacccctttt	cccccaactc	cttttttttt
1201	ttttttttt	tgagatggag	tttgcgtctt	gtcaccac	ctggagtgtca	atggtgtgtt
1261	cttggcttat	tgaagccctt	gcctcttggg	ttcaagtgtat	tcttcgtct	cagecctcttg
1321	agttagctgg	attacaggtt	cctgttacca	cgcccageta	atttttgtat	tttagtaga
1381	gacgaggctt	caccatgttgc	gcccaggcttgc	tctcgaactc	ctgttccctag	gtaatccgc
1441	cacccatcc	tcccaaaatgt	ctgggattac	aggcgtgac	cacagtgcct	ggccttctcc
1501	ctctccccac	tgccccccccc	aacttttttt	ttttttttt	ggcagggtct	cactctgtcg
1561	cccaggctgg	agtgcagtgg	cgtgatctcg	gtcactaca	acccgcacct	cttgggttca
1621	agtgattttc	ccaccccccgc	ctcccaagta	gtctgggat	cagggtgtg	ccactacggc
1681	tggcttaattt	ttgtatTTT	atgttagagaca	gggttccacca	tattttccag	gtctggcttgg
1741	aactcttgac	ctcaatgtat	ccaccccttct	tgtgttc	aagtgtgtag	atatacaggcg
1801	tgagctatca	caccacgcct	cccccttttt	tttcttaatag	gagactcttg	taccccttttc
1861	cgttttacct	atgtgtcg	tctgttaca	tttcttcttc	ccctcaggct	ttttttgggt
1921	ggtcctccaa	cctccaaatac	ccagggcttgg	ccttccaga	gtacccccc	ttccactttc
1981	cttgccttct	tccttataata	gtcgacataatc	aaattcatgc	tatgtgtg	aaagactac
2041	ttgactttgt	attataagct	ggaggatataat	atgtattttt	aaacagagta	aataacttaaag
2101	aggccaaata	gatgaatgg	agaatTTT	gaactgtgag	agggggacaa	gttgaagctt
2161	tcttggccct	gggaggaagc	tggctgtgg	agcgtagc	tctctcttc	tgctgtggc
2221	aggagccaaa	gagtaggggt	taattgtgt	aaggaaatct	gggttagagac	catttctcagg
2281	tgggtggggc	aggctaaaaga	ctgggagtttgc	ggttatata	tgcccttctc	gtgttatttt
2341	gtagagacgg	ggttttggca	tgttacccag	gctggctca	aacttcc	ctcaagcgat
2401	cctctctggct	cagccccc	aagtgtctgg	attacaggcg	tgaatcact	cgccctggctt
2461	cctcttctc	ttggaaaata	tttttttcat	acagcaaga	tgggacac	gtgtcccaagg
2521	taaaggacat	aaatgttaca	agtgttctgg	ccttcttgag	ggaggtgtgt	gcgcgttctgc
2581	agggtatTT	aacctgttgc	atgggaggag	gccat	tcccttgc	cagcctgaca
2641	aatcacagtg	agaatgttca	ccttataaggc	ttgtgttgg	gctcagg	aaagtgtgg
2701	gagtgtacat	gccttaggc	ccagctca	gtcattccagg	gcctgtgtcc	ctcccaaaacc
2761	cagggttcaac	ctgcttgc	ccaggcactag	aaggacaa	ctgcctact	cccatgaac
2821	ggggccctcaa	ggcttcttgg	atcttcttct	cccttctgtc	ctgttcttgc	ccctcaggac
2881	tgctggaaaa	taaatctttt	aaaatagtaa	aaaaaaaaaa	aaa	aaa

```

// Locus HSU83239 932 bp mRNA PRI 02-MAY-1997
DEFINITION Human CC chemokine STCP-1 mRNA, complete cds.
ACCESSION U83239
NID g2062424
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
REFERENCE Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS 1 (bases 1 to 932)
Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D., Meng,T., Boone,T. and Andrew,D.P.
TITLE Molecular cloning and functional characterization of a novel CC
chemokine STCP-1 which specifically acts on activated T
lymphocytes
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 932)
AUTHORS Chang,M.S., McNinch,J., Elias III,C., Manthey,C.L.,
Grosshans,D., Meng,T., Boone,T. and Andrew,D.P.
TITLE Direct Submission
JOURNAL Submitted (26-DEC-1996) Research Computing, Amgen Institute,
620 University Ave, Suite 706, Toronto, ON M5G 2C1, Canada
FEATURES Location/Qualifiers
source 1..932
/organism="Homo sapiens"
/note="Amgen EST program"
/db_xref="taxon:9606"
CDS 15..296
/codon_start=1
/product="CC chemokine STCP-1"
/db_xref="PID:g2062425"

```

/translation="MARLOTA L.VVI.VI.LAVALOATEAGRYGANMEDSYCCRDYURVE

BASE COUNT 166 a 330 c 201 g 235 t

ORIGIN

LPLRVVKHFYWTSDSCPRLGVLLTFRDKEICADPRVPWVKMILNKLSQ*

1 atacaggaca gaggatggct cgccctacaga ctgcactctt ggttgccttc gtcctccttg
 61 ctgtggcgct tcaagcaact gaggcaggcc cctacggcgc caacatggaa gacagcgct
 121 gtcggcgta ttacgtccgt taccgtctgc ccctgcgcgt ggtgaaacac ttctactgga
 181 ctcagactc ctggccgagg ctggcgctgg tggtaac cttcaggat aaggagatct
 241 gtggcgatc cagatggccc tgggtgaaaga tgatttcaaa taagctgagc caatgaagag
 301 cctactctga tgaccgtgce cttggctctt ccagaaggc tgccactctt ctgcattccc tgatctccat
 361 ccattatagc tgctccccc cagaaggctg tgccactctt ctgcattccc tgatctccat
 421 ccctgtggct gtcacccctt gtcacccctt tgctgtcaact gccatctccc ccctgacccc
 481 ttcacccat ctcgtccctt ctcgtccctt gtcacccctt gtcacccat gtcacccat
 541 ccctgtttaa accccttccat gactccccc tgccttaact tgagggtcagt ctcccaagcc
 601 tggcatgtgg ccctctggat ctgggttcca tctctgttcc cagcctgccc acttcccttc
 661 atgaatgttg gggttctatcc cctgttcccaaaaccata ctacatcc cacttctggg
 721 tcttgcctt ggatgttgc gacactcaga aagttccacc acctgcacat gtgtagcccc
 781 accagccctc caaggcattt ctcgtccctt ctcgttccca ctcgttccca aatgttccacc
 841 gtcccccttgc ctcgttccctt ctcgttccca ctcgttccca aatgttccacc
 901 atttgggggt tttctccccc accttcac ta

//

LOCUS HSMCP1 725 bp . RNA PRI 03-APR-1995

DEFINITION H.sapiens mRNA for monocyte chemoattractant protein 1 (MCP-1).

ACCESSION X14768

NID g34513

KEYWORDS monocyte chemoattractant protein 1.

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

REFERENCE Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.

AUTHORS 1 (bases 1 to 725)
 Yoshimura,T., Yuhki,N., Moore,S.K., Appella,E., Lerman,M.I. and Leonard,E.J.

TITLE Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA

cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE

JOURNAL FEBS Lett. 244 (2), 487-493 (1989)

MEDLINE 89153605

COMMENT ZAPII.

FEATURES

source Location/Qualifiers

1..725

/organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="glioma cells"
 /cell_line="U105MG"
 /clone_lib="lambda"

sig_peptide 54..122

/note="signal peptide (AA -23 to -1)"

CDS 54..353

/codon_start=1
 /product="monocyte chemoattractant preprotein"
 /db_xref="PID:g34514"
 /db_xref="SWISS-PROT:P13500"

/translation="MKVSAALLCLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKIS

VQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKVVQDSMDHLDKQTQTPKT*

mat_peptide 123..350

/note="MCP-1 (AA 1 - 76)"

misc_feature 162..170

/note="pot. N-linked glycosylation site"

misc_feature 707..712

/note="pot. polyA signal"

polyA_site 725

/note="polyA site"

BASE COUNT 208 a 171 c 126 g 220 t

ORIGIN

1 ctaacccaga aacatccaaat tctcaaaactg aagctcgac ttcgtccctt agcatgaaag
 61 tctctgtccgc ctttctgtgc ctgtgtca tagcagccac ctgcattccc caagggtcgg
 121 ttcagccaga tgcataat gccccacttca cttgtgtta taacttcacc aataggaaag
 181 ttcgtgtca gaggctcgac agctatagaa gaatcaccat cagcaagtgt cccaaagaag

```

241 ctgtgatctt caagaccatt gtggccaagg agatctgtgc tgaccccaag cagaagtggg
301 ttcaggattc catggaccac ctggacaagc aaacccaaac tccgaagact tgaacactca
361 ctccacaacc caagaatctg cagctaactt atttccctt agcttcccc agacaccctg
421 ttttattttt tataatgaa ttttgttgc tgatgtgaaa cattatgcct taagtaatgt
481 taatttttat ttaagttatt gatgtttaa gtttacatctt catgttacta gtgtttttt
541 gatacagaga ctggggaaa ttgccttttcc tcttgaacca cagtcttacc cctggatgt
601 tttgagggtc ttgcagaa tcattataac aaagaatttt tttaacattt ccaatgcatt
661 gctaaatattt tattgtggaa atgaatattt tgtaactattt acacaaaata aatataattt
721 tgtac
//
LOCUS      HSMCP2      2991 bp      DNA      PRI      20-MAR-1997
DEFINITION H.sapiens MCP-2 gene.
ACCESSION  X99886
NID        g1905800
KEYWORDS   MCP-2 gene; monocyte chemotactic protein 2; SCYA10 gene.
SOURCE     human.
ORGANISM   Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
REFERENCE  Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 2991)
AUTHORS    Van Coillie,E., Fiten,P., Nomiyama,H., Sakaki,Y., Miura,R.,
Yoshie,O., Van Damme,J. and Opdenakker,G.
TITLE      The human MCP-2 gene (SCYA8): cloning, sequence analysis,
tissue
expression, and assignment to the CC chemokine gene contig on
chromosome 17q11.2
JOURNAL    Genomics 40 (2), 323-331 (1997)
MEDLINE    97237052
REFERENCE  2 (bases 1 to 2991)
AUTHORS    Opdenakker,G.M.M.
TITLE      Direct Submission
JOURNAL    Submitted (07-AUG-1996) G.M.M. Opdenakker, Rega Institute for
Medical Research, Minderbroedersstraat 10, B 3000 Leuven.
BELGIUM
FEATURES   Location/Qualifiers
source
1..2991
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="17"
/map="q11.2"
repeat_region
209..219
/note="DR-A"
/rpt_type=DIRECT
repeat_region
240..248
/note="DR-B"
/rpt_type=DIRECT
CAAAT_signal
repeat_region
296..300
310..318
/note="IR-A"
/rpt_type=INVERTED
repeat_region
406..415
/note="DR-B"
/rpt_type=DIRECT
repeat_region
407..416
/note="IR-B"
/rpt_type=INVERTED
repeat_region
425..435
/note="DR-A"
/rpt_type=DIRECT
repeat_region
429..437
/note="IR-B"
/rpt_type=INVERTED
repeat_region
455..465
/note="IR-C"
/rpt_type=INVERTED
TATA_signal
repeat_region
467..472
492..502
/note="IR-C"
/rpt_type=INVERTED
repeat_region
492..500
/note="IR-A"

```

```

/rpt_type=INVERTED
exon      534..639
/gene="MCP-2 (SCYA10)"
/number=1
gene      534..1969
/gene="MCP-2 (SCYA10)"
join(534..639,1331..1448,1864..1969)
/gene="MCP-2 (SCYA10)"
/CDS       /codon_start=1
/product="monocyte chemotactic protein-2"
/db_xref="PID:e279930"
/db_xref="PID:g1905801"



```

2401 tataatacta tggaattttt aaaaaaaaaatt tcaaaaagaa aaaaatataat ataatatataa
 2461 actacttagt ctatttcttc ttggggtaac atttagctgg gagttagttt tggggatcat
 2521 gggtagacgt ttgggcattgg acggggcatt tttcaagaat gcttctggc tacgctggac
 2581 tcaaccagg tttccatggaga acttgggtgg accaggccag gatgttccag ctctctgact
 2641 ctatggctta acttcagcag ccctgatcc ctatggctt ttgtttctt tggttata
 2701 ttatccagcc taaggatattt tggttagct gcccaaaaag actaagataa
 2761 tctaccccca accccaatcc caagaactt caagcatcca tttaaaggcg tggAACCT
 2821 tcttttgcg agccctttaa ggtcaagatt cccctgtact tagtgagctt
 2881 tcttcaaaac atgtgaccgc ccatatttgcg ccatacatac cgagcttatt
 2941 cttattggga aacacacgtt aaggcaaca aattttatgt actgttgaac c
 //LOCUS HSY16645 1368 bp mRNA PRI 25-SEP-1998
 DEFINITION Homo sapiens mRNA for monocyte chemotactic protein-2.
 ACCESSION Y16645
 NID g2916795
 KEYWORDS MCP-2 gene; monocyte chemotactic protein 2.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1368)
 AUTHORS Van Coillie,E.
 TITLE Functional comparison of two human monocyte chemotactic
 protein-2
 isoforms, role of the amino-terminal pyroglutamic acid and
 processing by CD26/dipeptidyl peptidase IV
 JOURNAL Biochemistry 37, 12672-12680 (1998)
 REFERENCE 2 (bases 1 to 1368)
 AUTHORS Van Coillie,E.
 TITLE Direct Submission
 JOURNAL Submitted (23-FEB-1998) E. Van Coillie, Rega Institute for
 Medical Research, Minderbroedersstraat 10, 3000 Leuven, BELGIUM
 COMMENT Related sequences: X99886, Y10802.
 FEATURES Location/Qualifiers
 source 1..1368
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 /tissue_type="testis"
 /clone_lib="Clontech"
 /clone="HL1142q"
 /map="q11.2"
 gene 473..772
 /gene="MCP-2"
 sig_peptide 473..541
 /gene="MCP-2"
 CDS 473..772
 /gene="MCP-2"
 /codon_start=1
 /product="monocyte chemotactic protein-2"
 /db_xref="PID:e1253690"
 /db_xref="PID:g2916796"
 /translation="MKVSAALLCLLMAATFSPQGLAQPDVSIPITCCFNVINRKIP
 IQRLESYTRITNIQCPKEAVIFKTKRGKEVCADPKERWVRDSMVKHLDQIFQNLKP"
 mat_peptide 542..769
 /gene="MCP-2"
 variation 677
 /gene="MCP-2"
 /note="polymorphism, Lys -> Gln"
 /replace="c"
 BASE COUNT 457 a 292 c 243 g 376 t
 ORIGIN
 1 atccattgtg ctctaaagtgc atggagagca ccagcaagg ctttagggccc atccctggcc
 61 tcctgttacc cacagagggg tagggcccttg gctcttcc actatgacgt cagcttccat
 121 tttcccttc tttagacaa ttccatggat caaggaaatc agagccctta atagttcgt
 181 gggctactt tgctgacac aatccccatca cttccgcctt ctgcctccaca gaggctaaac
 241 aaaagataga aacttccaaac ttcccttgcgtt tgttatccg aaattatccc agatgttgg
 301 gcttactcag catattcaag gaaggcttta cttcattttt cttgttattgt gggatcc
 361 aggctcttg ctccctataa aaggcaggca gagccaccga ggaggcagaga ggttqagaac

421 aaccaggaaaa cttcaccc tcacgtgaa gtcacaccc ttgccttcca agatgaagg
481 ttctgcagcg cttctgtgcc tgcgtctat ggcagccact ttcagccctc agggacttgc
541 tcagccagat tcagtttcca ttccaaatcac ctgtgtttt aacgtatca ataggaaaat
601 tcctatccag aggtggaga gtcacacaag aatcacaac atccaaatgtc ccaaggaagc
661 tgcgtatccc aagacccaaac gggggcaagg ggtctgtgtc gaccccaagg agagatgggt
721 caggattccc atgaagcatt tggaccaat atttcaaat ctgagccat gagcccttcat
781 acatggactg agagtcagag cttaaagaaa agttttttt ttttccccca cctccccccag
841 gtgcagtgtg acattttttt attataacat ccacaaagag atttttttta aataatttt
901 agcataat ttctaaaaaa gtattttaat atatttaaatgt tttgtatgtt ttaacttcat
961 ctgtatataa ttcttagtgaat tttttttttt tttttttttt tttttttttt
1021 tttttctgtg agtcaacta agttcacggc aaaaatgtcat tttttttttt tttttttttt
1081 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
1141 aatcagtgtc cctgtaaatgc aatgtgtgc tttttttttt tttttttttt tttttttttt
1201 ctgtatataa ctatggaaat ttggaaaaaaa aatcaaaaaaaaaa gaaaaaaaata tatataat
1261 aaaaactaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa
1321 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa

//LOCUS HSMCP3A 1085 bp DNA PRI 25-JUL-1994
DEFINITION H.sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION X72308 S57464
NID g313707
KEYWORDS monocyte chemotactic protein 3.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1085)
REFERENCE AUTHORS Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of
JOURNAL MEDLINE Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
93213290
REFERENCE AUTHORS Opdenakker,G.M.
TITLE Direct Submission
JOURNAL Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
3 (bases 1 to 1085)
REFERENCE AUTHORS Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
Speleman,F., Laureys,G. and Van Damme,J.
TITLE The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
assignment to the C-C chemokine gene cluster on chromosome
17q11.2-q12
JOURNAL MEDLINE Genomics 21 (2), 403-408 (1994)
94375065
FEATURES source Location/Qualifiers
1..1085
/organism="Homo sapiens"
/db_xref="taxon:9606"
gene 299..810
/gene="MCP-3"
CDS 299..628
/gene="MCP-3"
/codon_start=1
/product="monocyte chemotactic protein-3"
/db_xref="PID:g313708"
/db_xref="SWISS-PROT:P80098"

/translation="MWKPPSPSNMKASAALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLESYRRTTSSHCPCREAVIFKTKLDKEICADPTQKWWQDFMKHLDK
KTQTPKL"
sig_peptide 299..397
/gene="MCP-3"
mat_peptide 398..625
/gene="MCP-3"
product="monocyte chemotactic protein-3"
polyA_signal 806..810
/gene="MCP-3"

BASE COUNT 314 a 214 c 229 g 328 t

ORIGIN

```

1 ggtttctatt gacttgggtt aatcgtgtga ccgcgggtggc tggcacgaaa ttgaccaacc
61 ctggggtag tatacgtag taaaacttc gtttattgtc aaaggtaat cactgctgtt
121 tcccggtggg gtgtggctag gctaagcggt ttgagctgca ttgctgcgtg cttgatgctt
181 gtccttttg atcgtgggtga tttagaggtt gaacttactg gaatggggat gcttgcgtt
241 gtaatcttac taagagctaa tagaaaggctt aggaccaaac cagaaaccc ccaattctcat
301 gtggaaagccc atgccttac cctccaaatc gaaaggcttgc cagacttc tttgtctgt
361 gctcacagca gctgcttca gcccccaagg gcttgcgtc ccagggtggg ttaatacttc
421 aactacatgc tgctacagat ttatcaataa gaaaatccct aagcagaggc tggagagctt
481 cagaaggacc accagtagcc actgtccccg ggaagctgtt atcttcaaga ccaaactgaa
541 caaggagatc tgctgctgacc ccacacagaa gtgggtccag gactttatgtt agcacctgaa
601 caaaaaacc caaactccaa agctttgtt attcatgact gaactgaaaaa caagccatgaa
661 cttgagaaac aaataattt gataccctgt ctttttcgtt agtgggtctg agattattt
721 aatctaattc taaggaatat gagctttatg taataatgtt aatcatgtt ttttttagta
781 gatttttaaa gtatttataa tttaattttt atcttccatg gatttttgtt gtttttgaa
841 ataaaggccctt ggatgttatat gtcatctcgt tgctgtaaaaa actgtggggat gtcctccctt
901 tctctacccat atgggggtat tgatgtttt ctttcaatggaaatc tcaatgttcaaa gatttgttt
961 aattgttaag atatgtatgtc cctatggaaatc catatgttta ttatataattt acatatttgc
1021 atatgtatgttcaatggaaatc atatgtttt gtataacaaa aaaaaaaaaaa
1081 aaaaaa

```

//

LOCUS HSMCP3A 1085 bp DNA **PRI** 25-JUL-1994
DEFINITION H. sapiens MCP-3 mRNA for monocyte chemotactic protein-3.
ACCESSION X72308 S57464
NID g313707
KEYWORDS monocyte chemotactic protein 3.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1085)
AUTHORS Opdenakker,G., Froyen,G., Fiten,P., Proost,P. and Van Damme,J.
TITLE Human monocyte chemotactic protein-3 (MCP-3): molecular cloning
of
JOURNAL the cDNA and comparison with other chemokines
MEDLINE Biochem. Biophys. Res. Commun. 191 (2), 535-542 (1993)
93213290
REFERENCE 2 (bases 1 to 1085)
AUTHORS Opdenakker,G.M.
TITLE Direct Submission
JOURNAL Submitted (27-MAY-1993) G.M. Opdenakker, Rega Institute,
University
of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
REFERENCE 3 (bases 1 to 1085)
AUTHORS Opdenakker,G., Fiten,P., Nys,G., Froyen,G., Van Roy,N.,
Speleman,F., Laureys,G. and Van Damme,J.
TITLE The human MCP-3 gene (SCYA7): cloning, sequence analysis, and
assignment to the C-C chemokine gene cluster on chromosome
17q11.2-q12
JOURNAL Genomics 21 (2), 403-408 (1994)
MEDLINE 94375065
FEATURES Location/Qualifiers
source 1..1085
/organism="Homo sapiens"
/db_xref="taxon:9606"
gene 299..810
/gene="MCP-3"
299..628
/gene="MCP-3"
/codon_start=1
/product="monocyte chemotactic protein-3"
/db_xref="PID:g313708"
/db_xref="SWISS-PROT:P80098"

/translation="MWKPMPSPSNMKASAALLCLLLTAAAFSPQGLAQPVGINTSTTC
CYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTKLDKEICADPTQKVVQDFMKHLDK
KTQTPKL"
sig_peptide 299..397
/gene="MCP-3"
mat_peptide 398..625

LQRLKSYVITTSRCPQKAVIFRTKLGKEICADPKEKVVQNYMKHLGRKAHTLKT"

gene 34..330
 /gene="MCP-4"
 mat_peptide 103..327
 /gene="MCP-4"

BASE COUNT 221 a 175 c 185 g 244 t
 ORIGIN

1 acatttgtaa atctccaaact cttaacccctc aacatgaaag tctctgcagt gcttctgtgc
 61 ctgctgtca tgacagcagc ttcaacccccc cagggacttgc tcagccaga tgcaactcaac
 121 gtcctatcta cttgtctttt cacatgtttc agtaagaaga tctcccttgc gaggctgaag
 181 agtcatgtta tcaccacccag cagggtttcc cagaaggcttgc tcatcttcag aaccaaactg
 241 ggcaggaga tctgtgtca cccaaaggag aagtgggtcc agaattatata gaaacaccc
 301 ggcggaaag cttcacacccctt gaagacttgc actctgtttcc cccctactgaa atcaagctgg
 361 agtacgttgc atgacttttc cattcttc tggcccttcc ttctatgtttt tggaatactt
 421 ctaccataat ttccaaatag gatgtttttc gttttgttgc ttgttggag ttttttgag tattgttgc
 481 agtaatatttgc gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
 541 ctttttttaaa gcaaggccctt gagcaagttttttt gttttttttt gttttttttt gttttttttt
 601 ctatgagttttttt ctggcagttttttt gttttttttt gttttttttt gttttttttt gttttttttt
 661 agtcatggac atgaagggtt gttttttttt gttttttttt gttttttttt gttttttttt gttttttttt
 721 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 781 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt

//LOCUS HSAMAC1 803 bp RNA PRI 10-AUG-1997

DEFINITION Homo sapiens mRNA for alternative activated macrophage specific CC

chemokine 1.

ACCESSION Y13710

NID g2326515

KEYWORDS AMAC-1 gene; CC-chemokine 1.

SOURCE human. ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;

Hominidae; Homo.

REFERENCE 1 (bases 1 to 803)

AUTHORS Politz,O.

TITLE Direct Submission

JOURNAL Submitted (10-JUN-1997) Politz O., Dermatology, Free University
 Benjamin Franklin Medical Center, Hindenburgdamm 30; 12200
 Berlin

GERMANY

REFERENCE 2 (bases 1 to 803)

AUTHORS Kodelja.V., Mueller,C., Politz,O., Hakiy,N., Orfanos,C.E. and
 Goerdt,S.

TITLE Cloning of alternative activated macrophage associated CC
 chemokine

1 (AMAC-1)

JOURNAL Unpublished

FEATURES Location/Qualifiers

source 1..803
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="macrophage"

sig_peptide 71..133
 /gene="amac-1"

CDS 71..340
 /gene="amac-1"
 /note="macrophage specific"
 /codon_start=1
 /product="CC-chemokine 1"
 /db_xref="PID:e321838"
 /db_xref="PID:g2326516"

/translation="MKGLAAALLVLVCTMALCSAQVGTNKELCCLVYTSWQIPQKFI
 VDYSETSPQCPKPGVILLTKRGRQICADPNKKWVQKYISDLKLNA"

gene 71..340
 /gene="amac-1"
 mat_peptide 134..337
 /gene="amac-1"

BASE COUNT 214 a 213 c 160 g 216 t
 ORIGIN

```

1 cccgcacgag aggagtttg agtttccaag ccccagctca ctctgaccac ttctctgcct
61 gcccagcatc atgaaggggcc ttgcagctgc cctccttgc ctcgtctgca ccatggccct
121 ctgcctctgt gcacaagttg gtaccaacaa agagctctgc tgccctcgct atacccctcg
181 gcagattcca caaaagttca tagttgacta ttctgaaacc agccccccagt gcccccaagcc
241 aggtgtcata ctccttaacca agagaggccg gcagatctgt gctgacccca ataagaagtg
301 ggtccagaaa tacatcagcg acctgaagct gaatgcctga ggggcctgga agctgcgagg
361 gcccagtgaa cttggggc ccaggaggg acaggagccg gagccaggcc aatggccctg
421 ccaccctgga gcccacccctc tctaaagatc ccatctgca tgccctgca cattaaactaa
481 cttaatctt agtttatgca tcatatttca ttttggaaatt gatttttattt gttgagctgc
541 attatgaaat tagtattttc tctgacatct catgacatttgc tctttatcat cttttccctt
601 ttccctcaa ctcttcgtac attcaatgca tggatcaatc agtgtgatta gctttctcag
661 cagacattgt gccatcatgta tcaaatgaca aatctttt gatgtgtt gtcagcacc
721 accttttaat atattggcag tacttattat ataaaaggtt aaccaggcatt ctactgtga
781 aaaaaaaaaa aaaaaaaaaa aaa

//
```

LOCUS HUMLD78A 3176 bp DNA **PRI** 17-JAN-1992

DEFINITION Human LD78 alpha gene.

ACCESSION D90144

NID g219905

KEYWORDS LD78; LD78 alpha; cytokine; inducible gene family; secreted peptide.

SOURCE Human blood lymphocyte DNA, clone Lm LD-3.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Homo.

Hominidae;

REFERENCE 1 (bases 1 to 3176)

AUTHORS Nakao, M., Nomiyama, H. and Shimada, K.

TITLE Structures of human genes coding for cytokine LD78 and their expression

JOURNAL Mol. Cell. Biol. 10 (7), 3646-3658 (1990)

MEDLINE 90287155

COMMENT These data kindly submitted in computer readable form by: Hisayuki

Nomiyama
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

FEATURES

source	Location/Qualifiers
	1..3176
	/organism="Homo sapiens"
	/db_xref="taxon:9606"
TATA_signal	1041..1045
exon	1069..1227
	/number=1
prim_transcript	1069..2957
	/note="LD78 alpha mRNA and introns"
sig_peptide	1155..1220
	/note="LD78 alpha signal peptide"
CDS	join(1155..1227,1916..2030,2451..2541)
	/codon_start=1
	/product="LD78 alpha precursor"
	/db_xref="PID:d1014875"
	/db_xref="PID:g219906"

/translation="MQVSTAALAVLLCTMALCNQFSASLAADTPTACCFSYTSRQIPQ

mat_peptide NFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWQKYVSDLELSA

join(1218..1227,1916..2030,2451..2538)

/partial

/note="LD78 alpha mature peptide"

intron 1228..1915

exon 1916..2030

/partial

/number=2

intron 2031..2450

exon 2451..2957

/number=3

BASE COUNT 833 a 741 c 752 g 850 t
 ORIGIN

1	acccaggggac	ctatcacaca	aatataagaa	ctattcattc	tttaaggcat	gtattccaa
61	gcctttgtat	tttttccat	gcttaggggt	ggcaagaat	atataatat	ttgtacaaat
121	atatatgtgt	atatgtacaa	atacatgtat	atatagtaca	aatatata	tatatttgta
181	caattcttca	gactttgtag	aatttgtata	atgtcgatc	ttgtttttt	taaccactga
241	tgttataaagc	atattttatgc	cacttcatc	attttagaga	ctaataata	aatgtatctag
301	tggataattt	atcattccct	gatggagaaa	aatttgcctt	tgtttattt	agagtataa
361	acgtatctgg	gtcaggatc	ttttagttt	aatgtgctc	cataatttggg	ttgtttccac
421	agaactttt	ccttggaaatg	cttttctag	gtaataggct	acagatattt	ctaggcacct
481	gacatattga	caccaccc	taaagtattt	ttatgatcca	caactagcgt	ttaacacagc
541	gcccctagtca	ctacatgact	aataataatg	caaatgcgt	aaacatgacc	tcatgctttc
601	tatcccttcca	gctttttc	agttcttgc	ctctggggg	aggaagggtt	ttgcagccct
661	ccacagcatc	agccatcaa	ccctatccct	gtggttatag	cagctgagga	agcagaattt
721	cagctctgtg	ggaaaggaaatg	gggctggaga	gttcatgcac	agaccatgtc	ttatgagaag
781	ggactgacta	agaatagcct	tgggttaca	tataccctc	ttcacactca	caggagaaac
841	catttcccta	tgaaactata	acaagtcatg	agttgagagc	tgagagttt	agaatagctc
901	aaagatgcct	ttcttggata	tcctgagccc	ctctgggtac	cagggaccc	gagttgtgca
961	acttagatcg	acagcatc	tacgcattaa	aatttccctc	ctcacccccc	gatccattt
1021	ccccatccgc	cagggtgtcc	tataaagagg	agagctggtt	tcagacttca	gaaggacacg
1081	ggcagcagac	agtggtcagt	cctttcttgg	ctctgctgac	actcgagccc	acattccgtc
1141	acctgttcag	aatcatgcag	gtcttccatc	ctgcccctgc	tgcttccctc	tgccaccatgg
1201	ctctgtccaa	ccagttctct	gcatcacgtg	agtcgtatc	tcgttgtggg	tatccactt
1261	ctctggccat	ggttagacca	catcaatctt	ttcttgcgc	ctaaaagccc	ccaagagaaa
1321	agagaacttc	ttaaaggggct	gccaaacatc	ttggttttc	tcttaagac	tttttatttt
1381	atctctagaa	ggggtcttag	ccccctagt	tccaggatgc	agaatctagg	caggggcagg
1441	ggagtttacag	tcccttttac	agatagaaaa	acagggttcg	aaacgaatat	gttagcaaga
1501	ggcagaatcc	agggtctgtt	acttttttt	gggttatgtt	gttctacttc	cagctactc
1561	tagtctccc	aggagctctg	tcccttggat	gtcttatgt	agatgtccaa	ggcttcttct
1621	gggttgggg	atgacttctt	gaaccagaca	aaatttccctg	aagagaactg	agataagaga
1681	acagttccgtt	caggatctgc	gatcacacag	agaacacag	aaccactat	gaagagtc
1741	ggagaaaaag	ggatacagac	agaaaacaag	agacatttc	cagaaaaat	gccccaaatgc
1801	cttccagtc	cttggcttc	gcaagctgc	cttccttcaac	tgctcgggga	tcagaagctg
1861	cctggccctt	tctttgagc	tgtgactcgg	gtcatttctc	ttcttttctc	cacagttgt
1921	gctgacacgc	cgaccgcctg	ctgcttca	tacaccccc	ggeagatcc	acagaaattt
1981	atagtcgtact	actttggac	gaggacccag	tgcttca	ccgggtgtcat	gtaaatgc
2041	gttcttctgc	tcacccctat	ggaggttggg	agggtcagg	ttggggcaga	gacaggccac
2101	aaggctatcc	tggaaaggcc	cagccttcag	gagccatc	gggatacagg	ccttgcaccc
2161	ccgagggtgt	acctgacttg	gagctggagt	gaggcatgt	ttacagagtc	ttggccaaag
2221	gccccagccc	agagggaaagg	gacaggaaga	aggaggcage	gggacactt	tttcccaacc
2281	cctactgtgt	cacttgagaga	agcttctat	agacatgtat	ccggggggcc	atatgtc
2341	gagcaagccc	tgagtcgtcc	aggacagaga	gcaatgtgt	ggggccatgg	ttttccaaacc
2401	atccccctgc	tggattttccc	agtgtttaac	tcttccccc	ttctccacag	atagtcgt
2461	aagcgaagcc	ggcagggtctg	tgctgacccc	agtgtggagt	gggtccaga	tcgggtggc
2521	gaccttggac	tgatgtcc	aggggtccag	aacttgcag	gcccagcgc	cacagttacc
2581	ccagtgggg	ggaggcaggag	cctggccctt	gggaaatctc	gtgtgaccc	tttttttttt
2641	tcttctatgg	actgttttt	gcaaaacatc	cacactgtgg	gacttttctt	aactttaattt
2701	ttaattttt	tataactat	agtttttgc	atttattttc	gatttcacag	tgtgtttgt
2761	attgtttgt	ctgagatgtt	ccctgtcccc	tcccttttcc	ctcacacccgc	gtctgtgtac
2821	aaccgtgtt	ctgtcatc	cctgtgttag	cagtcatggc	accaaagcca	ccagatgtac
2881	aatatgttat	cggatgtttt	tggtttagggc	tgtgtatggc	ctggggaaat	aataaaatgt
2941	ctctttaaa	aggtaaacc	gtattgagg	tggtttttt	tttctggca	ataaaaatca
3001	ctggtaaga	ggaatcatag	gcaaaagat	ggaaggtgt	aaatggaggg	aaattggag
3061	agatggggag	ggctaccaca	gagttatca	ctttacac	gagacacagt	tctggaaat
3121	tgtttttttt	aatatgttat	aactcaaatac	ataacatgc	tgctctagga	gaattt

of

Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong, Sosa-gu, Bucheon 422-231, Korea

COMMENT forward primer (5'-tgcgcacacttgctgctgaca-3')
reverse primer (5'-cttctggaccctcaggcact-3').

FEATURES source Location/Qualifiers
1..225
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="PHA-treated peripheral blood leukocyte"
gene <1..225
/gene="MIP1a"
primer_bind <1..19
/gene="MIP1a"
/PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30 cycles;
CDS DeltaCycler II from Ericomp
<1..213
/gene="MIP1a"
/function="CC chemokine"
/function="proinflammatory cytokine involved in inflammation"
/note="8-10 kDa"
/codon_start=1
/product="macrophage inflammatory protein 1 alpha"
/db_xref="PID:g2905628"

/translation="ASLAADTPTACCFSYTSRQIPQNFIAIDYFETSSQCSKPGVIFLT
KRSRQVCADPSEEWVQKYVSDLELSA"
primer_bind complement (205..225)
/gene="MIP1a"

BASE COUNT 50 a 68 c 62 g 45 t
ORIGIN

1 gcatcaacttg ctgctgacac gcccggcc tgctgttca getacaccc tcggcagatt
61 ccacagaatt tcatacgctga ctacttttag acggacgagcc agtgctccaa gccccgggtgc
121 atcttcctaa ccaaggcgaag ccggcagggtc tggctgacc ccagtggagga gtgggtccag
181 aaatatgtca gcgacaccttga gctgagtggcc tgagggggtcc agaag

//

LOCUS HUMLD78B 3112 bp DNA PRI 17-JAN-1992
DEFINITION Human LD78 beta gene.
ACCESSION D90145
NID g219907
KEYWORDS LD78; LD78 beta; cytokine; inducible gene family; secreted peptide.
SOURCE Human placenta DNA, clone Lm LD-1.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE 1 (bases 1 to 3112)
AUTHORS Nakao,M., Nomiyama,H. and Shimada,K.
TITLE Structures of human genes coding for cytokine LD78 and their expression
JOURNAL Mol. Cell. Biol. 10 (7), 3646-3658 (1990)
MEDLINE 90287155
COMMENT These data kindly submitted in computer readable form by:
Hisayuki
Nomiyama
Department of Biochemistry
Kumamoto University Medical School
2-2-1 Honjo, Kumamoto 860
Japan
Phone: 096-344-2111
Fax: 096-372-6140.

FEATURES source Location/Qualifiers
1..3112
/organism="Homo sapiens"
/db_xref="taxon:9606"
repeat_unit 498..797
/note="Alu repeat"

2521 tgaccccagt gaggagtggg tccagaaata cgtcagtgc ctggagctga gtgcctgagg
 2581 ggtccagaag cttcgaggcc cagcgcaccc agtggggcca gtggggagga gcaggagcc
 2641 gaggcttggg aacatgcgtg tgacctcac agctaccctc tctatggact ggttattgcc
 2701 aaacagccac actgtggac tcttcttaac tttaaatttttta atttattttat actattttatg
 2761 ttttataatt tatttttgc ttcacagtgt gtttgatt gtttgctctg agagttttcc
 2821 ctgtcccttc caccttccct cacagtgtgt ctggtgacga ccgagtggct gtcatcgcc
 2881 tgcgtggcgtc gtcatggcac caaaggcacc agactgacaa atgtgtatca gatgcttttgc
 2941 ttccaggctgt tgatccgc gggggaaataa taaagatgtt cttttaaacg gtaaaaccagg
 3001 atttagtttgc gttttgtttt tctggcaaat caaaatcaact atgtaagagg aatcataggc
 3061 aaagatttagg aagaggtgaa atggaggggaa actggagagc atggggagcg ct

//

LOCUS HUMACT2A 696 bp mRNA **PRI** 30-OCT-1994
DEFINITION Human activation (Act-2) mRNA, complete cds.
ACCESSION J04130
NID g178017
KEYWORDS act2 gene; immune activation gene.
SOURCE Human (Hut-102B2 library) activated T cells, cDNA to mRNA.
ORGANISM Homo sapiens
 Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 696)
AUTHORS Lipes,M.A., Napolitano,M., Jeang,K.T., Chang,N.T. and
 Leonard,W.J.
TITLE Identification, cloning, and characterization of an immune
 activation gene
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 85 (24), 9704-9708 (1988)
MEDLINE 89071764
COMMENT Draft entry and computer-readable sequence [1] kindly submitted
 by W.Leonard, 09-JAN-1989.
FEATURES Location/Qualifiers
 source 1..696
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /map="Unassigned"
 mRNA <1..696
 /note="act-2 mRNA"
 sig_peptide 109..177
 /gene="LAG2"
 /note="act-2 protein signal peptide"
 gene 109..387
 /gene="LAG2"
 CDS 109..387
 /gene="LAG2"
 /note="act-2 protein precursor"
 /codon_start=1
 /db_xref="GDB:G00-127-452"
 /db_xref="PID:g178018"

/translation="MKLCVTVLSLLMLVAACFCSPALSAAPMGSDPPTACCSYTAARKLP
 RNFVVVDYYETSSLCSQPAVVFQTKRSKQVCADPSESWVQEYVYDLELN"
 mat_peptide 178..384
 /gene="LAG2"
 /note="act-2 protein"

BASE COUNT 157 a 203 c 139 g 197 t
ORIGIN Unreported.

1 ttccccccccc cccccccccc ccccgcccgaa gcacaggaca cagctgggtt ctgaagcttc
 .61 tgaggcttcg acgttcaccc ctgagaaaaac ctctttcca ccaataccat gaagctctgc
 121 gtgactgtcc tgctctctcc catgttaga gtcgtcttc gtcgtccagc gtcgtccagca
 181 ccaatgggct cagaccctcc caccgcctgc tgctttttt acaccgcggag gaagcttctc
 241 cgcaactttg tggtagatta ctatgagacc agcagccctc gtcgtccagcc agctgtggta
 301 ttcccaacca aaaaagcaa gcaagtctgt gtcgtatcca gtaatcctg gttccaggag
 361 tacgtgtatg acctggaaact gaactgact gtcgtccagac aggaagtctt cagggaaagg
 421 cacctggagcc cggatgcttc tccatggagac acatctccctc catactcagg actcctctcc
 481 gcagttcctg tcccttctct taatttatc ttttttatgt gcctgttat tttttaggt
 541 gtcatttcca ttatttatat tagtttagcc aaaggataag tgcctatgg ggatggtcca
 601 ctgtcaactgt ttctctgttgc ttgcaataac atggataaca catttgattc tttgtgtttt
 661 ccataataaa actttaaaat aaaaatcgaga cagttt

//

LOCUS AF031587 481 bp mRNA **PRI** 02-JAN-1998
DEFINITION Homo sapiens MIP-1 delta mRNA, complete cds.

ACCESSION AF031587
 NID g2739163
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Molecular cloning and characterization of a new CC chemokine
 MIP-1
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 481)
 AUTHORS Wang, W.
 TITLE Direct Submission
 JOURNAL Submitted (27-OCT-1997) Immunobiology, DNAX Research Institute,
 901 California Ave, Palo Alto, CA 94304, USA
 FEATURES Location/Qualifiers
 source 1..481
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 CDS 1..342
 /note="CC or beta chemokine"
 /codon_start=1
 /product="MIP-1 delta"
 /db_xref="PID:g2739164"
 /translation="MKVSVAALSLMLVAVLGSQAQFINDAETELMMSKLPLENPVVL
 NSFHFAADCCTS YISQSIPCSLMKSYFETSSEC SKPGVIFLT KGRQVCAKPSGPGVQ
 DCMKKLPYSI"
 BASE COUNT 140 a 112 c 100 g 129 t
 ORIGIN
 1 atgaaggctt ccgtggctgc ccttccttc ctcatgttggctgtcc tggatccccag
 61 gcccaggatca taaatgtatc agagacagag ttaatgtatgt caaagttcc actggaaaat
 121 ccagtagttc tgaacagatc tcactttgtc gctgactgtc gcacccctta catctcacaa
 181 agcatccgt gttcaactcat gaaaagttat tttgaaacga gcagcgagtgc ctccaaagcca
 241 ggtgtcatat tcctcaccaa gaaggggagg caagtcgtgc ccaaaccagg tggtccggga
 301 gttcaggatt gcatgaaaaa gctgaagccc tactcaatat aataataaag agacaaaaga
 361 gggcagccac ccaaccttccaa cacctctgt gagtttcttg gtctgaaata cttaaaaat
 421 atatatattt ttgtgtctgg taatgaaagt aatgcataataaagagata ttcaatttt
 481 t
 //
 LOCUS AF043340 234 bp mRNA PRI 23-FEB-1998
 DEFINITION Homo sapiens macrophage inflammatory protein 2 alpha (MIP2a)
 mRNA, partial cds.
 ACCESSION AF043340
 NID g2905629
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 234)
 AUTHORS Jang, J.S. and Kim, B.E.
 TITLE Direct Submission
 JOURNAL Submitted (15-JAN-1998) Protein Engineering, General Institute
 of Technology, Hyundai Pharm. Ind. Co., Ltd., 213 Sosa Bon 1-dong,
 Sosa-gu, Bucheon 422-231, Korea
 COMMENT forward primer (5'-tgcgcacccctggccactgaactg-3')
 reverse primer (5'-ctttccttcgttgcgttgg-3').
 FEATURES Location/Qualifiers
 source 1..234
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PHA-treated peripheral blood leukocyte"

```

        gene      <1..234
        /gene="MIP2a"
        primer_bind <1..21
        /gene="MIP2a"
        /PCR_conditions="94C-1min, 50C-1min, 72C-3min, 30
cycles:
        CDS      DeltaCycler II from Ericomp
        <1..222
        /gene="MIP2a"
        /function="CXC chemokine"
        /function="proinflammatory cytokine involved in
        inflammation"
        /note="8-10 kDa"
        /codon_start=1
        /product="macrophage inflammatory protein 2 alpha"
        /db_xref="PID:g2905630"

/translation="APLATERCQCLQTLQGIHLKNIQSVKVVKSPGPNCQTEVIATL
KNGQKACLNPAСПMVKKIEKMLKNGKSN"
primer_bind complement(214..234)
/gene="MIP2a"

BASE COUNT      74 a      70 c      54 g      36 t
ORIGIN

1  gcacccttgg  ccaactgaact  gcgcgtccag  tgcttgcaga  ccctgcaggg  aattcaccc
61 aagaacatcc  aaagtgtgaa  ggtgaagtcc  cccggacccc  actgcgccta  aaccgaagtc
121 atagccacac  tcaagaatgg  gcagaaaagct  tgtctcaacc  cccatcgcc  catggtaag
181 aaaatccatcg  aaaagatgct  gaaaaatggc  aaatccaact  gaccagaagg  aagg
//
LOCUS      HSU77035      764 bp      mRNA      PRI      23-JAN-1997
DEFINITION  Human macrophage inflammatory protein 3 alpha (MIP-3a) mRNA,
complete cds.
ACCESSION  U77035
NID        g1790924
KEYWORDS
SOURCE      human.
ORGANISM  Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 764)
AUTHORS  Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and
Zlotnik,A.
TITLE      Identification through bioinformatics of two new macrophage
proinflammatory human chemokines: MIP-3alpha and MIP-3beta
JOURNAL  J. Immunol. 158 (3), 1033-1036 (1997)
MEDLINE  97166046
REFERENCE  2 (bases 1 to 764)
AUTHORS  Rossi,D.L. and Zlotnik,A.
TITLE      Direct Submission
JOURNAL  Submitted (31-OCT-1996) Immunology, DNAX Research Institute,
901
FEATURES  California Ave., Palo Alto, CA 94304. USA
source      Location/Qualifiers
            1..764
            /organism="Homo sapiens"
            /db_xref="taxon:9606"
            /cell_type="elutriated monocytes activated with
            LPS/IFN-GAMMA"
            1..291
            /gene="MIP-3a"
CDS        1..291
            /gene="MIP-3a"
            /note="chemokine"
            /codon_start=1
            /product="macrophage inflammatory protein 3 alpha"
            /db_xref="PID:g1790925"

/translation="MCCTKSLLAALMSVLLHLCGESEAAASFDCCLGYTDRILHPK
FIVGFTRQLANECDINAIIFHTKKLSTCANPKQTWVKYIVRLLSKVKNM"
BASE COUNT      235 a      121 c      146 g      260 t      2 others
ORIGIN

1  atgtgctgtt  ccaagagttt  gtcctggct  gctttatgt  cagtgtgt  actccaccc

```

```

61 tgccggcgaat cagaaggcgc aagcaacttt gactgtgtc ttggatacac agaccgtatt
121 cttcatccta aattttatgt gggcttcaca cggcagctgg ccaatgaagg ctgtgacatc
181 aatgttatca tctttcacac aaagaaaaag ttgtctgtt ggcgaaatcc aaaacagact
241 tgggtgaaat atattgtcg tctccctcgt aaaaaagtca agaacatgtt aaaaatgtgg
301 cttttcttgc atggaaatgg agatagccca agaacagaaa gaaccttgc ggggtggag
361 gtttccatgg cactatcatgg agggtttagt gcttatctaa ttgtgcctc actggacttg
421 tccaaatataa gaagttgatt catattgtcat ctagtttgc ttgtttaag catcacatata
481 aagttaaact gtatttatgt ttatgtttagt ctgtgtttt tctgtgtttt gcttataat
541 actaattttt cataagctat ttgggttttagt tgcaagttt aaaaattat ttggggggga
601 ataagattat atggactttt ttgcaagcga caagtttattt tttaaaamma actatattaa
661 attctttgtt ttatattgtt ttgtctccca aattttgttattt attgttgcattt aaaaataagaa
721 aatattataat aagacaaata ttgaaaataa agaaacaaaa agtt

// Locus HSU77180 545 bp mRNA PRI 23-JAN-1997
Definition Human macrophage inflammatory protein 3 beta (MIP-3beta) mRNA, complete cds.
Accession U77180
NID g1791002
Keywords .
Source human.
Organism Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata: Eutheria; Primates; Catarrhini; Hominidae; Homo.
Reference 1 (bases 1 to 545)
Authors Rossi,D.L., Vicari,A.P., Franz-Bacon,K., McClanahan,T.K. and Zlotnik,A.
Title Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta
Journal J. Immunol. 158 (3), 1033-1036 (1997)
Medline 97166046
Reference 2 (bases 1 to 545)
Authors Vicari,A. and Zlotnik,A.
Title Direct Submission
Journal Submitted (01-NOV-1996) Immunology, DNAX Research Institute,
901 California Ave, Palo Alto, CA 94304, USA
Features Location/Qualifiers
source 1..545
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="macrophages activated with LPS or IFNg"
/chromosome="9"
gene 1..297
/gene="MIP-3beta"
CDS 1..297
/gene="MIP-3beta"
/function="chemokine"
/codon_start=1
/product="macrophage inflammatory protein 3 beta"
/db_xref="PID:g1791003"



```

KEYWORDS Alu repeat; T-cell-specific protein.
SOURCE Human peripheral blood (T lymphocyte) cell line AH2, cDNA to mRNA.
ORGANISM clone 228.
AUTHORS Homo sapiens
REFERENCE Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
COMMENT Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
Clayberger,C., 1 (bases 1 to 1160)
AUTHORS Schall,T.J., Jongstra,J., Dyer,B.J., Jorgensen,J..
TITLE Davis,M.M. and Krensky,A.M.
JOURNAL A human T cell-specific molecule is a member of a new gene family
MEDLINE J. Immunol. 141, 1018-1025 (1988)
COMMENT 88285659
provided Draft entry and computer-readable sequence for [1] kindly
FEATURES by A.M.Krensky, 24-OCT-1988.
source Location/Qualifiers
CDS 1..1160
repeat_region /organism="Homo sapiens"
repeat_region /db_xref="taxon:9606"
repeat_region 27..302
repeat_region /note="T cell-specific protein precursor"
repeat_region /codon_start=1
repeat_region /db_xref="PID:g339421"

/translation = "MKVSAARLAVILIATALCAPASASPYSSDTTPCCFAYIARPLPR
sig_peptide AHIKEFYTSGKCSNPAAVVFVTRKNRQVCANPEKKWREYINSLEMS" 27..95
mat_peptide /note="T cell-specific protein signal peptide"
repeat_region 96..299
repeat_region /note="T cell-specific protein"
repeat_region 450..950
repeat_region /note="Alu-related repeats"
BASE COUNT 298 a 332 c 295 g 235 t
ORIGIN 276 bp upstream of RsaI site.
1 cctccggacag ccttccaca ggttaccatga aggtctccgc ggcacgcctc gctgtcatcc
61 tcattgtcac tgcctctgc gtcctctgcat ctgcctcccc atattcctcg gacaccacac
121 cctgtgttt tgccctacatt gcccggccac tgcggcgtgc ccacatcaag gaggatattct
181 acaccgtgg caagtgtcc aaccggcag tcgttcttgc caccggaaag aaccggccaag
241 tgggtggccaa cccaggaga aatgggttc gggaggatcat caacttcttg gagatggat
301 agatggaga gtccttgaac ctgaaacttac acaaatttgc ctgttctgc ttgtctttgt
361 cctagcttgg gaggttcccc ctcaactatcc taccggcacc gtccttggaa gggccggagat
421 tctggccacg acggcggca gtttacaaaaa ctttccccag gtcggacgtg gtggctcagc
481 ctgttaatcc cagcaacttgc gggggccaaatggggatcatggatggat caggagttcg
541 agacggctgc gcaacatga tggaaatccca tgggttactaa aatataaaaaa atttggccgg
601 gctgtgttgc gggccctgt agtcccagct actcggggagg ctggggcagg aagatggcg
661 gaacccggga gcgaggcttgc cagtggcc agatcgcc actgcactcc agcctggcg
721 acagggcgac acttccgttcc aaaaaaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaaaatataca aaaaaaaaaaaaaatggcc
781 gctgtgttgc ccacggctgt aatccccatgc actcggggagg ctaaggcagg aaaaatttggtt
841 gaacccggga ggtggggatgc gcaatggatgc gagatttgc cacttcaatc caggcctgggt
901 gacaaatgtga gactccgtca caacaacaaac aacaaaaaaatgc ttcccaact aaagctttaga
961 agactcttgc agggcgttgc ttgtcaaaaaaag gaatgttctta ggttcttgc tctggctttg
1021 ccttggctt gcaagggttgc ttgtacaagg aaggaaatgc gcatgttcttgc agaggcaagg
1081 aaggggggaa cactggacttcaatggatgc ttaagcttcc ggcgttccaa cccctcacag gagcttactt
1141 gcaaaatgtga aaaaatgggg

LOCUS HUMTLI309 520 bp mRNA PRI 14-JAN-1995
DEFINITION Human secreted protein (I-309) mRNA, complete cds.
ACCESSION M57502
NID g339728
KEYWORDS secreted protein.
SOURCE Human T-cell, cDNA to mRNA.
ORGANISM Homo sapiens
REFERENCE Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
AUTHORS Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE 1 (bases 1 to 520)
JOURNAL Miller,M.D., Hata,S., De Waal Malefyt,R. and Krangel,M.S.
COMMENT A novel polypeptide secreted by activated human T lymphocytes
provided J. Immunol. 143 (9), 2907-2916 (1989)

MEDLINE 90038522
 FEATURES Location/Qualifiers
 source 1..520
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="T-cell"
 /germline
 /map="17"
 mRNA 1..520
 <1..520
 /gene="SCYA1"
 /note="G00-118-872"
 gene 1..520
 /gene="SCYA1"
 CDS 51..341
 /gene="SCYA1"
 /codon_start=1
 /db_xref="GDB:G00-118-872"
 /product="secreted protein I-309"
 /db_xref="PID:g339729"

 /translation="MQIITTALVCLLLAGMWPEDVDSKSMQVPSRCCFSFAEQEIPRLAILCYRNTSSICSNEGLIFKLKRGEACALDTVGVWQRHRKMLRHCP SKRK"
 BASE COUNT 140 a 137 c 122 g 121 t
 ORIGIN
 1 accaggctca tcaaagctgc tccaggaagg cccaaaggccag accagaagac atgcagatca
 61 tcaccacagc cctgggtgc ttgctgtcg ctggatgtg gccggaaagat gtggacagca
 121 agaggcatgca ggtacccttc tccagatgtt gcttctcatt tgcggagcaa gagatcccc
 181 tgagggcaat cctgtgttac agaaataccca gctccatctg ctccaaatgag ggcttaataat
 241 tcaagctgaa gagaggccaa gaggcctgcg cttggacatcg agttggatgg gttcagaggc
 301 acagaaaaat gctgaggcac tgcccgtaaa aaaaaaaaaat agcagatttc tttccattgt
 361 gggctctgga aaccacatgg ctteacatgtt ccccgaaact accagcccta caccattcct
 421 tctgcctgc ttttgcttagg tcacagagga tctgcttggg cttgataagc tatgttgg
 481 cactttaaac attaaatata tacaatcata aacccccaac
 //
 LOCUS AB000887 687 bp mRNA PRI 05-JUN-1997
 DEFINITION Human mRNA for EBI1-ligand chemokine, complete cds.
 ACCESSION AB000887
 NID g2189952
 KEYWORDS EBI1-ligand chemokine; ELC.
 SOURCE Homo sapiens fetal tissue_lib:lung cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (bases 1 to 687)
 AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
 Kitaura,M.,
 Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.
 TITLE Direct Submission
 JOURNAL Submitted (05-FEB-1997) to the DDBJ/EMBL/GenBank databases.
 Hisayuki Nomiyama, Kumamoto University Medical School,
 Department of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan
 (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)
 REFERENCE 2 (sites)
 AUTHORS Yoshida,R., Imai,T., Hieshima,K., Kusuda,J., Baba,M.,
 Kitaura,M.,
 Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O.
 TITLE Molecular cloning of a novel human CC chemokine EBI1-ligand
 chemokine that is a specific functional ligand for EBI1. CCR7
 J. Biol. Chem. 272 (21), 13803-13809 (1997)
 MEDLINE 97298088
 FEATURES Location/Qualifiers
 source 1..687
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="fetal"
 /tissue_lib="lung"
 gene 139..435
 /gene="ELC"

CDS

```

139..435
/gene="ELC"
/note="CC chemokine"
/codon_start=1
/product="EBI1-ligand chemokine"
/db_xref="PID:d1021215"
/db_xref="PID:g2189953"

```

/translation="MALLALSLVLWTSPAPLTLGNTDAEDCCLSVTQKPIPGYIVR

NFHYLLIKDGCRRPAVVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMRRSS*

mat_peptide 202..432
/gene="ELC"
/product="EBI1-ligand chemokine"

polyA_signal 657..662

BASE COUNT 154 a 223 c 173 g 137 t

ORIGIN

```

1 cattccca gctcacatcac tcacacccatg cattcaccc ctgcacatccca gtcgcctgc
61 agcctcacac agatectgca cacacccaga cagctggcgc tcacacatc accgtggcc
121 tgcctctgtt cacccctccat ggcctgtca ctggccctca gcctgtctgt tctttggat
181 tccccagccc caactctgag tggcacaat gatgtctgaaatgactgtgcct gtctgtgacc
241 cagaaaaccca tccctggta catctgtgagg aacttccact accttctcat caaggatggc
301 tgcagggtgc ctgtctgtgt gttcaccaca ctgaggggcc gccagctctg tgccccccca
361 gaccggccctt gggtagaaacg catcatccag agactcgaga ggacccatcgc caagatgaa
421 cggccgcacca gttaaacctat gaccgtgcag agggaggcccg gagtcggatg caagcattt
481 gaattattttac ctaacctggg gaaccggagga ccagaaggaa ggaccaggct tccagctcc
541 ctgcaccaca cctgaccacgc caggacaggg cctgggggtgt gtgtgagtgt gagtgtgagc
601 gagagggtga gtgtgttcag agttaaagctg ctccacccca agattgcaat gctaccaata
661 aagccgcctt gtgtttacaa ctaattt

```

//

LOCUS AB000221 760 bp mRNA PRI 31-JUL-1997

DEFINITION Homo sapiens mRNA for CC chemokine, complete cds.

ACCESSION AB000221

NID g2289718

KEYWORDS CC chemokine; PARC; pulmonary and activation-regulated chemokine.

SOURCE Homo sapiens lung cDNA to mRNA.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae;

REFERENCE 1 (bases 1 to 760)

AUTHORS Nomiyama, H.

TITLE Direct Submission

JOURNAL Submitted (04-JAN-1997) to the DDBJ/EMBL/GenBank databases.

Department Hisayuki Nomiyama, Kumamoto University Medical School, of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan (E-mail: nomiyama@gpo.kumamoto-u.ac.jp, Tel: 81-96-373-5063, Fax: 81-96-372-6140)

REFERENCE 2 (sites)

AUTHORS Hieshima, K., Imai, T., Baba, M., Shoudai, K., Ishizuka, K., Nakagawa, T., Tsuruta, J., Takeya, M., Sakaki, Y., Takatsuki, K., Miura, R., Opendenker, G., Damme, J., Yoshie, O. and Nomiyama, H.

TITLE A novel human CC chemokine PARC that is most homologous to macrophage-inflammatory protein-1alpha/LD78alpha and chemotactic

JOURNAL for T lymphocytes, but not for monocytes

MEDLINE J. Immunol. 159 (3), 1140-1149 (1997)

97376836

FEATURES Location/Qualifiers

source 1..760

/organism="Homo sapiens"

/db_xref="taxon:9606"

/tissue_type="lung"

gene 64..333

/gene="PARC"

CDS 64..333

/gene="PARC"

/note="pulmonary and activation-regulated chemokine"

```

/codon_start=1
/product="CC chemokine"
/db_xref="PID:d1022520"
/db_xref="PID:g2289719"



LOCUS D86955 799 bp mRNA PRI 06-MAR-1997



DEFINITION Human mRNA for CC chemokine LARC precursor, complete cds.



ACCESSION D86955



NID g1871138



KEYWORDS CC chemokine LARC precursor.



SOURCE Homo sapiens cDNA to mRNA.



ORGANISM Homo sapiens



Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.



REFERENCE 1 (sites)



AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J., Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and Nomiyama,H.



TITLE Molecular cloning of a novel human CC chemokine liver and activation-regulated chemokine (LARC) expressed in liver. Chemotactic activity for lymphocytes and gene localization on chromosome 2



JOURNAL J. Biol. Chem. 272 (9), 5846-5853 (1997)



MEDLINE 97190319



REFERENCE 2 (bases 1 to 799)



AUTHORS Hieshima,K., Imai,T., Opdenakker,G., Van Damme,J., Kusuda,J., Tei,H., Sakaki,Y., Takatsuki,K., Miura,R., Yoshie,O. and Nomiyama,H.



JOURNAL Unpublished (1996)



REFERENCE 3 (bases 1 to 799)



AUTHORS Nomiyama,H.



TITLE Direct Submission



JOURNAL Submitted (08-AUG-1996) to the DDBJ/EMBL/GenBank databases.



Department Hisayuki Nomiyama, Kumamoto University Medical School, of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:+81-96-373-5063)



FEATURES source Location/Qualifiers



1..799



/organism="Homo sapiens"



/db_xref="taxon:9606"



/chromosome="2"



/map="q33-37"



sig_peptide 59..136



/gene="LARC"



CDS 59..349



/gene="LARC"



/codon_start=1



/product="CC chemokine LARC precursor"



/db_xref="PID:d1013880"



/db_xref="PID:g1871139"


```


BASE COUNT 118 a 168 c 149 g 103 t
 ORIGIN

```

  1 ccctgagcag agggacctgc acacagagac tccctctgg gctcctggca ccatggcccc
  61 actgaagatg ctggccctgg tcaccctcct cctggggct tctctgcgc acatccacgc
  121 agctcgaggg accaatgtgg gccgggagtg ctgcctggag tacttcaagg gagccattcc
  181 ccttagaaag ctgaagacgt ggtaccagac atctgaggac tgctccaggg atgcccacgt
  241 tttttaact gtgcaggcga gggccatctg ttcgggcccc aacaacaaga gagtgaagaa
  301 tgcagttaaa tacctgcaaa gccttgagag gtcttgaagc ctccctcacc cagactcctg
  361 actgtctccc gggactactt gggacacttca ccgttgggtgt tcaccggccc caccctgagc
  421 gcctgggtcc agggaggcc ttccaggac gaagaagagc cacagtgagg gagatcccat
  481 ccccttgtct gaactggagc catggcaca aaggggccag attaaagtct ttatccctc
  //
```

LOCUS HUMEOTAXIN 807 bp mRNA PRI 25-SEP-1996
 DEFINITION Human mRNA for eotaxin, complete cds.
 ACCESSION D49372
 NID g1552240
 KEYWORDS eotaxin; eosinophil-selective CC chemokine; chemoattractant.
 SOURCE Homo sapiens Small intestine, proximal cDNA to mRNA, clone:141.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (bases 1 to 807)
 AUTHORS Kitaura,M., Nakajima,T., Imai,T., Harada,S., Combadiere,C.,
 Tiffany,H.L., Murphy,P.M. and Yoshie,O.
 TITLE Molecular cloning of human eotaxin, an eosinophil-selective CC
 chemokine, and identification of a specific eosinophil eotaxin
 receptor, CC chemokine receptor 3
 JOURNAL J. Biol. Chem. 271 (13), 7725-7730 (1996)
 MEDLINE 96205964
 REFERENCE 2 (bases 1 to 807)
 AUTHORS Yoshie,O.
 TITLE Direct Submission
 JOURNAL Submitted (15-FEB-1995) to the DDBJ/EMBL/GenBank databases.
 Osamu Yoshie, Shionogi Institute for Medical Science; 2-5-1 Mishima,
 Settsu, Osaka 566, Japan (E-mail:osamu.yoshie@shionogi.co.jp,
 Tel:06-382-2612, Fax:06-382-2598)
 COMMENT On Sep 20, 1996 this sequence version replaced gi:1313900.
 FEATURES Location/Qualifiers
 source 1..807
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="141"
 /tissue_type="Small intestine, proximal"
 CDS 99..392
 /codon_start=1
 /product="eotaxin"
 /db_xref="PID:d1008966"
 /db_xref="PID:g1552241"

 /translation="MKVSAALLWLLLIAAAFPQGLAGPASVPTTCCFNLANRKIPLQR
 RLESYRRITSGKCPQKAVIFTKLAKDICADPKKKWVQDSMKYLDQKSPTPKP"
 misc_signal 548..557
 /note="mRNA destabilization signal"
 polyA_signal 775..780
 polyA_site 807
 BASE COUNT 229 a 198 c 147 g 233 t
 ORIGIN

```

  1 gcattttttc aagttttatg atttatttaa cttgtggAAC aaaaataaaAC cagaaaccAC
  61 cacccctcac gccaaagctc acacccctcg cctccaaact gaaggtctcc gcagccacttc
  121 tgtggctgct gctcatagca gtcgcctca gcccccaagg gctcgctggg ccagcttctg
  181 tcccaaccac ctgtgcctt aacctggcca atagaaatg accccctcg cgaactagaga
  241 gctacaggag aatcaccagt ggccaaatgtc cccagaaAGC tgtgatcttc aagacccaaAC
  301 tggccaaaggatatctgtgcc gaccccaaga agaagtgggt gcaggattcc atgaagtatc
  361 tggacaaaaatctccaact ccaaaggccat aaataatcac cattttgaa accaaaccag
  421 agcctgatgt ttgccttaatttgcctt ctttacaatg cattttgagg taacccatt
  481 atcagttccaa agggcatggg ttttattata tatataataa tttttttttt aaaaaaaaaac
  541 gtattgcatt taatttatttgcctt aacttacccat catgaatatc agttttttttt
  //
```

601 aaactgtaaa gctttgtca gattctttac cccctggag ccccaattcg atccccgtc
 661 acgtgtggc aatgttcccc ctctccttc ttcctccctg gaatcttgta aaggctctgg
 721 caaagatgtat cagttggaaa atgtcatgt tcttgtaac ccaaagtgtg actcattaaa
 781 tggaagtaaa tggtgttta ggaatac
 //
 LOCUS HSCCCHEM 232 bp RNA
 DEFINITION H.sapiens mRNA for CC-chemokine.
 ACCESSION Z69291
 NID g1181148
 KEYWORDS CC-chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 232)
 AUTHORS Bartels,J.H., Schlueter,C., Richter,E., Christophers,E. and
 Schroeder,J.M.
 TITLE Cloning of a novel human chemokine homologous to human monocyte
 chemoattractant proteins and rodent eotaxins
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 232)
 AUTHORS Bartels,J.H.
 TITLE Direct Submission
 JOURNAL Submitted (01-FEB-1996) Bartels J. H.,
 Christian-Albrechts-Universitaet zu Kiel,
 Dermatology/Hautklinik,
 Mol.Biol.Lab.609, Schittenhelmstr. 7, Kiel, Schleswig-Holstein,
 Germany, D-24105
 REFERENCE 3 (bases 1 to 232)
 AUTHORS Bartels,J., Schluter,C., Richter,E., Noso,N., Kulke,R.,
 Christophers,E. and Schroeder,J.M.
 TITLE Human dermal fibroblasts express eotaxin: molecular cloning,
 mRNA expression, and identification of eotaxin sequence variants
 JOURNAL Biochem. Biophys. Res. Commun. 225 (3), 1045-1051 (1996)
 MEDLINE 96374440
 FEATURES Location/Qualifiers
 source 1..232
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="clones 4 (9512),
 14(9512),15(9512),10(9601),11(9601)"
 /tissue_type="foreskin"
 /cell_type="fibroblast"
 /sex="Male"
 mRNA <1..>232
 /citation=[1]
 /product="CC-chemokine"
 sig_peptide 56..109
 /citation=[1]
 CDS 56..>232
 /function="putative chemoattractant protein"
 /note="sequence homology to human MCP-1, MCP-2 and
 MCP-3
 and to rodent eotaxins"
 /citation=[1]
 /codon_start=1
 /product="CC-chemokine, preprotein"
 /db_xref="PID:e221070"
 /db_xref="PID:g1181149"
 /db_xref="SWISS-PROT:P50877"
 /translation="MKVSAALLWLLLIAAAFPQGLAGPASVPTTCCFNLANRKIPLQR
 RLEYRRITSGKCPQ"
 mat_peptide 110..>232
 /citation=[1]
 /function="putative chemoattractant protein"
 /product="CC-chemokine"
 BASE COUNT 55 a 82 c 50 g 42 t 3 others
 ORIGIN 1 accaaaccag aaaccwccam ytctcacgcc aaagctcaca ccttcagcct ccaacatgaa

61 ggtctccgca gcgcgttctgt ggctgctgct catacgggct gccttcagcc cccaggggct
 121 cgctgggcca gcttctgtcc caaccacctg ctgtttaac ctggccaata ggaagatacc
 181 cttcagcga cttagagact acaggagaat caccagtggc aatgtcccc ag
 //
 LOCUS HSHCC1GEN 4037 bp DNA PRI 01-OCT-1995
 DEFINITION H.sapiens gene for chemokine HCC-1.
 ACCESSION Z49269
 NID g1004266
 KEYWORDS chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 4037)
 AUTHORS Pardigol,A., Maegert,H.J., Cieslak,A., Hill,O., Schulz-
 Knappe,P.
 and Forssmann,W.G.
 TITLE Nucleotide Sequence of the Gene for the Human Chemokine HCC-1
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 4037)
 AUTHORS Pardigol,A.
 TITLE Direct Submission
 JOURNAL Submitted (18-MAY-1995) Andreas Pardigol, Molecular Biology,
 Lower Saxony Institute for Peptide Research, Feodor-Lynen-Strasse 31,
 Hannover, Lower Saxon, 30625, Germany
 FEATURES Location/Qualifiers
 source 1..4037
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="ph3b7"
 /dev_stage="adult"
 /tissue_type="placenta"
 /clone_lib="lambda FIX II, Cat.Nr. 946203, Stratagene"
 /sex="male"
 TATA_signal 727..733
 /note="putative, determined by consensus rules."
 5'UTR 764..833
 /note="first base determined by means of consensus
 rules"
 exon 764..912
 /note="first base determined by means of consensus
 rules;
 base 780 is the first base of cDNA (Z49270)"
 CDS /number=1
 join(834..912,3021..3135,3585..3672)
 /codon_start=1
 /product="chemokine HCC-1"
 /db_xref="PID:g1004267"

 /translation="MKISVAAIPFFLLITIALGKTESSSRGPYHPSECCFTYTTYKI
 PRQRIMDYYETNSQCSKPGIVFITKRGHSVCTNPSDKWVQDYIKDMKEN"
 intron 913..3020
 /number=1
 exon 3021..3135
 /number=2
 intron 3136..3584
 /number=2
 exon 3585..3817
 /number=3
 3'UTR 3673..3817
 BASE COUNT 1023 a 1048 c 1004 g 962 t
 ORIGIN
 1 gagctccgtt gggagtccca tggataatg ggtgagaaca cagacttgg
 61 agccaaacca cctgaatttg aaccccgatg ccatttacca actgtcaaaa gcttaggctt
 121 tgattctaag cctgtttctt caactgctgt tctaaagatt aaataggcta atattcataa
 181 ggcaactggg acatggctt gtgtgtatag caaccatatt ataagtgaat tatctactga
 241 gcaccacacg acttcttacac tccatgggtt ggtgaccaga atggatgac gacagagaac
 301 tgcagggttctt gcttcggatgg ttaagtttagga tttcccttga ccaatggatc ctgacttgg
 361 ggagtccctgg cctcattccca ttaccccaaa caccctctag tctctatgtt aacagatcct
 421 gaatgtccag gccccacgtg gcctgttcta aggccctgaga tggaaattggaa tacaggacac

481 atccaggcctt gagatctttt gctaagtgtg acacagtgc cccagccctg tgctcatgt
 541 catgcctagg gaaaggcttc tatcaaaaaga gttgaacttc tttccactgg gatggaaagaa
 601 ccatttcctc ccttaaaacct tggctctcc tgcttccttc aggccaccaa caacacatgt
 661 gcaggatatg aaattgtcga ggcactactg ctttcctact tccttccaa gtctcagctc
 721 cttatTTTA aaaaatTTT ggcctcaatg atcatTTT aacaatTTT caccgcaggaa
 781 gctctgaag ctcccacca gccagcttc cttccacaaac agcttccac
 841 tctccgtggc tgccattccc ttcttccttc tcatcaccat cgccttggg
 901 aatccctcctc acgtgagtgc aatgccttgg cttccctcca acttagagcc
 961 taaggcaggag tgagggtggg gctcaggggg agaccaggag cagggactca
 1021 ctggatTTT ctggaaattt gttgtatgc aacatatat aaatgaatta
 1081 accacacgc ttacccccc ggtgtggta gcaggatgg gatggactt
 1141 gttctgtta agagtttaag ttggatctt ccagccttga ccaatggac
 1201 agactccagg ctccattcca tttcccaaaa tgcccttag tctccaaata
 1261 gaatcccg gcctcacatg gccttgcattt cttatcattt ccccccaggaa
 1321 ctggcctca aggacatggg gtgagaccag cctgcctc tttccctca
 1381 ctggcgcgt aagaaaaaaat gttggccccc ccattttggg tatatttcc
 1441 aggagcagtg tcttggcccc ctcagggca tttttttattt ggctccctga
 1501 cagcctgtttt ccagcgtcac ctgtggccag tgagtgcage attgttggg
 1561 gggggaaacac gacagtgtgg ggtccatctt aggccccctt ttctcagctg
 1621 ataagctggc tttagagata accaaaaactt ttatcactt ttccatTTT
 1681 tttagaaaaaaat ctggggggaa acggaaagggtt gttaaaataac agctaaagtt
 1741 tgcacagttt gacttgcctt ctccgatgtc attttgcgc tcaaggagac
 1801 agtataggag ctctgactgg gtctcaggaa acagggggcc cttatggccgt
 1861 gtgaggatgc tgccctggaaat ggagctggaa aacaggatga gacccttcca
 1921 tggccaccc tctggatgc tggggccat gtgtgcaca tccatgattt
 1981 ggtcacataa catgcacaca cctgtatTTT ccactccata accacaacat
 2041 gtacagggct ctggcctac aatgtcttc ctgtctactt tataattcaa
 2101 gctgctgtca ccttgcTTT cctataaaaag ccatgaaaact tctcaatcg
 2161 aaaaaatcac ccaatccatg gattttaaa acttttttaga ccacaaaacc
 2221 gcaatattt ccacagggc ccaatatgtc aaacagaaaa aatgggttga
 2281 agacaccact ctccaaatgc gcaaggccctt cacaatagtcc cctgaggccc
 2341 gtgtaaaaaaac cactgtgc gtcggggcc ctcattttaca gaggggggaa
 2401 gtaaaatggc cacagttcac aggaaggcaca ggcagggtt ggttaggatt
 2461 gactctgtgg ccttgcTTT tggggcttgc tggtggccatc ctgtctctc
 2521 cgggtcaatg gggacatggg cagggtgggg cactaggagg ggctgggtt
 2581 atggcatgtc tccaaatccc tattgggatt tcttccaaat atttccctt
 2641 cttdcccgaa taaggcatga aggctgcattt atattggcca agtccctagc
 2701 agtcggcccc cagagatgtt gtaagaagat ctgagttgtc tgctttca
 2761 gaaagtcatc caccagtctt tccaaaggggg gttgaagaaa aggaggaaagg
 2821 ataggggggg agaaaaaaa gaggccaggaa tgccatggaa gaaggagaag
 2881 gaaagcttac tctccctcc aagttcttagg gggctgtc tcttccttcc
 2941 tgccttcaggc ttgcaggagc agccaatggg atggccTTT acaagggggcc
 3001 atctgtatgtc ctctccatgc ggggacccctt ccacccctca gagtgctgt
 3061 tacctacaag atcccgcttc agccgattat ggattactat gagaccaaca
 3121 caagcccgga attgtgttagg tggtacacac acatcacact ggggggggg
 3181 gggcctctg gagggaaagca gggagttggg gtggaaatggg gaccccccagg
 3241 ggtgtgacta catggggaga ggcagcttag gggcaatctg agcgttttct
 3301 tgcaggagcc atggggaaac tgacccttgc gatgggggaga tgacagagaa
 3361 ggcaggaggc cacttccctc gggggacaca gagactatg gggcttggg
 3421 ccgaagagta tgcctcagag aggagactgg ctctaaatgc cctctgtgg
 3481 agcagtatag gtcagggtggg gaatttttagga gggagggaaat gatggctgtc
 3541 actggggcccc tgggtttgtg atcccttc tcttgcattt acagcttcat
 3601 ggccatcccg tctgtacca cccctggatgc aagtgggtcc aggactatat
 3661 aaggagaact gatgtgacca gaaagggtgg cttaaaggcaca gtcagagac
 3721 gatgccaagg ccccttcctc caccctccatgc taactctcag cccctgtgg
 3781 cttdccctgtt ttgaattaaa gaccactcat gcttccctt ggcttcattt
 3841 gatttactca ttggccatgc actgaggaca ccagggtgtg gcaccctcg
 3901 cgctctgcag aagttttgtt ggagctgtgtt acaaaaaaaat ggtcaggct
 3961 tagtggaaag cagaaggatg gaaagaaaaag cagtgtaaag accgtctctt
 4021 aacagttagca gacccccc

//
LOCUS HS221 925 bp mRNA PRI 30-JUN-1998
DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-1.
ACCESSION Z70292
NID g1296608
KEYWORDS chemokine CC-1; chemokine CC-2.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 925)

AUTHORS Pardigol,A., Forssmann,U., Zucht,H.D., Loetscher,P.,
 Schulz-Knappe,P., Baggiolini,M., Forssmann,W.G. and Magert,H.J.
 and HCC-2, a human chemokine: gene structure, expression pattern,
 biological activity
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 95 (11), 6308-6313 (1998)
 MEDLINE 98263352
 REFERENCE 2 (bases 1 to 925)
 AUTHORS Pardigol,A.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 Biology, Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 Strasse 31, Hannover, Lower Saxony, 30625, Germany
 FEATURES Location/Qualifiers
 source 1..925
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5'UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233855"
 /db_xref="PID:g1296609"
 /db_xref="SWISS-PROT:Q16663".

 /translation="MKVVAALSCMLVAVLGSAQFTNDAETELMMSKLPENPVVL
 NSFHFAADCCTSISQSIPCSLMKSYFETSSCSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI".
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the bicistronic mRNA"
 CDS 499..780
 /codon_start=1
 /evidence=experimental
 /product="chemokine CC-1"
 /db_xref="PID:e233856"
 /db_xref="PID:g1296610"
 /db_xref="SWISS-PROT:Q16627".

 /translation="MKISVAAIPFFLITIALGKTTESSSRGPYHPSECCFTYTTYKI
 PRQRIMDYETNSQCSKPGIVFITKRGHSVCTNPSDKWVQDYIKDMKEN".
 3'UTR 781..925
 polyA_signal 902..908
 BASE COUNT 240 a 296 c 199 g 190 t
 ORIGIN
 1 ccaggaagca gtgagccca ggtgcctcgg ccagccctgc ctgcccacca ggaggatgaa
 61 ggtctccgtg gtcgcctct cctgcctcat gcttgtgtc gtccctggat cccaggccca
 121 gttcacaatat gatgcagaga cagagttaat gatgtcaaaag cttccactgg aaaaatccat
 181 agttctgaac agtttcaact ttgctgtcga ctgctgcacc tcctacatct cacaaggcat
 241 cccgtgtca ctcatgaaaaa gttatggta aacgaggcage gagtgctcca agccagggtgt
 301 catattctc accaagaagg ggcggcaagt ctgtgcctaaa cccagtggtc cgggagttca
 361 ggattgcattt aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gcccacccacc tccaaacaccct cctgagccctc tgaagctccc accaggccag ctctccccc
 481 acaacagctt cccacacgcat gaagatctcc gtggctgcctt ttcccttctt cctccctcatc
 541 accatcgcccc tagggaccaa gactgaatcc tcctcacggg gaccttacca cccctcagag
 601 tgctgcttca cttacactac ctacaagatc cccgcgtcaggc ggattatggta ttactatgag
 661 accaacagcc agtgctccaa gcccggaaatt gtcttcatca cccaaagggg ccattccgtc
 721 tgtaccaacc ccagtgcacaa gtgggtccag gactatatac aggacatgaa ggagaactgaa
 781 gtgaccggaga agggtggc aaggcacacgc tcagagacat aaagagaaga tgccaaaggcc
 841 ccctcccca cccacccgcta acttcgcacc ccagtccccc tcttggact tccctgctt
 901 gaattaaaga ccactcatgc ttttc
 //"

LOCUS HSCC23 973 bp RNA PRI 03-MAY-1996
 DEFINITION H.sapiens mRNA for chemokine CC-2 and CC-3.
 ACCESSION 270293
 NID g1296611
 KEYWORDS Human chemokine CC-2; Human chemokine CC-3.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 973)
 AUTHORS Pardigol,A., Maegert,H.J., Zucht,HD., Forssmann,W.G. and
 Schulz-Knappe,P.
 TITLE Transcription of a Human Tandem Gene results in a Mature
 Bicistronic mRNA encoding two Novel CC-Chemokines
 Unpublished
 JOURNAL 2 (bases 1 to 973)
 REFERENCE Pardigol,A.
 AUTHORS Direct Submission
 TITLE Submitted (25-MAR-1996) Andreas Pardigol, IV - Molecular
 JOURNAL Biology
 Strasse Lower Saxony Institute for Peptide Research, Feodor-Lynen-
 31, Hannover, Lower Saxony, 30625, Germany
 FEATURES Location/Qualifiers
 source 1..973
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /dev_stage="adult"
 /tissue_type="liver"
 /clone_lib="PCR fragments"
 5' UTR 1..55
 CDS 56..397
 /note="putative; first coding region of a bicistronic
 mRNA"
 /codon_start=1
 /product="chemokine CC-2"
 /db_xref="PID:e233857"
 /db_xref="PID:g1296612"

 /translation="MKVSVAALSLMLVALGSQAQFTNDAETELMMSKLPLENPVVL
 NSFHFAADCCTSYISQSIPCSLSMKSYFETSSECSKPGVIFLTKKGRQVCAKPSGPGVQ
 DCMKKLKPYSI"
 misc_feature 398..498
 /note="spacing region between two coding regions of
 the
 bicistronic mRNA"
 CDS 499..828
 /note="putative"
 /codon_start=1
 /product="chemokine CC-3"
 /db_xref="PID:e233858"
 /db_xref="PID:g1296613"

 /translation="MKISVAAIPFFLLITIALGTKTESSSQGGKPKVVKIQLKLVGG
 PYHPSECCFTYTTYKIPRQRIMDYETNSQCSKPGIVFITKRGHSVCTNPSDKWVQDY
 IKDMKEN"
 3' UTR 829..973
 polyA_signal 950..956
 BASE COUNT 257 a 301 c 215 g 200 t
 ORIGIN
 1 ccaggaagca gtgagccccag gagtcctcg ccagccctgc ctgccccacca ggaggatgaa
 61 ggtctccgtg gctgccctct cctgcctcat gcttggct gtccttggat cccaggccca
 121 gttcacaaat gatgcagaga cagagttaat gatgtcaag cttccactgg aaaaatccagt
 181 agttctgaac agcttcact ttgctgctga ctgctgcacc tcctacatct cacaagacat
 241 cccgtgtca ctcatgaaaaa gttatggta aacgagcagc gagtgctcca agccagggtgt
 301 catatccctc accaagaagg ggcggcaagt ctgtccaaa cccagtggtc cgggagttca
 361 ggattgcatg aaaaagctga agccctactc aatataataa taaagagaca aaagaggcca
 421 gccacccacc tccaaacacct cctgagcctc tgaagctccc accaggccag ctctccccc

481 acaaacagctt cccacagcat gaagatctcc gtggctgcca ttcccttctt cctcctcatc
 541 accatcgcacc tagggccaa gactgaatcc tcctcacaaa ctggggggaa accgaaggtt
 601 gttaaaatac agctaaagtt ggtggggga ccttaccacc ccttagagtg ctgcttcacc
 661 tacactaccc acaagatccc gcgtcagcgg attatgatt actatgagac caacagccag
 721 tgctccaagc ccggaaattgt ttcatcacc aaaaggggcc attccgtctg taccacccc
 781 agtgacaagt gggccagga ctatataaag gacatgaagg agaactgagt gacccagaag
 841 gggccggaa ggcacagctc agagacataa agagaagatg ccaaggcccc ctccctccacc
 901 caccgctaact tcctcagcccc agtcacccctc ttggagcttc cctgcttga attaaagacc
 961 actcatgctc ttc
 //

LOCUS HSU91746 1430 bp mRNA **PRI** 12-MAR-1998
DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
cds
ACCESSION U91746
NID g2581780
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
 Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1430)
AUTHORS Hedrick, J.A., Helms, A., Gorman, D. and Zlotnik, A.
TITLE Identification of a novel human CC chemokine upregulated by IL-
 10
JOURNAL Blood (1998) In press
REFERENCE 2 (bases 1 to 1430)
AUTHORS Hedrick, J.A., Helms, A., Gorman, D. and Zlotnik, A.
TITLE Direct Submission
JOURNAL Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
 901 California Ave, Palo Alto, CA 94304, USA
FEATURES
source Location/Qualifiers
 1..1430
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
gene 1..1430
 /gene="HCC-4"
CDS 1..363
 /gene="HCC-4"
 /note="CC or beta chemokine family member"
 /codon_start=1
 /product="IL-10-inducible chemokine"
 /db_xref="PID:g2581781"

/translation="MKVSEAAALSLVLILITASRSQPKVPEWVNTPSTCCLKYKEK
VLPRRLVVGYRKALNCLPAIIFVTKRNRVCTNPNDWVQEYIKDPNLPLLPTRNLS
TVKIITAKNGQPOLLNSQ"
BASE COUNT 401 a 351 c 293 g 385 t
ORIGIN

```

    1 atgaaggctt ccgaggctgc cctgtctctc cttgtccatca tccttatcat tacttcggct
    61 tctcgcaccc agccaaaggat tcctgagtgg gtgaacaccc catccacctg ctgcctgaag
    121 tattatgaga aagtgttgc aaggagacta gtggggat acagaaaaggc cctcaactgt
    181 cacctgccag caatcatctt cgtcaccaag aggaaccggag aagtctgcac caaccccaat
    241 gacgactggg tccaagagta catcaaggat cccaaacctc ctttctgccc taccaggaac
    301 ttgtccaccc ttaaaaattt tacagcaaag aatggtaac cccagctctt caactcccgag
    361 tgatgaccgg gcttttagtgg aaggccctgtt ttacagaaga gaggggtaaa cctatgaaaa
    421 caggggaaagc cttttaggc tgaaaatgc cagtcacattt gaggaaagca gaaacaatgtat
    481 caaaaataaag gagaagtatt tcgaatattt tctcaatctt aggaggaaat accaaaggta
    541 agggacgtgg gcagaggtac gctttttat tttttatattt atttttat ttttttggaaa
    601 taggtcttac tctgtcaccc aggtctggatgc gcatgtgtt gatcttggct cacttgatct
    661 tggctcaactg taacatccac ctccccaggctt caagtgatcc tcccacccca gcctcccgag
    721 tagctggac tacaggcttgc cggccacca cctggctaat ttttggat ttttggat
    781 cgggatttcta ccatgttgc caggctggtc tcaaaactctgt gtgcccggc aatccaccc
    841 cctcagccctt cccaaaggatgc tgggatttaca ggcgtgagcc accacatccg gccagggtcac
    901 tcttaataca cagaaaaata tatttccat ccttctccctg ctctctttca attctctact
    961 tcacaccaggat acacaagcca ttctaaatac tttagccaggat tccagccctt cagatgtatct
    1021 ttggccctctg ggtcttgcacc cattaaagagc cccatagaac ttttgat ttttgcctt
    1081 ctttatggat ttttctggat ctatatttcc ttcaattttt ctttcatattt ataatgcaac
  
```

1141 ttttcatag gaagtccgga tggaatatt cacattaatc attttgtag agactttgt
 1201 agatcctctc atattttgtc ttccctcagg tggcagggtt acagagatg cctgatttga
 1261 aaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctaccc
 1321 ccatgttaag ctttgcagga caggaaaga aaggatgtga gacacggcta gggtaact
 1381 cttagtccaa aacccaagca tgcaataat aaaactccct tatttgacaa
 //

LOCUS AB007454 1503 bp mRNA PRI 09-APR-1998
 DEFINITION Homo sapiens mRNA for chemokine LEC precursor, complete cds.
 ACCESSION AB007454
 NID g2723285
 KEYWORDS chemokine LEC precursor.
 SOURCE Homo sapiens liver cDNA to mRNA.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (sites)
 AUTHORS Shoudai,K., Hieshima,K., Fukuda,S., Iio,M., Miura,R., Imai,T.,
 Yoshie,O. and Nomiyama,H.
 TITLE Isolation of cDNA encoding a novel human CC chemokine NCC-4/LEC
 JOURNAL Biochim. Biophys. Acta 1396 (3), 273-277 (1998)
 MEDLINE 98207719
 REFERENCE 2 (bases 1 to 1503)
 AUTHORS Nomiyama,H.
 TITLE Direct Submission
 JOURNAL Submitted (19-SEP-1997) to the DDBJ/EMBL/GenBank databases.
 Department Hisayuki Nomiyama, Kumamoto University Medical School,
 of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860-0811,
 Japan (E-mail: nomiyama@gpo.kumamoto-u.ac.jp, Tel: 81-96-373-5063,
 Fax: 81-96-372-6140)
 FEATURES Location/Qualifiers
 source 1..1503
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /tissue_type="liver"
 sig_peptide 77..145
 CDS 77..439
 /codon_start=1
 /product="chemokine LEC precursor"
 /db_xref="PID:d1024963"
 /db_xref="PID:g2723286"
 /translation="MKVSEAALSLVLILIIITSASRSQPKVPEWVNPSTCCLKYEK
 VLPRLVVGYRKALNCHLPAlIFVTKRNREVCTNPNDWVQEYIKDPNLPLPTRNLS
 TVKIITAKNGQPQLLNSQ"
 mat_peptide 146..436
 polyA_signal 560..565
 polyA_signal 1485..1490
 BASE COUNT 417 a 374 c 312 g 400 t
 ORIGIN
 1 gttggcaagc ggaccaccag caacagacaaa catttcatt cggctctccc tgaagctgt
 61 ctgcctcgct gagaggatga aggtctccga ggctgcctg tcttccttgc ttctcatcc
 121 tatcattact tcggcttcgc ctagccagcc aaaagtccct gagtggttga acacccatc
 181 cacctgtgc ctgaagtatt agagaaagt gttgccaagg agactgttgg tgggatacag
 241 aaaggccctc aactgtcacc tgccagcaat catttcgtc accaagagga accgagaagt
 301 ctgcaccaac cccaaatgacg actgggtcca agagtacatc aaggatccca acctacattt
 361 gctgcctacc aggaacttgc ccacggtaa aattattaca gcaaagaatg gtcaacccca
 421 gctcctcaac tcccagtat gaccaggctt tagtggaaac ccttgcattac agaagagagg
 481 ggttaaaccta tggaaacagg ggaaggctta ttaggctaa actagccagt cacattgaga
 541 gaagcagaac aatgtatcaa ataaaggaga atgttttgc atattttctc aatctttagga
 601 gaaataccat aagttaaaggc acgtggcag aggtacgtc ttttattttt atatttat
 661 ttttattttt ttgagatagg gtcttactct gtcacccagg ctggagtgcgtt gttgtgttat
 721 ctggctcac ttgatcttgc ctcaactgtaa cctccaccc tcaggtctaa gtgatccct
 781 caccatccatc tcccaggatgc ctgggactac aggttgcgc caccacaccc ggtttat
 841 tgtatcttgc ttgagatagg gatttacca tggccatgg gttgtctca aactctgtgt
 901 cccaaatccatc ccacccgttccat cagccttcca aaagtgttgc gtttacaggc gtgagccacc
 961 acatccggcc agtgcactct taatacacaag aaaaaatata ttcacatccct ttcctgtctc
 1021 tctttcaattt ctcacttca caccatgtca caagccatc taaatacttca ggcgtttcc

1081 agccttccag atgatctttg ccctctgggt cttgaccat taagagcccc atagaactct
 1141 tgattttcc tgtccatctt tatggatttt tctggatcta tattttcttc aattattctt
 1201 tcattttata atgcaacttt ttcataggaa gtccggatgg gaatattcac attaatcatt
 1261 ttgcagaga ctttgcata tcctctcata ttttgccttc ctcagggtgg caggggtaca
 1321 gagatgtctt gattggaaaa aaaaaaaaaa gagagagaga gagaagaaga agaagaagag
 1381 acacaaatct ctacctccca tgtaagctt tgcaaggacag ggaaagaaaag ggtatgagac
 1441 acggcttaggg gtaaaactt agtccaaaac ccaagcatgc aataaataaa actcccttat
 1501 ttg

//

LOCUS AF001979 800 bp mRNA PRI 20-NOV-1997
 DEFINITION Homo sapiens beta chemokine mRNA, complete cds.

ACCESSION AF001979
 NID g2624924

KEYWORDS

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 800)

AUTHORS Hedrick, J.A. and Zlotnik, A.

TITLE Identification and characterization of a novel beta chemokine
 containing six conserved cysteines

JOURNAL J. Immunol. 159 (4), 1589-1593 (1997)
 MEDLINE 97400322

REFERENCE 2 (bases 1 to 800)

AUTHORS Hedrick, J.A. and Zlotnik, A.

TITLE Direct Submission

JOURNAL Submitted (01-MAY-1997) Immunobiology, DNAX Research Institute,
 901 California Ave, Palo Alto, CA 94304, USA

FEATURES source Location/Qualifiers
 1..800

/organism="Homo sapiens"
 /db_xref="taxon:9606"

CDS 1..405
 /note="6Ckine; CC chemokine"
 /codon_start=1
 /product="beta chemokine"
 /db_xref="PID:g2624925"

/translation="MAQSLALSLLILVLAFIGIPRTQGSDGGAQDCCCLKYSQRKIPAKV

VRSYRKQEP SLGCSIPAILFLP RKR SQAE LADPKELWVQQLMQHLDKTPSPQKPAQG
 CRKD RGA SKTGKKGSKGCKRTERS QTPKGP"

BASE COUNT 203 a 248 c 210 g 139 t
 ORIGIN

1 atggctcagt cactggctct gaggccctt atcctggttc tggcctttgg aatccccagg
 61 acccaaggca gtatggagg ggctcaggac tttgcctca agtacagcca aaggaagatt
 121 cccgccaagg ttgtcccgag ctacccggaa caggaaccaa gcttaggctg ctccatccca
 181 gctatccgt tcttgcctcg caagcgctct caggcagagc tatgtgcaga cccaaaggag
 241 ctctgggtgc agcactgtat gcagcatgtc gacaagacac catccccaca gaaaccagcc
 301 caggcgtcaaga ggaaggacag gggggcctcc aagactggca agaaaggaaa gggctccaaa
 361 ggctgcagaaga ggactggacg gtcacagacc cttaaaggcc catagcccag tgacgcct
 421 ggagccctgg agacccccc accgcttccatca ggcgttgcag cctgaaaccca agatgcaga
 481 aggaggat gtcaggggc cttggagcag ccacccatg ctggccttgc cacactttt
 541 ctcctgtttt aaccacccca ttcgcattcc cagcttccatc ctgcatggct gagctgccca
 601 cagcaggccca ggtccagaga gaccggagg ggagatgttc ccaggagca tgagggagg
 661 cagcaggact gttcccttga aggagaatca tcaggaccc ggactgtata cggtccccca
 721 gtacacccca cttttccctt gtaaaatatga ttatataacta actgaataaa aagctgttct
 781 gtcttccac ccaaaaaaaaa

//

LOCUS HSU64197 821 bp mRNA PRI 25-JUN-1997
 DEFINITION Homo sapiens chemokine exodus-1 mRNA, complete cds.

ACCESSION U64197
 NID g1778716

KEYWORDS

SOURCE human.

ORGANISM Homo sapiens

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;

Hominidae; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Homo.
 REFERENCE 1 (bases 1 to 821)
 AUTHORS Hromas,R., Gray,P.W., Chantry,D., Godiska,R., Krathwohl,M.,
 Fife,K., Bell,G.I., Takeda,J., Aronica,S., Gordon,M.,
 Cooper,S., Broxmeyer,H.E. and Klemsz,M.J.
 TITLE Cloning and characterization of exodus, a novel beta-chemokine
 JOURNAL Blood 89 (9), 3315-3322 (1997)
 MEDLINE 97275143
 REFERENCE 2 (bases 1 to 821)
 AUTHORS Hromas,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (17-JUL-1996) Indiana University Medical Center,
 Medicine, 975 W. Walnut St., Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..821
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="Exodus-1"
 /cell_type="islet"
 /tissue_type="pancreas"
 /dev_stage="adult"
 CDS 43..330
 /function="inhibits proliferation of hematopoietic
 progenitors and HIV"
 /codon_start=1
 /product="chemokine exodus-1"
 /db_xref="PID:g1778717"
 /translation="MCCTKSLLLALMSVLLLHLCGESEASNFDCCLGYTDRILHPKF
 IVGFTRQLANECDINAIIFHTKKKLSCVANPKQTWVKYIVRLLSKKVKNM"
 variation 121^122
 encoding /note="insertion of an extra codon GCA at nt 121,
 position for an alanine after the alanine at amino acid
 transcript 26, represents the allelic difference of the
 isolated from macrophages.
 BASE COUNT 258 a 134 c 156 g 273 t
 ORIGIN
 1 ggtactcaac actgaggcaga tctgttcttt gagctaaaaa ccatgtgctg taccaggat
 61 ttgctctgg ctgcgttgc gtcagtgcg ctactccacc tctgcggcga atcagaagca
 121 agcaactttg actgctgtct tggatacaca gaccgtattt ttcatcctaa atttatttg
 181 ggcttcacac ggcagctggc caatgaaggc tgtgacatca atgctatcat ctttcacaca
 241 aaaaaaaaaaagt tgtctgtgt cgccaaatcca aaacagactt gggtaaataa tattgtgcgt
 301 ctcctcaactt aaaaaggtaaa acatgttaa aaactgtggc tttctggaa tggaaattgga
 361 catagcccaa gaacagaaaag aaccttgcg gggttggagg tttcacttgc acatcatgg
 421 gggtttagt cttatctaat ttgtgcctca cctggacttg tccaaatataa gaagttgatt
 481 catatggat ctagttgtc ttgtttaag catcacat aagtggaaact gtatattat
 541 ttatattatag ctgttaggtt ctgtgtttt gctatttaat actaattttc cataagctat
 601 ttgggtttag tgccaaaggtaaaaattatata ttgggggggataaattttat atggactttc
 661 ttgcaagcaa caagctattt tttaaaaaaaa actatggaaacttccatctttt
 721 ttgtctctta aattgttgc atgtcattat aaaaataagaa aatattat aagacaaaata
 781 ttgaaaataa agaaacaaaa agtgcattttt tttttttttt a
 //

LOCUS HSU88320 828 bp mRNA PRI 18-DEC-1997
 DEFINITION Human beta chemokine Exodus-2 mRNA, complete cds.
 ACCESSION U88320
 NID g2196919
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 828)
 AUTHORS Hromas,R., Kim,C.H., Klemsz,M., Krathwohl,M., Fife,K.,
 Cooper,S.,

TITLE Schnizlein-Bick, C. and Broxmeyer, H.E.
 chemokine Isolation and characterization of Exodus-2, a novel C-C
 with a unique 37-amino acid carboxyl-terminal extension
 JOURNAL J. Immunol. 159 (6), 2554-2558 (1997)
 MEDLINE 97444139
 REFERENCE 2 (bases 1 to 828)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission.
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..828
 /organism="Homo sapiens"
 /note="PCR amplified from activated THP-1 cells"
 /db_xref="taxon:9606"
 /clone_lib="Soares human placenta cDNA"
 /cell_line="THP-1"
 /cell_type="monoblast"
 CDS 15..419
 /codon_start=1
 /product="beta chemokine Exodus-2"
 /db_xref="PID:g2196920"

 /translation="MAQSLALSLLILVLA~~FGI~~PRTQGSDGGAQDCCLKYSQRKIPAKV
 VRSYRKQEP~~SLG~~CSIPAILFLPRKRSQAE~~LC~~ADPKELWVQQLMQHLDKTPSPQKPAQG
 CRKDRGASKTGKKGKGSKGCKRTERSQT~~PKGP~~"
 BASE COUNT 218 a 255 c 216 g 139 t
 ORIGIN
 1 ggcacgagggc agacatggct cagtcactgg ctctgagcct ctttatcctg gttctggcct
 61 ttggcatccc caggacccaa ggcagtatg gggggctca ggactgttgc ctcaagtaca
 121 gccaaaggaa gattcccccc aagggttgtcc gcagctaccc gaacggcaggaa ccaagcttag
 181 gctgtccat cccagctatc ctgttcttc cccgcaaggc ctctcaggca gagctatgtg
 241 cagacccaaa ggagctctgg gtgcagcagc tgatgcagca tctggacaag acaccatccc
 301 cacagaaacc agccaggcgc tgccaggaaagg acaggggggc ctccaaagact ggcaagaaaag
 361 gaaaggggctc caaaggctgc aagaggactg aegggctaca gaccctaaa gggccatagc
 421 ccagttagca gcctggagcc ctggagaccc caccaggctc accagcgtt gaaaggctgaa
 481 cccaaagatgc aagaaggagg ctatgctcag gggcccttgg gcaggccaccc catgtggcc
 541 ttgcacact ctttctctg cttaaccac cccatctgca ttccctgctc tcaccctgca
 601 tggctgatgc tgcccacagc aggccaggcgc cagagagacc gaggaggag agtctcccag
 661 ggagcatgag aggaggcgc aggactgtcc ccttggagga gaatcatcag gaccctggac
 721 ctgatacggc tccccagtagc accccaccc ttccttggtaa atatgattta tacctaactg
 781 aataaaaagc tggctgtct tccccccaa aaaaaaaaaa aaaaaaaaaa
 //
 LOCUS HSU88321 502 bp mRNA PRI 22-JUN-1998
 DEFINITION Human beta chemokine Exodus-3 mRNA, complete cds.
 ACCESSION U88321
 NID g2196921
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 502)
 AUTHORS Hromas, R.A., Gray, P., Klemsz, M., Fife, K. and Broxmeyer, H.
 TITLE DCCL chemokines represent a novel beta chemokine subfamily
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (04-FEB-1997) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REFERENCE 3 (bases 1 to 502)
 AUTHORS Hromas, R.A.
 TITLE Direct Submission
 JOURNAL Submitted (22-JUN-1998) Medicine, Indiana University Medical
 Center, 975 West Walnut, Indianapolis, IN 46202, USA
 REMARK Amino acid sequence updated by submitter
 FEATURES Location/Qualifiers
 source 1..502

```

/organism="Homo sapiens"
/note="PCR amplified from THP-1 cells"
/db_xref="taxon:9606"
/cell_line="THP-1"
/cell_type="monoblast"
/dev_stage="adult"
120..416
/note="Mip-3alpha/ELC/CKbeta1"
/codon_start=1
/product="beta chemokine Exodus-3"
/db_xref="PID:g3243080"

/translation="MALLLALSLLVLWTSPAPTLSGTNDADCCLSVTQKPIPGYIVR
NFHYLLIKDGCRVPAAVFTTLRGRQLCAPPDQPWVERIIQRLQRTSAKMRRSS"
BASE COUNT 113 a 170 c 121 g 98 t
ORIGIN
1 ctcacacccctt gcatttcacc cctgcattccc atgcgccttg cagcctcaca cagatcctgc
61 acacacccag acagctggcg ctcacacatt caccgttggc ttgcctctgt tcaccctcca
121 tggccctgtct actggccctc agccctgtgg ttctctggac ttcccccagcc ccaactctga
181 gtggcaccaa tggatgtgaa gactgtgtcc ttgtgtgtac ccggaaaccc atccctgggt
241 acatctgtggaa gaaactccac taccttcgtca tcaaggatgg ctgcagggtg cctgtgttag
301 tggccaccc actgggggc cgccagctt gtgcacccccc agaccagccc tgggttagaa
361 gcacatcca gagactcgac aggacctcg ccaagatgaa gcgcgcgcgc agttaaccta
421 tgaccgtgca gaggggagccc cgagtcggag tcaagcattt gtaatttta ctaactggaa
481 acgaggacag aaggaggac ag
//"

LOCUS HSU86358 879 bp mRNA PRI 11-SEP-1997
DEFINITION Human chemokine (TECK) mRNA, complete cds.
ACCESSION U86358
NID g2388626
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 879)
AUTHORS Vicari,A.P., Figueroa,D.J., Hedrick,J.A., Foster,J.S.,
Singh,K.P.
and Menon,S., Copeland,N.G., Gilbert,D.J., Jenkins,N.A., Bacon,K.B.
Zlotnik,A.
TITLE TECK: a novel cc chemokine specifically expressed by thymic
dendritic cells and potentially involved in T cell development
JOURNAL Immunology 7, 291-301 (1997)
REFERENCE 2 (bases 1 to 879)
AUTHORS Vicari,A.P. and Zlotnik,A.
TITLE Direct Submission
JOURNAL Submitted (21-JAN-1997) Immunology, DNAX Research Institute,
901 California Ave., Palo Alto, CA 94304, USA
FEATURES Location/Qualifiers
source 1..879
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/tissue_type="thymus"
gene 1..879
/gene="TECK"
CDS 1..453
/gene="TECK"
/codon_start=1
/product="chemokine"
/db_xref="PID:g2388627"

/translation="MNLWLLACLVAGFLGAWAPAVHTQGVFEDCLAYHYPIGWAVLR
RAWTYRIQEVSGLCNLPAAIFYLPKRHRKVCGNPKSREVQRAMKLLDARNKVFALKH
NMQTFQAGPHAVKKLSSGNSKLSSKFSNPISSSKRNVSLISANGL"
BASE COUNT 191 a 264 c 218 g 206 t

```

ORIGIN

```

1 atgaacctgt ggcccttggc ctgcctggc gccggcttcc tgggagcctg ggcccccgt
61 gtccacaccc aagggtgtt tgaggactgc tgccctggc accactaccc cattgggtgg
121 gctgtgtcc ggcgcctg gacttacccg atccaggagg tgagcggag ctgcaatctg
181 cctgcgtcga tattctaccc ccccaagaga cacaggaagg tgggtggaa ccccaaaagc
241 agggaggtgc agagagccat gaagctcctg gatgctcga ataagggttt tgcaagctc
301 caccacaaca tgcacaccc ccaagcaggc cctcatctg taaagaagtt gagttctgga
361 aactccaagt tattatcatc caagtttagc aatcccatca gcagcagcaa gaggaatgtc
421 tccctcttgc tattagctaa ttccaggactg tgagccgct catttctggg ctccatcggc
481 acaggagggg ccggatctt ctccgataaa accgtcggcc tacagaccca gctgtcccc
541 cgcctctgc ttgggttca agtcttaatc cctgcacccg atgggttctt cccttcgcac
601 cccccaccacc tcctggccctg ctggcaactg gaaagaagga gttggctga ttttaacctt
661 ttggccgtcc ggggaaacage acaatccctgg gcagccagtg gctttgttag agaaaactta
721 ggataacctct ctcactttctt gtttcttgc gtcaccccg ggcacatgcca gtgtgtccctc
781 tgggtccctt cccaaaatct ggtcattcaa ggatccctc ccaaggctat gcttttctat
841 aacttttaaa taaaccccttgg ggggtgaatg gaataaaaa
//
```

/

LOCUS	AB002409	852 bp	mRNA	PRI	15-AUG-1997		
DEFINITION	Homo sapiens mRNA for SLC, complete cds.						
ACCESSION	AB002409						
NID	g2335034						
KEYWORDS	SLC; mature ELC.						
SOURCE	Homo sapiens cDNA to mRNA.						
ORGANISM	Homo sapiens Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;						
Hominidae;	Homo.						
REFERENCE	1 (bases 1 to 852)						
AUTHORS	Nomiyama,H.						
TITLE	Direct Submission						
JOURNAL	Submitted (28-MAR-1997) to the DDBJ/EMBL/GenBank databases. Hisayuki Nomiyama, Kumamoto University Medical School,						
Department	of Biochemistry; Honjo 2-2-1, Kumamoto, Kumamoto 860, Japan (E-mail:nomiyama@gpo.kumamoto-u.ac.jp, Tel:81-96-373-5063, Fax:81-96-372-6140)						
REFERENCE	2 (bases 1 to 852)						
AUTHORS	Nagira,M., Imai,T., Hieshima,K., Kusuda,J., Ridanpaa,M., Takagi,S.,						
TITLE	Nishimura,M., Kakizaki,M., Nomiyama,H. and Yoshie,O. Molecular Cloning of a Novel Human CC Chemokine Secondary Lymphoid-Tissue Chemokine (SLC) That is an Efficient Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13 Unpublished (1997)						
JOURNAL							
FEATURES	Location/Qualifiers						
source	1..852 /organism="Homo sapiens" /db_xref="taxon:9606"						
CDS	59..463 /codon_start=1 /product="SLC" /db_xref="PID:d1022673" /db_xref="PID:g2335035"						
<i>/translation=MAQSLALSLLILVLAFCIPIRQGSDGGAQDCCLKYQRKIPAKV VRSYRKQEP SLGCSI PAILFLPRKR SQAE LCA DP KELWVQQLM QHLDKTPSPQKPAQG CRKDRGASKTGKGKGSKGCKRTERSQTPKGP</i>							
mat_peptide	<107..460 /product="mature ELC"						
polyA_site	823..828						
BASE COUNT	205	a	279	c	217		
ORIGIN	1	cttgcagctg	cccacctcac	cctcagctt	ggccctttac	tcacccctta	ccacagacat
	61	ggctcagtca	ctggctctga	gccttcctat	cctgggttctg	gcctttggca	tccccaggac
	121	ccaaggcagt	gtggagggg	ctcaggactg	ttgcctcaag	tacagccaaa	ggaagattcc
	181	cgccaaagg	gtccgcagct	accggaaagca	ggaaccaagc	ttaggctgt	ccatccccagc
	241	tatccgttc	ttggcccccga	agcgtctca	ggcagagct	tgtgcagacc	caaaggagct
	301	ctgggtcag	cagctgtatgc	agcatctgga	caagacacca	tccccacaga	aaccagccca

361 gggctgcagg aaggacaggg gggcctccaa gactggcaag aaaggaaagg gctccaaagg
 421 ctgcagaagg actgagcggt cacagacccc taaaggccca tagcccagtg agcagcctgg
 481 agccctggag acccccacag cctcaccaac gcttgcggcc tgaacccaaag atgcaagaag
 541 gaggcttatgc tcaggggccc tggagcagcc accccatgtt ggcttgccca cactcttct
 601 cctgtttaa ccacccatc tgcatccccca gcttacccctt gcatggctga gctgcccaca
 661 gcagggccagg tccagagaga ccgaggaggg agagtctccc agggagcatg agaggagcca
 721 gcaggactgt ccccttgaag gagaatcatc aggacccctgg acctgatacg gctccccagt
 781 acacccacc tttcccttgtt aaatatgatt tatacctaac tgaataaaaaa gctgttctgt
 841 cttccaccc gc
 //
 LOCUS AF055467 1481 bp mRNA PRI 06-AUG-1998
 DEFINITION Homo sapiens monotactin-1 mRNA, complete cds.
 ACCESSION AF055467
 NID g3395775
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1481)
 AUTHORS Youn, B.S., Zhang, S., Broxmeyer, H.E., Antol, K., Fraser, M.J. Jr.,
 Hangoc, G. and Kwon, B.S.
 TITLE Isolation and characterization of LMC, a novel lymphocyte and
 monocyte chemoattractant human CC chemokine, with
 myelosuppressive
 activity
 JOURNAL Biochem. Biophys. Res. Commun. 247 (2), 217-222 (1998)
 MEDLINE 98308096
 REFERENCE 2 (bases 1 to 1481)
 AUTHORS Youn, B.S. and Kwon, B.S.
 TITLE Direct Submission
 JOURNAL Submitted (24-MAR-1998) Microbiology and Immunology, Indiana
 University, School of Medicine, 605 Barnhill Dr. Medical
 Science Bldg., Indianapolis, IN 46202, USA
 FEATURES Location/Qualifiers
 source 1..1481
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 5' UTR 1..34
 CDS 35..397
 /note="Mtn-1; LMC; lymphocyte and monocyte
 chemoattractant CC chemokine"
 /codon_start=1
 /product="monotactin-1"
 /db_xref="PID:g3395776"
 /translation="MKVSEAALSLVLILIIITSASRSQPKVPEWVNTPSTCCLKYYEK
 VLPRLVVGYRKALNCHLPAIIIFVTKRNREVCTNPNDWVQEYIKDPNLPLPTRNLS
 TVKLIITAKNGQFQLLNSQ"
 3' UTR 398..1481
 BASE COUNT 412 a 362 c 302 g 405 t
 ORIGIN
 1 gcacgagctg aagctgtact gcctcgctga gaggatgaag gtctccgagg ctgcctgtc
 61 tctccctgtc ctcatcctta tcattacttc ggcttcgtc agccagccaa aagttcctga
 121 gtgggtgaac accccatcca cctgtgcctt gaagtattat gagaaggatgt tgccaggag
 181 actagtggtg ggatcacagaa agggccctaa ctgtcacctg ccagcaatca ttttcgtcac
 241 caagaggaaac cgagaaggct gcaccaaccc caatgacgac tgggtccaag agtacatcaa
 301 ggatccccaaac ttttttttttgc tgccttccacca gaaactgtcc acggttaaaa ttattacagc
 361 aaagaatgtt caaccccccgc ttctcaacttc ccagtgtatga ccaagcttta gtggaaagccc
 421 ttgttttacag aagagagggg taaactatga aaacagggga agcccttatta ggctgaaact
 481 agcccaacttccat attgagagaaa gcagaacaat gatcaaaaata aaggagaagt atttcgaata
 541 ttttctcaat ctttagggaa aatccaaaag ttaaggacg tgggcagagg tacgctctt
 601 tatttttataat ttttatattttt tatttttttgg agatagggtc ttactctgtc accccaggctg
 661 gagtgcaatgt gtgtatctt ggctcaactt atcttggctc actgttaaccc cccacccca
 721 ggctcaatgtt atcccccac cccaccctcc cgatgtactt ggactacagg ttgcgcac
 781 cacacccgc taattttggta gagacggat tctaccatgt tgccaggat

841 ggtctcaaac tcgtgtgccc aagcaatcca cctgcctcag ccttccaaaa gtgctggct
 901 tacaggcgtg agccaccaca tccggccagt ccactcttaa tacacagaaa aatatatttc
 961 acatcctct cctgctctct ttcaattcct cactcacac cagtagacaa gccattctaa
 1021 atacttagcc agttccagc cttccagatg atcttgcct tctgggtctt gaccattaa
 1081 gagccccata gaactcttga ttttctgt ccactttat gggattttc tggatctata
 1141 ttttcttcaa ttattcttca attttataat gcaactttt cataggaagt ccgttaggaa
 1201 atattcacat taatcatttt tgtagagact ttgcttagatc ctctcatatt ttgtcttcct
 1261 cagggtggca ggggtacaga agtgcctgat tggttttttt tttttttag agagagagag
 1321 aagaagaaga agaagagaca caaatctcta cctccatgt taagctttgc aggacaggga
 1381 aagaagggt atgagacacg gctagggtaa actcttagtc caaaacccaa gcatgcaata
 1441 aataaaatc ctttatttga caaaaaaaaaaaaaaaa aaaaaaaaaa a

//

LOCUS HSRNAATAC 557 bp RNA PRI 06-JUL-1995
 DEFINITION H.sapiens mRNA for ATAC protein.
 ACCESSION X86474
 NID g895846
 KEYWORDS ATAC gene.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 557)
 AUTHORS Muller,S., Dorner,B., Korthauer,U., Mages,H.W., D'Apuzzo,M.,
 Senger,G. and Kroczeck,R.A.
 TITLE Cloning of ATAC, an activation-induced, chemokine-related
 molecule
 JOURNAL Eur. J. Immunol. 25 (6), 1744-1748 (1995)
 MEDLINE 95339892
 REFERENCE 2 (bases 1 to 557)
 AUTHORS Kroczeck,R.A.
 TITLE Direct Submission
 JOURNAL Submitted (20-APR-1995) R.A. Kroczeck, Molecular Immunology,
 Robert-Koch-Institute, Nordufer 20, 13353 Berlin, FRG
 FEATURES Location/Qualifiers
 source 1..557
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /tissue_type="peripheral blood"
 /cell_type="lymphocyte"
 /chromosome="1"
 /map="q23"
 gene 25..369
 /gene="ATAC"
 CDS 25..369
 /gene="ATAC"
 /codon_start=1
 /product="CD8+T cell specific protein"
 /db_xref="PID:g895847"
 /db_xref="SWISS-PROT:P47992"

 /translation="MRLLILALLGICSLTAYIVEVGVGSEVSDKRTCVSLTQRLPVSR
 IKTYTITEGSLRAVIFITKRLKVCADPQATWVRDVVRSMDRKSNTNNMIQTKPTGT
 QQSTNTAVTLTG"
 polyA_signal 469..474
 polyA_signal 534..539
 BASE COUNT 157 a 139 c 112 g 149 t
 ORIGIN
 1 gcacagctca gcaggaccc agccatgaga cttctcatcc tggccctcct tggcatctgc
 61 tctctactg catacattgt ggaaggtgt gggagtgaag ttcagataa gaggacctgt
 121 gtgagctca stacccagcg actgcccgtt agcagaatca agacccatcac catcacggaa
 181 ggctcttga gagcagtaat ttttattacc aaacgtggcc taaaagtctg tgctgatcca
 241 caagccacat gggtagaga cgtggtcagg agcatggaca gggaaatccaa caccagaaat
 301 aacatgatcc agaccaagcc aacaggaacc cagaatcga ccaatacagc tttgactctg
 361 actggctagt agtctctggc accctgtccg tctccagccca gcccagctcat ttcaactttac
 421 acgctcatgg actgatgttta tactcgcctt ttatgaaagc actgcatgaa taaaattatt
 481 cctttgtatt ttatcttta aatgtcttct gtattcactt atatgttcta attaataat
 541 tatattat taagaat

//

LOCUS HSU85767 **563 bp** **mRNA** **PRI** 01-APR-1997
DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-1 mRNA, complete
cds.
ACCESSION U85767
NID g1916249
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 563)
AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
TITLE Molecular and functional characterization of two novel human C-
C chemokines as inhibitors of two distinct classes of myeloid progenitors
JOURNAL J. Exp. Med. (1997) In press
REFERENCE 2 (bases 1 to 563)
AUTHORS Li,H. and Patel,V.P.
TITLE Direct Submission
JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences, 9410
FEATURES Keywest Ave., Rockville, MD 20850, USA
source Location/Qualifiers
1..563
/organism="Homo sapiens"
/db_xref="taxon:9606"
CDS 31..393
/note="myeloid progenitor inhibitory factor-1"
/codon_start=1
/product="MPIF-1"
/db_xref="PID:g1916250"

/translation="MKVSVAALSLMLVTALGSQARVTKDAETEFMMSKLPLENPVLL
DRFHATSADCCISYTPRSIPCSLLESYFETNSECSKPGVIFLTKKRRFCANPSDKQV
QVCMRMLKLDTRIKTRKN"
BASE COUNT 164 a 143 c 117 g 139 t
ORIGIN
1 ctcagccagc cctgcctgcc caccaggagg atgaaggctc ccgtggctgc ccttcctgc
61 ctcatgtttt ttactgcctt tgatcccag gcccgggtca caaaagatgc agagacagag
121 ttcatgtatgt caaagcttcc attggaaaat ccagacttc tgacagatt ccatgtctact
181 agtgctgact gctgcatttc ctacacccca cgaagcatcc cgtgttcaact cctggagagt
241 tactttgaaa cgaacagcga gtgctccaag ccgggtgtca tcttcctcac caagaagggg
301 cgacgtttct gtgccaaccc cagtgtataag caagtctagg ttgcatttag aatgtctgaag
361 ctggacacac ggatcaagac caggaagaat tgaacttgc aaggtgaagg gacacaagtt
421 gccagccacc aactttcttg cctcaactac cttccatgtat tattttttta agaaggattt
481 attcttgtt tctggattta gagcaattca tctaataaac agtttctcac ttttaaaaaaa
541 aaaaaaaaaa aaaaaaaaaa aaa
//
LOCUS HSU85768 **360 bp** **mRNA** **PRI** 01-APR-1997
DEFINITION Human myeloid progenitor inhibitory factor-1 MPIF-2 mRNA, complete
cds.
ACCESSION U85768
NID g1916251
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 360)
AUTHORS Patel,V.P., Kreider,B.L., Li,Y., Li,H., Leung,K., Salcedo,T., Nardelli,B., Pippalla,V., Gentz,S., Thotakura,R., Parmelee,D., Gentz,R. and Garotta,G.
TITLE Molecular and functional characterization of two novel human C-

C

chemokines as inhibitors of two distinct classes of myeloid progenitors

JOURNAL J. Exp. Med. (1997) In press
 REFERENCE 2 (bases 1 to 360)
 AUTHORS Li, H. and Patel, V.P.
 TITLE Direct Submission
 JOURNAL Submitted (17-JAN-1997) Cell Biology, Human Genome Sciences,
 9410 Keywest Ave., Rockville, MD 20850, USA
 FEATURES Location/Qualifiers
 source 1..360
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 1..360
 /note="myeloid progenitor inhibitory factor-2"
 /codon_start=1
 /product="MPIF-2"
 /db_xref="PID:g1916252"

/translation="MAGLMTIVTSLFLGVCAHHIPTGSVVI PSCPCCMFVSKRIPE

NRVVSYQLSSRSTCLKGGVIFTTKKGQQFCGDPKQEWVQRYMKNLDAKQKKASPRARA
 VAVKGPVQRYPGNQTT"

BASE COUNT 85 a 106 c 96 g 73 t

ORIGIN

1 atggcaggcc tggatgaccat agtaaccagg cttctgttcc ttgggtgtctg tgcccaccac
 61 atccatcccta cgggctctgt ggtcataccccc tccctctgt gcatgttctt tgggttccaaag
 121 agaattcttg agaaccggat ggtcagctac cagctgtccca gcaggaggac atgcctcaag
 181 ggaggaggatgta tcttcaccac caacaaggcc cagcgttctt gtggcaccac caaggaggag
 241 tgggtccaga ggtacatgaa gaaacctggac gccaaggcaga agaaggcttc ccctaggccc
 301 agggcagtgg ctgtcaaggg ccctgtccag agatatcctg gcaaccaaac cacctgtctaa

//

LOCUS HUMSDF1A 1847 bp mRNA PRI 26-DEC-1996
 DEFINITION Human pre-B cell stimulating factor homologue (SDF1a) mRNA,
 complete cds.
 ACCESSION L36034
 NID g1220363
 KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating
 factor

SOURCE homologue; alpha-chemokine.
 ORGANISM human.

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1847)

AUTHORS Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H.,
 Shinohara, T. and Honjo, T.

TITLE Structure and chromosomal localization of the human stromal
 cell-derived factor 1 (SDF1) gene

JOURNAL Genomics 28 (3), 495-500 (1995)
 MEDLINE 96039262

FEATURES Location/Qualifiers
 source 1..1847
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="h5"
 /cell_line="FLEB14-14"
 sig_peptide 80..142
 /gene="SDF1a"
 CDS 80..349
 /codon_start=1
 /product="pre-B cell stimulating factor homologue"
 /db_xref="PID:g1220364"

/translation="MNAKVVVVLVLVLTALCLSDGKPVSLSYRCPCRF FESHVARANV

KHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALNK"

gene 80..346
 /gene="SDF1a"

mat_peptide 143..346

```

/gene="SDF1a"
/product="pre-B cell stimulating factor homologue"
BASE COUNT      459 a      471 c      417 g      500 t
ORIGIN
  1 ttcggcgttag ccgcattgcc cgtcgccgt cggccccccg acccggtgtc gtccggccgc
  61 ccggccggcc gccccggcca tgaacgcca ggtcggtc gtgtgtgtcc tctgtgtgac
  121 cgcgtctgc ctcagcgacg ggaagcccg cagccgtgac tacagatgcc catggcatt
  181 cttcgaaagc ctagttgcca gagccaaagt caagcatctc aaaattctca acactccaa
  241 ctgtggcctt cagattgtag cccggctgaa gaacaacaac agacaagtgt gcatgtaccc
  301 gaagcttaag tggattcagg agtacctgt gaaaggctta aacaagtaag cacaacaggc
  361 aaaaaggact ttccgctaga cccactcgag gaaaactaaa accttggtag agatggaaag
  421 gcaaagacgt gggggagggg gccttaacca tgaggaccag gtgtgtgtg ggggtggca
  481 cattgtatcg ggatcgccgc tgagggttgc agcatttaga ccctgcattt atagcatacg
  541 gtatgtatatt gcagcttata ttccatccatg cccgttaccc gtgcacgttg gaaactttat
  601 tactgggtt ttcttaagata aaaaattgtt tttatcaacag cattttcaag cagttgtatc
  661 cttcatgtatc atcacaatca tcatcattt cattcttcat ttttaaatcc acaggacttt
  721 caagatctga atttggcttg ttggagcat ctccctctgtt cccctgggaa gtctggcac
  781 agtcgggtt tggtttaaca gggagctgaa aaaagtgtcc tttttcaga cactgaggtt
  841 cccgcagcag cgcggcttccc aagggaaagg ctctgtggc actccatatac gactggggc
  901 tggggcgcggcc cactgtgtt caccctctt tttttttttt atgttggc tctgtggggc
  961 ccattgttagaa gccactattt ctgggactgt ctcagagacc ccttcccaag tcttccatc
  1021 tctctcccccg actccggagag catgtttat cttgtttctg ctttcttattt ctgttagctg
  1081 atcagcggccg caccagccgg gaaggggtt attgttgggg ctctgtggccct gcatcccttca
  1141 cttccccaggc cttggggccac agctggggc ctctgtgaga tccgtttttt gcttcccttca
  1201 gaatggagct ggccctctcc tggggatgtt taatgttccc cctgttttacc cggaaagac
  1261 aagtctttac agaatcaaattt gcaattttaa atctggagac tcgttttgat gactgggtt
  1321 gtgattgttctt ctgaaggctt tttatggccat ggaggccacta acaaaactctg aggtttccga
  1381 aatcagaagc gaaaaaaatca gtgaataaac catcatcttgc ccacttccccc ctctgtaaagc
  1441 cacagcagggtt gttcagggtt ccatttttttccatccaaac tttttttttt ctttttttttccat
  1501 tgcgatccac agaagggttcc ttttttttttccatccaaac ttttttttttccat
  1561 tattttttgtt ctttttttttccatccaaat ttttttttttccatccaaat ttttttttttccat
  1621 ttatagtcgaaatccatccaaat ttttttttttccatccaaat ttttttttttccat
  1681 ttttttttttccatccaaat ttttttttttccatccaaat ttttttttttccat
  1741 ttgcagtttttccatccaaat ttttttttttccatccaaat ttttttttttccat
  1801 tgtgacatttttccatccaaat ttttttttttccatccaaat ttttttttttccat

```

LOCUS HUMSDF1B 3524 bp mRNA PRI 26-DEC-1996
DEFINITION Human pre-B cell stimulating factor homologue (SDF1b) mRNA, complete cds.
ACCESSION L36033
NID g1220365
KEYWORDS intercrine; intercrine CXC subfamily; pre-B cell stimulating factor
SOURCE homologue; alpha-chemokine.
ORGANISM human.
REFERENCE Homo sapiens
AUTHORS Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
TITLE Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL 1 (bases 1 to 3524).
MEDLINE Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H.,
FEATURES Shinozaki, T. and Honjo, T.
source Structure and chromosomal localization of the human stromal
sig_peptide cell-derived factor 1 (SDF1) gene
CDS Genomics 28 (3), 495-500 (1995)
96039262
Location/Qualifiers
source 1..3524
sig_peptide /organism="Homo sapiens"
CDS /db_xref="taxon:9606"
source /clone="h17"
sig_peptide /cell_line="FLEB14-14"
CDS 80..142
source /gene="SDF1b"
sig_peptide 80..361
CDS /codon_start=1
source /product="pre-B cell stimulating factor homologue"
sig_peptide /db_xref="PID:g1220366"
translation="MNAKVVVVVLVVLTLALCLSDGKPVSLSYRCPCRFFESHVARANV
KHLKILNTPNCALQIVARLKKNNRQVCIDPKLKWIQEYLEKALNKRFKM"

gene 80..358
 /gene="SDF1b"
 mat_peptide 143..358
 /gene="SDF1b"
 /product="pre-B cell stimulating factor homologue"
 BASE COUNT 903 a 886 c 793 g 942 t
 ORIGIN

```

  1 tcccgctcag cccgattgcc cgctcggtc cggccccccg acccggtgctc gtccgccccgc
  61 cccggccccc gcccgcaca tgaacgcca ggtcggtgc gtgtgggtcc tcgtgctgac
  121 cgcgcctcgc ctcagcgacg ggaagccgt cagcctgagc tacatgtcc catgcccatt
  181 cttcgaaaggc catgttgcga gaggccaaacgt caagcatcctt aaaaattctca acactccaaa
  241 ctgtggccctt cagatgttag cccggctgaa gaaacaacaa agacaagtgt gcattgaccc
  301 gaagctaaag tggattcagg agtacgttgc gaaagcttta aacaagaggt tcaagatgtg
  361 agagggtcag acgcctgagg aacccttaca gttaggagccc agctctgaaa ccagtgttag
  421 ggaaggccctt gccacagcc cccctggccag ggcaggggccc caggcattgc caagggctt
  481 gttttgcaca ctttgcata ttttccat ttcgtgtca ctggcgcacac gtacagctt agactaaggc
  541 tttttcattt agttgttgc tttagtgc ttcacccat ttcacccgtt ccactcctct gactcaggc
  601 cattattgtt cttgcctttag tagagtgttgc ttccacccgtt ccactcctct gactcaggc
  661 tccctgggtt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  721 cccatggtca gccttaggtt ggagggccac caaggggac gctctgggggtt gccaggacca
  781 gtcaacactgg cggaaaggcata gtggggccat ctctctgtgg gatggatgg tggaggccca
  841 catggggaggc tcaccccttgc ctccatccat atggggccgg ggtctggctc ttctggggagg
  901 gcaggcaggc taccctgagc tgaggcagca gtgtgaggcc agggcagagt gagaccac
  961 cctcatcccg agcacccatca cccatccatccat gttctgtca tcatttcctt ttcattccat
  1021 catcatgtgt gtcacactg gtcctcatgg ccccgaaaaa ggactctcgac gaccaaagct
  1081 ttcatgttaaa ctgtgcacca agcaggaaat gaaaatgttct tttttttttt tttttttttt
  1141 tgcacatctg tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  1201 gccaggggtcc tcctctgtga ccaatgtttt gatgcacatc ctgtttttttt tttttttttt
  1261 ctgggggggg agatgttgc tttttttttt tttttttttt tttttttttt tttttttttt
  1321 ttgggggttgc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  1381 agcccaagggg aatttgggtt gcaaccagggtt tgaccccaaaa ggatttgcgc cccatcgtt
  1441 ctcccttcaca tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  1501 agcatttcaca actttttttt gttttttttt aaccatgttca caaaataacc aatccctggac
  1561 ataaagatcc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  1621 catcttcgtc ctccatccat gggcccttc tttttttttt tttttttttt tttttttttt
  1681 tcccacagga catttcctca agagaacaat gttttttttt tttttttttt tttttttttt
  1741 gacattttttt gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  1801 aatattttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  1861 ctttacgttca cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  1921 agtggaaaac aaggaaagtca aaggaaaggaa actatgttca atgttaggaag taggaagttaa
  1981 attatagtgtt gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2041 tagtaatctt gttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2101 aaaccatca aaaaaattt tttttttttt tttttttttt tttttttttt tttttttttt
  2161 atattttttt aatagaggc tttttttttt tttttttttt tttttttttt tttttttttt
  2221 aaacccatccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2281 attatccatccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2341 cccaaatccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2401 ctgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2461 gagttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2521 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2581 aaaaatccat tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2641 gagttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2701 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2761 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2821 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2881 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  2941 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3001 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3061 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3121 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3181 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3241 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3301 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3361 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3421 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  3481 cttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
  //

```

LOCUS HSJ002211 663 bp mRNA PRI 11-MAR-1998
 DEFINITION Homo sapiens cDNA for a CXC chemokine.
 ACCESSION AJ002211

NID g2832410
 KEYWORDS CXC chemokine.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 663)
 AUTHORS Legler,D.F., Loetscher,M., Roos,R.S., Clark-Lewis,I.,
 Baggolini,M.
 and Moser,B.
 TITLE B cell-attracting chemokine 1, a human CXC chemokine expressed
 in lymphoid tissues, selectively attracts B lymphocytes via
 BLR1/CXCR5
 JOURNAL J. Exp. Med. 187 (4), 655-660 (1998)
 MEDLINE 98130629
 REFERENCE 2 (bases 1 to 663)
 AUTHORS Moser,B.
 TITLE Direct Submission
 JOURNAL Submitted (05-NOV-1997) Moser B., University of Bern, Theodor
 Kocher Institute, Freiestrasse 1, CH-3012 Bern, SWITZERLAND
 FEATURES Location/Qualifiers
 source 1..663
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PBL"
 sig_peptide 35..100
 /gene="BCA-1"
 CDS 35..364
 /gene="BCA-1"
 /codon_start=1
 /product="CXC chemokine"
 /db_xref="PID:e1249325"
 /db_xref="PID:g2832411"

 /translation="MKFISTSLMLLVSSLSPVQGVLEVYYTSLRCRCVQESSVFIP
 RRFIDRIQILPRGNCPKIEIIWKKNKSIVCVDPQAEWIQRMMEVLRKRSSTLPV
 VFKRKP"
 gene 35..364
 /gene="BCA-1"
 mat_peptide 101..361
 /gene="BCA-1"
 BASE COUNT 176 a 136 c 145 g 198 t 8 others
 ORIGIN
 1 cagagctcaa gtctgaactc tacctccaga cagaatgaag ttcatctcga catctctgct
 61 tcttcatgtcg ctgtcagca gcctcttc agtccaaggt ttcttgagg ttattacac
 121 aagcttgagg ttagatgtg tccaagagag ctcagtcctt atcccttagac gtttcattga
 181 tcgaatcaa atcttgcggcc ttggaaatgg ttgtccaa aaaaatca tagtctggaa
 241 gaagaacaag tcaattgtgt ttgtggaccct tcaagctaa tggataaaaaa gaatgtggaa
 301 agtattggaga aaaagaagtt ttcaactctt accagtccaa gtgtttaaga gaaagattcc
 361 ctgtatgtca tatttccact aagaacaccc gcattttcc ttatccctg ctctgggatt
 421 ttatgtttgt gcttagttt acatccatc gggagaaaga actccccat acaaataagg
 481 catgaggact atgtaaaaat aacccatc gggagaaaga actccccat acaaataagg
 541 tttcactcca caggcaccc attnaacact tgggggtttt gcnttcttn ttcntcagg
 601 gggggggaaa gtttctttt gaaantagtt ntccagttt ttaggttata cagggttntt
 661 ttt
 //
 LOCUS HSHUMIG 2545 bp RNA PRI 16-NOV-1993
 DEFINITION H.sapiens Humig mRNA.
 ACCESSION X72755 S60728
 NID g311375
 KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 2545)
 AUTHORS Farber,J.M.
 TITLE Direct Submission
 JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School

of

USA Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
 REFERENCE 2 (bases 1 to 2545)
 AUTHORS Farber, J.M.
 TITLE HuMig: a new human member of the chemokine family of cytokines
 JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
 MEDLINE 93236577
 FEATURES Location/Qualifiers
 source 1..2545
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /germline
 /dev_stage="child"
 /tissue_type="leukaemia"
 /cell_type="monocyte"
 /cell_line="THP-1"
 /clone_lib="THP-1/IFN-gamma cDNA"
 /clone="H-1-3"
 misc_feature 13..19
 /note="cis-acting element; putative"
 gene 40..417
 /gene="Humig"
 CDS 40..417
 /gene="Humig"
 /codon_start=1
 /db_xref="PID:g311376"
 /db_xref="SWISS-PROT:Q07325"

/translation="MKKSGVLFLLGIILLVLIGVQGTPVVRKGRCSCISTNQGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNVGQTCLNPDSADVKELIKWKQVQSVQKKQKNG
 KKHQKKVVLKVRKSQRSRQKTT"

BASE COUNT 755 a 581 c 457 g 752 t

ORIGIN

1 atccaaataca ggagtgaattt ggaactccat tctatcacta tgaagaaaag tggtgttctt
 61 ttectcttgg gcatcatctt gctgggttctt attggagtgc aaggaacccc agtagtgaga
 121 aagggtcgct gttcctgcattt cagcaccaac caaggacttccatcata atcccttggaaa
 181 gacctttaac aatttgcctt aagcccttccatcata ttggagaaaa ttggaaatcat tggatctgg
 241 aagaatggag ttcaaaatcatg tctaaacccca gattcagcag atgtgaagga actgatttttt
 301 aagtggggaga aacaggatcg ccaaaagaaaa aagcaaaaga atggggaaaa acatcaaaaa
 361 aagaatgttc tggaaatgttc aaaaatctcaat cgttctgcggc aaaagaagac tacataagag
 421 accacttcac caataatgtt tctgtgtttaa aatgttctttaa tttaattt accgtatcatc
 481 ttccaaagga ggtatggcata taatacataaag gtttattat ttgtactagaa aatttttttt
 541 attactctga aattgttaact aaagttagaa agttgatttt aagaatccaa acgtttaagaa
 601 ttgttaaagg ctatgttgc tttttttttt ctaccacccca ccgttgcattt ttcatcatgc
 661 ttaaggccat gatttttagca ataccatgtt ctacacatgtt ccacatccca
 721 ctcacaaacag ctgcctggaa gagcgcgcctt aggttccatc gtactgcgc ctccagagag
 781 tatctgaggc acatgtcagc aagtccatag cctgttagca tgctgttgag ccaagcagg
 841 tggaaatgttgc ctggacatca ccaagctgtt gtggccatca acctctgtt ttgtatcage
 901 ctacaggccat cacacacaat gtgttgcata gattcatgtt gatttttattt gggtatcacc
 961 actggagatc accagtgtgtt ggttttccatc gcttccttccatc tggcttttggaa agccatgtga
 1021 ttccatcttgc cccgttcagg ctgaccactt tattttttttt tggccccctt tggccatcc
 1081 aagtcaatc ttccatccatcc taccacaaatg cagtgcctt tttcttcataa gtgcacatgt
 1141 catatgttctt gatttatctg agtcaactcc tttcttcataa ttgtccccaaac accccacaga
 1201 agtgccttctt tccatccatcc taccacaaatg cagtgcctt tttcttcataa gtgcacatgt
 1261 aaataaaatccat tttttggacac acaaaatccat tttttttttt tttttttttt gtttcatgt
 1321 cacatgggttgc aacactcaat ggttaactaa ttcttgggttgc tttttttttt tttttttttt
 1381 agattgttgc tttttttttt ggtttttttt tttttttttt tttttttttt tttttttttt
 1441 ctaataataatc tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 1501 tggcaacccatc accattgttgc cagacggat gttttttttt tttttttttt tttttttttt
 1561 ctatccatccatcc taccacaaatg cagtgcctt tttttttttt tttttttttt tttttttttt
 1621 gatgtttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 1681 gcacgtgttgc aacacttgc ggtttttttt tttttttttt tttttttttt tttttttttt
 1741 aaaaatccatc aatccatc tttttttttt tttttttttt tttttttttt tttttttttt
 1801 ccaaccatc aaaaatccatc tttttttttt tttttttttt tttttttttt tttttttttt
 1861 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 1921 agttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 1981 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt
 2041 tagtggaaatc atgatgttgc cccatgttgc tttttttttt tttttttttt tttttttttt
 2101 ggaggttcag tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt

2161 ctttccccaaa ttgaatcact gctcacactg ctgatgattt agagtgtgt ccgggtggaga
2221 tcccccccgaa acgttttatc taatcatgaa actccctagt tccttcatgt aacttccctg
2281 aaaaatctaa gtgtttcata aatttgagag tctgtgacc acttacettg catctcacag
2341 gttagacgatg tataactaac aaccaaagac tacatattgt cactgacaca cacgttataa
2401 tcattttatca tataatatac tacatgcata cactctcaaa gcaaataatt tttcaacttca
2461 aaacagtatt gacttgata ccttggtaatt tggaaatattt tctttgttaa aatagaatgg
2521 tatcaataaa tagaccattt atcag

11

LOCUS HSHUMIG 2545 bp RNA **PRI** 16-NOV-1993
DEFINITION *H. sapiens* Humig mRNA.
ACCESSION X72755 S60728
NID g311375
KEYWORDS chemokine; cytokine; Humig gene; secreted protein.
SOURCE human.
ORGANISM *Homo sapiens*
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 2545)
AUTHORS Farber, J.M.
TITLE Direct Submission
JOURNAL Submitted (22-MAR-1993) J.M. Farber, Johns Hopkins Univ. School
of Medicine, Ross 1147, 720 Rutland Avenue, Baltimore, MD 21205,
USA
REFERENCE 2 (bases 1 to 2545)
AUTHORS Farber, J.M.
TITLE HuMig: a new human member of the chemokine family of cytokines
JOURNAL Biochem. Biophys. Res. Commun. 192 (1), 223-230 (1993)
MEDLINE 93236577
FEATURES
source Location/Qualifiers
1..2545
/organism="Homo sapiens"
/db_xref="taxon:9606"
/germline
/dev_stage="child"
/tissue_type="leukaemia"
/cell_type="monocyte"
/cell_line="THP-1"
/clone_lib="THP-1/IFN-gamma cDNA"
/clone="H-1-3"
misc_feature 13..19
/notes="cis-acting element; putative"
gene 40..417
/gene="Humig"
CDS 40..417
/gene="Humig"
/codon_start=1
/db_xref="PID:g311376"
/db_xref="SWISS-PROT:Q007325"

/translation="MKKSGVLFLLGIILLVLIGVOGTPVVRKGRCSCIISTNOGTIHLQ

SLKDLKQFAPSPSCEKIEIIATLKNVGQTCLNPDSADVKELIKWKQVSQKKQKNG
KKHOKKKVVLKVVKSORSPOKTTT

BASE COUNT 755 a 581 c 457 g 752 t
ORIGIN

1 atccaaataca ggagtgactt ggaactccat tctatcacta tgaagaaaaag tggtgttctt
61 ttccttcttgg gcatcatctt gctggttctg attggagtgc aaggaacccc agtagtgaga
121 aagggtgcgt gttccatgtc cagcaccaac caagggacta tccacactaca atccttggaa
181 gacccctaaac aatttggccc aagcccttcc tgcagaaaaaa ttgaaatcat tgctacactg
241 aagaatggag ttcaaacatg tctaaaaacc gattcagcag atgtgaaagg actgataaaa
301 aagtgggaga aacagggtcg cccaaaagaaa aagcaaaaga atggggaaaaa acatcaaaaa
361 aagaagatc tggaaagtccg aaaaatctaa cgtttccgtc aaaagaagac tacataagag
421 accacttccat caataagat tctgtttaa aatagtttctt ttttattat accgtatca
481 ttccaaaggag ggatggcata taatacacaag gctttaattat ttgactagaaa aattttaaac
541 attactctga aattgttaact aaagtttagaa agttgatttt aagaatccaa acgttaagaa
601 ttgtttaaagg. ctatgattgt ctttggttctt ctaccacccca ccagttgaat ttcatcatgc
661 ttaaggccat gattttagca ataccatgt ctacacatg gttcaccccaa ccacatccca
721 ctcacacacag ctgcctggaa gagcagccctt aggttccac tgactgcgc ctcagagag
781 tatctggggc acatgtcgc aagtccctaa cctgttagca tgctggtagag ccaaqcagt

841 taaaatttagg ctggacctca ccaagctgct gtggccatca acctctgtat ttgaatcagc
 901 ctacaggcct cacacacaat gttctgaga gattcatgt gattgttatt gggtatcacc
 961 actggagatc accagtgtgt ggcttcaga gcctcccttc tggcttggaa agccatgtga
 1021 ttccatcttg cccgctcagg ctgaccactt tatttcttt tggcccttgc tgcttcattc
 1081 aagtcaagtc ttctccatcc taccacaatg cagtcactt ctctcttcca gtgcacctgt
 1141 catatgtctt gatttatctg agtcaactt tttctatct tggcccaac accccacaga
 1201 agtgccttct tctcccaatt catcctcaat cagtcagct tagtcaagt cctgccttct
 1261 aataaaacct tttggacac acaaattatc taaaacttcc ttgttcaactt ggttcagtt
 1321 cacatgggtg aacactcaat ggtaactaa ttcttgggtg ttatccat ctctccaaacc
 1381 agattgttagt ctcccttggg gcaagagcca cagttatattt ccctgtttt tccacagtgc
 1441 ctaataatca tggaaactt gggttttaat tttatattat tgggttggg atgggcagga
 1501 tggcaaccag accattgtctt cagcggat gctggctt tccctggctac tccatgttg
 1561 ctagcctctg gtaacccctt acttattatc ttcaaggacac tcactacagg gaccaggat
 1621 gatgcaacat ctttgcctt ttatgacagg atgtttgtc agtttcttca acaataagaa
 1681 gcacgttgcgta aacacttgc ggatattctg gactgtttt aaaaatata cagtttaccc
 1741 aaaatcatat aatcttacaa tggaaaggac tttatagatc agccagtgc acacccatcc
 1801 ccaaccatca aaaaatttcc ttcccggaa gaaaaagggtt ttctcaataa gcctcagctt
 1861 tctaagatct aacaagatag ccaccggat ctttacatcgaa acttattttt gggaaatatg
 1921 agtttatttgc tccgtttact tgggttccat tttatgtt gattatcaat taccacacca
 1981 tctcccatga agaaaaggaa cggtaactt ctaaggcgtt gggaaaggac ccaagtcgg
 2041 tagtggaaagc atgattgtt cccatgttgc ctctggggaa accatccatg tccctccagg
 2101 ggagggttgc tggaaatgtt agggaggtt gctgtggcc agatattaaa cttatactca
 2161 ctttcccaaa ttgtatcaat gtcacactt ctgtatgtt agagtgtgtt ccgggtggaga
 2221 tcccccccgta acgttcttca taatcatgaa actccctgtt tccctcatgt aacttccctg
 2281 aaaaatctaa gtgtttcata aatggggat tctgtggcc accatccatg catctccacag
 2341 gtagacagta tataactaac aaccaaaagac tacatgtt cactgacaca cacgttataa
 2401 tcattttatca tataatataca tacatgcata cactctcaaa gcaataattt tttacttca
 2461 aaacagtatt gacttgcata ctttgcataa tggaaatattt tctttgtttaa aatagaatgg
 2521 tatcaataaa tagaccattt atccat

//

LOCUS AF002985 995 bp mRNA PRI 01-NOV-1997
 DEFINITION Homo sapiens putative alpha chemokine (H174) mRNA, complete
 cds.
 ACCESSION AF002985
 NID g2580585
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 995)
 AUTHORS Jacobs, K.A., Collins-Racie, L.A., Colbert, M., Duckett, M.,
 Golden-Fleet, M., Kelleher, K., Kriz, R., LaVallie, E.R.,
 Merberg, D.,
 Spaulding, V., Stover, J., Williamson, M.J. and McCoy, J.M.
 TITLE A genetic selection for isolating cDNAs encoding secreted
 proteins
 JOURNAL Gene 198 (1-2), 289-296 (1997)
 MEDLINE 98036061
 REFERENCE 2 (bases 1 to 995)
 AUTHORS Jacobs, K.A., Collins-Racie, L.A., Colbert, M., Duckett, M.,
 Golden-Fleet, M., Kelleher, K., Kriz, R., LaVallie, E.R.,
 Merberg, D.,
 Spaulding, V., Stover, J., Williamson, M.J. and McCoy, J.M.
 TITLE Direct Submission
 JOURNAL Submitted (07-MAY-1997) Genetics Institute, 87 Cambridge Park
 Drive, Cambridge, MA 02140, USA
 FEATURES Location/Qualifiers
 source 1..995
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="PHA and PMA activated human peripheral
 blood mononuclear cells"
 gene 1..995
 /gene="H174"
 CDS 88..372
 /gene="H174"
 /codon_start=1
 /product="putative alpha chemokine"

/db_xref="PID:g2580586"
 /translation="MSVKGMAIALAVILCATVVQGFPMPKRGRCCLCIGPGVKAVKVAD
 IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSQARLIKKVERKNF"
 BASE COUNT 382 a 170 c 194 g 249 t
 ORIGIN

```

1. gaattcgccc aaagaggcct acttccaaga agagcagcaa agctgaagta gcagcaacag
61. caccaggcgc aacagcaaaa aacaaacatg agtgtgaaagg gcatggctat agccttgct
121. gtgatattgt gtgctacagt tttcaaggc ttccccatgt tcaaaagagg acgtgtctt
181. tgcataaggcc ctggggtaaa agcagtgaaat gtggcagata ttgagaaagc ctccataatg
241. tacccaaatgca acaaactgtga caaaatagaa gtgattatta ccttggaaaga aaataaagga
301. caacatgccc taaatccca atcgaagccaa gcaagctta taatcaaaaa agttgaaaga
361. aagaatttt aaaaatatca aaacatatga agtctggaa aaggccatct gaaaaaccta
421. gaacaagttt aactgtgact actgaaatga caagaattct acatggaaactgagactt
481. ttctatgtttt ttgtgactt caactttgtt acagttatgtt gaaggatgaa aggtgggtga
541. aaggccaaa aacagaaa aacatggaaat cagtcttctt gaatgatgaa caatcagaat tccactgccc
601. aaaggagtcc aacaataaaa tggattttt gggaaagctt ccttggaaa ggctgggtac
661. catcgagtt tacaaatgtc ttacgttctt ttacttggttt tattatacat tcatgcattt
721. ctaggctaga gaaccttcta gatttgatgc ttacaactat tctgttgc tctatgagaaac
781. atttctgtct ctagaaatgtt tctgtctgtt ttgatcttta tgctatattttt ctatctgtgg
841. ttacagtgaa gacattgttca ttattactgg agtcaagccc ttataagtca aaaggcaccta
901. ttgtgtcgtaa agcatttcctt aacatttaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa
961. aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa aaaaaaaaaaaaaaaa
  //
```

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
 DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.
 ACCESSION AF030514
 NID g3219692
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
 Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1371)
 AUTHORS Cole, K.E., Strick, C.A., Paradis, T.J., Ogborne, K.T.,
 Loetscher, M., Gladue, R.P., Lin, W., Boyd, J.G., Moser, B., Wood, D.E.,
 Sahagan, B.G.
 and Neote, K.
 TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a
 novel non-ELR CXC chemokine with potent activity on activated T cells
 through selective high affinity binding to CXCR3
 J. Exp. Med. 187 (12), 2009-2021 (1998)
 JOURNAL 98290735
 MEDLINE
 REFERENCE 2 (bases 1 to 1371)
 AUTHORS Cole, K.E., Strick, C.A. and Sahagan, B.G.
 TITLE Direct Submission
 JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
 Eastern
 FEATURES Point Road, Groton, CT 06340, USA
 source Location/Qualifiers
 1..1371
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="4"
 /cell_type="astrocytes"
 sig_peptide 70..132
 CDS 70..354
 /note="chemokine; I-TAC"
 /codon_start=1
 /product="interferon stimulated T-cell alpha chemoattractant precursor"
 /db_xref="PID:g3219693"
 /translation="MSVKGMAIALAVILCATVVQGFPMPKRGRCCLCIGPGVKAVKVAD
 IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSQARLIKKVERKNF"
 mat_peptide 133..351
 /evidence=not_experimental

/product="interferon stimulated T-cell alpha chemoattractant"

BASE COUNT 487 a 228 c 244 g 411 t 1 others

ORIGIN

```

1 ctccttccaa gaagagcgcg aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagcctgg ctgtatatt gttgtctaca
121 gttttcaag gctcccccattt gttcaaaaga ggacgctgc tttgcataagg ccctggggta
181 aaagcgtga aagtggcaga tattgagaaa gcctccataa tgcaccaag taacaactgt
241 gacaaaatag aagtattat taccctgaaa gaaaataaag gacaacgtg cctaaatccc
301 aaatcgaaagc aagcaaggct tataatcaa aaggtgaaa gaaaatgtt aaaaat
361 caaaacatataa gaaatccctgg aaaagggcat ctgaaaacc tagacaatgtt taaatgtt
421 ctactgaaat gacaagaattt ctacagttagg aaactgagac tttctatgg tttgtact
481 ttcaactttt gtacagttagt gtgaaggatg aaaggtgggt gaaaggacca aaaacagaaa
541 tacagtttc ctgtatgatgaa gacaatcaga attcactgc ccaaaagggtt ccacgtt
601 aatggatttc tagggaaaagc taccttaaga aaggctgtt accatggatg ttacaaatgtt
661 gcttcacgt tcttacttgtt tgcattatac attcatgtat ttctaggctt gagaacatcc
721 tagattgtat gcttacaaacttctgtt gactatgaga acatttctgt ctctagaatgt
781 tatctgtctg tattgtatc tatgtatatac tattatgtt ggttacatgtt gacatgtt
841 cattattact ggagtcaagc ctttataatgtt gaaatgtt tttttttttt tttttttt
901 tcaaaatccat tttcatgcaaa atacacaytt cttttccaa atatcatgtt gacatgtt
961 atgttagggaa acatctttt gcatcattttt gtttttttta taaccaatcc attaaatgtt
1021 atttcataaaa ttgtactatgaa aaaaattttt acgttatggg atactggaa cagtgcacat
1081 atttcataac caaaatggca gcaacgggtt taattttgtt gttttttttt tttttttt
1141 gagatgtttt gaagaatataa ggatatgtt gttttttttt tttttttt tttttttt
1201 gtatataatgtt tagcaatatac ttggacatc ttgaaatatac aaatgtttttt gttttttt
1261 gaaaaataatgtt gaaaataaag caaatgttatac cttttttttt tttttttt tttttttt
1321 tttttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt

```

//

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998

DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant precursor, mRNA, complete cds.

ACCESSION AF030514

NID g3219692

KEYWORDS

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1371)

AUTHORS Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T., Poetscher,M., Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E., Sahagan,B.G.

TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3

JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)

MEDLINE 98290735

REFERENCE 2 (bases 1 to 1371)

AUTHORS Cole,K.E., Strick,C.A. and Sahagan,B.G.

TITLE Direct Submission

JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,

astern

FEATURES Point Road, Groton, CT 06340, USA

source Location/Qualifiers

1..1371

/organism="Homo sapiens"

/db_xref="taxon:9606"

/chromosome="4"

/cell_type="astrocytes"

sig_peptide 70..132

CDS 70..354

/note="chemokine; I-TAC"

/codon_start=1

/product="interferon stimulated T-cell alpha chemoattractant precursor"

/db_xref="PID:g3219692"

```

/translation="MSVKGMAIALAVILCATVVQGFPMFKRGRCCLCIGPGVKAVKVAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"
BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN
1 ctccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaca tgagtgtgaa gggcatggct atagccttgg ctgtatgtt gtgtgtcata
121 gttgttcaag gcttcccat gttcaaaaaga ggacgctgtc ttgcattttt ccctgggtt
181 aaagcagtga aagtggcaga tattgagaaa gcctccatata tgtaaccaag taacaactgt
241 gacaaaatag aagtgttatt taccctgaaa gaaaataaaag gacaacgatg cctaaatccc
301 aaatcgaagc aagcaggct tataatcaaa aaagtggaaa gaaaagaattt ttaaaaatata
361 caaaacatata gaagtccctgg aaaagggcat ctgaaaaacc tagacaatgt ttaactgtga
421 ctactgaaat gacaagaattt ctacagttagg aaactgagac tttctatgg ttttgtact
481 ttcaactttt gtacatgtt gtgaaggatg aaagggtgggt gaaaggacca aaaacagaaaa
541 tacatgttcc tctgttccaaatgaaat gacaatcaga attcactgc ccaaggatg ccagcaatata
601 aatggatttc tagggaaaagc tacccttgg aaggctgggtt accatcggat tttacaaatgt
661 gctttcacgt tcttacttgc tttttttttt attcatgtat ttcttggat gagaaccccttc
721 tagatgttgc gcttcaactt attctgttgc gactatgaga acatctgtt ctcttagatgt
781 tatctgttgc tttttttttt attcatgtat tttttttttt ttcttggat gggatgttgc
841 cattattact ggatgttgc ctttataatg caaaaggatc tttttttttt ttcttggat gggatgttgc
901 tcaaaatattt tttttttttt ttcttggat gggatgttgc tttttttttt ttcttggat gggatgttgc
961 atgttagggaa acatcttgc tttttttttt ttcttggat gggatgttgc tttttttttt ttcttggat gggatgttgc
1021 attcataaaa ttgttgc tttttttttt ttcttggat gggatgttgc tttttttttt ttcttggat gggatgttgc
1081 atttccataac caaatttagca gttttttttt ttcttggat gggatgttgc tttttttttt ttcttggat gggatgttgc
1141 gagatgtttt gaagatgttgc tttttttttt ttcttggat gggatgttgc tttttttttt ttcttggat gggatgttgc
1201 gtataaatgtt tagcaatatc ttggacatcat ttggacatcat ttggacatcat ttggacatcat ttggacatcat ttggacatcat
1261 gaaaatgtt gaaaatataag caaatgttgc tttttttttt ttcttggat gggatgttgc tttttttttt ttcttggat gggatgttgc
1321 tttttttttt ttcttggat gggatgttgc tttttttttt ttcttggat gggatgttgc tttttttttt ttcttggat gggatgttgc
//"

LOCUS AF030514 1371 bp mRNA PRI 17-JUN-1998
DEFINITION Homo sapiens interferon stimulated T-cell alpha chemoattractant
ACCESSION AF030514
NID g3219692
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Mammalia; Eutheria;
Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1371)
AUTHORS Cole,K.E., Strick,C.A., Paradis,T.J., Ogborne,K.T.,
Loetscher,M.,
Gladue,R.P., Lin,W., Boyd,J.G., Moser,B., Wood,D.E.,
Sahagan,B.G.
and Neote,K.
TITLE Interferon-inducible T cell alpha chemoattractant (I-TAC): a
novel
non-ELR CXC chemokine with potent activity on activated T cells
through selective high affinity binding to CXCR3
JOURNAL J. Exp. Med. 187 (12), 2009-2021 (1998)
MEDLINE 98290735
REFERENCE 2 (bases 1 to 1371)
AUTHORS Cole,K.E., Strick,C.A. and Sahagan,B.G.
TITLE Direct Submission
JOURNAL Submitted (20-OCT-1997) Molecular Sciences, Pfizer, Inc.,
Eastern
FEATURES Point Road, Groton, CT 06340, USA
source Location/Qualifiers
1..1371
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="4"
/cell_type="astrocytes"
sig_peptide 70..132
CDS 70..354
/note="chemokine; I-TAC"
/codon_start=1

```

```

/product="interferon stimulated T-cell alpha
chemoattractant precursor"
/db_xref="PID:g3219693"

/translation="MSVKGMAIALAVILCATVVQGFPMPFKRGRCCLCIGPGVKAVKVAD
IEKASIMYPSNNCDKIEVIITLKENKGQRCLNPKSQARLIKKVERKNF"
mat_peptide 133..351
/evidence=not_experimental
/product="interferon stimulated T-cell alpha
chemoattractant"

BASE COUNT 487 a 228 c 244 g 411 t 1 others
ORIGIN

1 ctcccttccaa gaagagcagc aaagctgaag tagcagcaac agcaccagca gcaacagcaa
61 aaaacaaaaca tgagtgtcaa gggcatggct atagccttgg ctgtgtatatt gtgtgtacaa
121 gttgttcaag gcttccccat gttcaaaaaga ggacgctgtc tttgtcatagg ccctggggta
181 aaagcagtga aagtggcaga tattgagaaa gcctccataa tgtacccaag taacaactgt
241 gacaaaatag aagtgttatt taccctgaaa gaaaataaaag gacaacgatg cctaaaatccc
301 aaatcgaagc aagcaggct tataatcaa aaaaatgtaaa gaaagaattt taaaaaatat
361 caaaacatataa gaagtccctgg aaaagggcat ctgaaaaacc tagaacaagt ttaactgtga
421 ctactgaaat gacaagaatt ctacagttagg aaactgagac tttctatgg ttttgtact
481 ttcaactttt gtacagtat gtgaaggatg aaagggtggt gaaaggacca aaaacagaaa
541 tacagtttc ctgaaatgtat gacaatcaga attccactgc ccaaaggagt ccagcaattt
601 aatggatttc tagggaaaagg tacctttaaga aaggctgtttt accatcgagg ttatcaaagt
661 gctttcacgt tcttacttgt ttttattatac attcatgtat ttctaggcta gagaaccttc
721 tagatgtt gtttacactt attctgttgtt gactatgaga acatttctgt ctcttagaagt
781 tatctgtctg tattgtatctt tatgtatata tactatctgt gtttacagtg gagacattga
841 cattattact ggagtcaagc ccttataatgtt caaaaggatc tatgtgtcgt aaagcattcc
901 tcaaacatattt ttcatgcaa atacacaytt ctttcccaa atatcatgtt gacatcaat
961 atgttagggaa acattttttt gcatcatttg gtttgtttttaaaccatc attaaatgtt
1021 atttccataaa ttgtactatgaaaattt acgtatggg atactggcaa cagtgcacat
1081 atttccatcac caaaatggca gcaccggctt taatttctgtt ttttcaact ttatttctt
1141 gagatgtttt gaagcaattt ggatgtgtt gtttactgtt cttttgtttt tgatccgttt
1201 gtatataatgtt tagcaatatac ttggacacat ttgaaataca aaatgtttttt gtctaccaaa
1261 gaaaaatgtt gaaaataaag caaatgtata ccttagcaatc actttactt ttgtatattc
1321 tgtctcttag aaaaatacat aatctaatac aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a

//



LOCUS HSMDNCF 1560 bp RNA PRI 31-MAR-1995
DEFINITION Human mRNA for MDNCF (monocyte-derived neutrophil chemotactic
factor).
ACCESSION Y00787
NID g34518
KEYWORDS cytokine.
SOURCE human.
ORGANISM Homo sapiens
Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1. (bases 1 to 1560)
AUTHORS Matsushima,K.
TITLE Direct Submission
JOURNAL Submitted (03-MAY-1988) Matsushima K., National Cancer
Institute, Bldg 560, Rm 31-19, Frederick, MD 21701
REFERENCE 2 (bases 1 to 1560)
AUTHORS Matsushima,K., Morishita,K., Yoshimura,T., Lavi,S.,
Kobayashi,Y., Lew,W., Appella,E., Kung,H.F., Leonard,E.J. and Oppenheim,J.J.
TITLE Molecular cloning of a human monocyte-derived neutrophil
chemotactic factor (MDNCF) and the induction of MDNCF mRNA by
interleukin 1 and tumor necrosis factor
JOURNAL J. Exp. Med. 167 (6), 1883-1893 (1988)
MEDLINE 88258376
COMMENT for overlapping sequence see M17016 - M17017.
FEATURES Location/Qualifiers
source 1..1560
/organism="Homo sapiens"
/db_xref="taxon:9606"
/cell_type="monocyte"
/clone_lib="lambda gt10"
sig_peptide 102..182
/note="signal peptide (AA -27 to -1)"
```


sig_peptide 67..129
CDS /note="pot. signal peptide (aa-21 to -1)"
77) 67..363
 /note="early response precursor polypeptide (aa-21 to
 /codon_start=1
 /db_xref="PID:g33918"
 /db_xref="SWISS-PROT:P02778"

/translation="MNQTAILICLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRS
LEKLEIIPASQFCPRVEIIATMKKKGEKRLNPEKA
SKAINLLKAVSKEMSKRSP"
mat_peptide 130..360
old_sequence /note="mature early response polypeptide (aa 1-77)"
1138..1141
old_sequence /note="uga was uga in [1]"
1146..1148
old_sequence /note="caa was ca in [1]"
1155..1160
misc_feature /citation=[1]
polyA_site 1172
polyA_site /note="pot. polyA signal"
polyA_site /note="polyA site"
BASE COUNT 384 a 231 c 208 g 349 t
ORIGIN
1 gagacattcc tcaattgctt agacatattc tgagcctaca gcagaggaac ctccagtc
61 agcaccatga atcaactgc gattctgatt tgctgcctt tctttctgc tcttaagtggc
121 attcaaggag tacccctctc tagaaccgta cgctgtacat gcatacgat tagataatccaa
181 cctgttaatc caaggctttt agaaaaactt gaaatatttc ctgcgaagcca attttgtccaa
241 cgtgttggaa tcattgtcac aatgaaaaag aagggtgaga agagatgtct gaatccagaa
301 tcgaaggcca tcaagaattt actgaaagca gttagcaagg aaatgtctaa aagatctct
361 taaaaccaga ggggagcaaa atccatgcgac tgcttccaaag gatggaccac acaggcgt
421 cctctcccat cacttccctt catggatgtat atgtcaagcc ataaattgttc ttatgttgc
481 gttacactaa aagggtgacca atgatggtca ccaaattcgc tgctactact cctgttaggaa
541 ggttaatgtt catccatctt aacttatttcg taataactt accctggcac tataatgtaa
601 gctctactga ggtgctatgt tcttagtggg tggctgcacc ctgtcttcaaa tatttccctc
661 accttccca tcttccaaagg gtactaaggg atcttttgc tttgggtttt atcagaatcc
721 tcagaatctc aaataactaa aagggtatgc atcaaaatctg cttttttaaag aatgtcttt
781 acttcatggaa ctccactgc catccctccca agggggccaa atttcttcg tggctaccta
841 catacaatttccaaacacata caggaaggta gaaatatctg aaaaatgtatg tggtaagtatt
901 cttttaatgaaaggactgt acaaaggatata agtcttagat gtatattttt cctatattgt
961 ttccatgtta catggataaa catgtatata agtactatgtt atcaatgatg aacaggaaaa
1021 tttttaaaaat acagatagat atatgtctg catgttacat aagataatg tggtaatgg
1081 ttttcaaaataaaaatgaggactcttgc aatattaaag aagactatcc taaatgttga
1141 aagatcaaaa ggttaataaa gtaattataa ct
//
LOCUS SYNRPF4A 225 bp DNA
DEFINITION Human recombinant platelet factor 4 (PF4) gene, complete cds.
ACCESSION M20901
NID g209285
KEYWORDS platelet factor; platelet factor 4.
SOURCE Synthetic oligonucleotide DNA, clone pIN-III-ompA-2.
ORGANISM artificial sequence
REFERENCE 1 (bases 1 to 225)
AUTHORS Barone,A.D., Ghrayeb,J., Hammerling,U., Zucker,M.B. and Thorbecke,G.J.
TITLE The expression in Escherichia coli of recombinant human
platelet
JOURNAL factor 4, a protein with immunoregulatory activity
MEDLINE J. Biol. Chem. 263, 8710-8715 (1988)
FEATURES 88243725
source Location/Qualifiers
1..225
/organism="artificial sequence"
/db_xref="taxon:29278"
<1..>225
/note="recombinant platelet factor 4"
/codon_start=2

ACCESSION M36820
 NID g183628
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-beta.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1110)
 AUTHORS Haskill,S., Peace,A., Morris,J., Sporn,S.A., Anisowicz,A.,
 Lee,S.W., Smith,T., Martin,G., Ralph,P. and Sager,R.
 TITLE Identification of three related human GRO genes encoding
 cytokine functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S.Haskill, 20-JUL-1990.
 FEATURES Location/Qualifiers
 source 1..1110
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-beta"
 /tissue_type="monocyte and lymphocyte"
 gene 75..398
 /gene="GRO-beta"
 CDS 75..398
 /gene="GRO-beta"
 /codon_start=1
 /product="cytokine gro-beta"
 /db_xref="PID:g183629"

 /translation="MARATLSAAPSNPRLRVALLLLLVAASRRAAGAPLATELRCQ
 CLQTLQGIHLKNIQSVKVKSPGPQHCAQTEVIATLKNGQKACLNPPASPMVKIIIEKMLK
 NGKSN"
 BASE COUNT 300 a 247 c 247 g 316 t
 ORIGIN
 1 gacagagccc gggccacgg a gtccttgcg agctctcctc ctcgcacagc cgctcgaa
 61 gcctgtgg cccatggcc cgcgcacgc tctccggcg ccccagcaat ccccggtc
 121 tgcgggtggc gtcgtgc tgcgtcttgc tggccggccg cggcgcgc gcaaggagc
 181 ccctggccac tgaatgcgc tggccgtgc tgcagaccc tcggaaat caccctaa
 241 acatccaaag tgcgtggtgc aatgtccccc gacccactg cggccaaacc gaatgtca
 301 ccacatcaa gaatggccgaa agacttgc tcaacccgc atcggccatg gttaaagaaaa
 361 tcatcgaaaa gatgtggaa atggccaaat ccaactgacc agaaggaaagg agaaggctt
 421 ttggtggtgc ttccgtggagg agggccctgc ttacaggaa acggaggaa agagac
 481 agctgcagag gcccacccgc ttgcgcctaa tgcgtttgg cataacttagg agaaggctt
 541 tattttat tttat tttttttt tttttttt tttttttt tttttttt atatttat
 601 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
 661 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
 721 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
 781 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
 841 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
 901 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
 961 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
 1021 tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt tttttttt
 1081 agaacaggaa aataaaat tttttttt tttttttt
 //
 LOCUS HUMGROG5 1064 bp mRNA PRI 07-MAR-1995
 DEFINITION Human cytokine (GRO-gamma) mRNA, complete cds.
 ACCESSION M36821
 NID g183632
 KEYWORDS cytokine.
 SOURCE Human lymphocyte, cDNA to mRNA, clone GRO-gamma.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1064)
 AUTHORS Haskill,S., Peace,A., Morris,J., Sporn,S.A., Anisowicz,A.,

TITLE Lee, S.W., Smith, T., Martin, G., Ralph, P. and Sager, R.
 cytokine Identification of three related human GRO genes encoding
 functions
 JOURNAL Proc. Natl. Acad. Sci. U.S.A. 87 (19), 7732-7736 (1990)
 MEDLINE 91017578
 COMMENT Draft entry and computer-readable sequence for [Proc. Natl.
 Acad. Sci. U.S.A. (1990) In press] kindly submitted
 by S. Haskill, 20-JUL-1990.
 FEATURES Location/Qualifiers
 source 1..1064
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="GRO-gamma"
 /tissue_type="lymphocyte and monocyte"
 gene 78..398
 /gene="GRO-gamma"
 CDS 78..398
 /gene="GRO-gamma"
 /codon_start=1
 /product="cytokine GRO-gamma"
 /db_xref="PID:g183633"

 /translation="MAHATLSAAPSNPRLRVALLLVLVGSRRAGASVVTTELRCQC
 LQTLQGIHLKNIQSVNVRSPGPCHQTEVIATLNGKKACLNPMQVKIIIEKILNK
 GSTN"
 BASE COUNT 281 a 237 c 239 g 305 t 2 others
 ORIGIN
 1 cacagccggg tcgcaggcac ctcggcggcc agctctcccg cattctgcac agcttcccg
 61 cgcgtctgtc gagccccatg gcccacgcca cgctctccgc cggcccccagc aatccccggc
 121 tcctgggggt ggcgtctgtc ctctgtcc tggggcag cccggcgcga gcaggagcgt
 181 ccgtgtcac tgaactggc tggcagtgtc tgcagact gcaggaaatt caccccaaga
 241 acatccaaag tgtgaatgtc aggtcccccg gacccactg cggccaaacc gaagtcatag
 301 ccacactcaa gaatggaaag aaagcttgtc tcaacccgc atccccatg gttcagaaaa
 361 tcatcgaaaa gatactgaaac aagggggagca ccaactgaca ggagagaatg aagaagctt
 421 tcagcgatc attgacactt cctgcagggt ggtccctgc cttaaccagag ctgaaaatga
 481 aaaagagaac agcagtttc tagggacagc tggaaaggga ctaatgtgt ttgactattt
 541 cttcaggagg ttctacttat ttatgtattt atttttgaaa gtttgtattt taatatttt
 601 catgtgtta tttaaagatgt tgatgtgtt tcatccaaaca tagctcagtc ctgattattt
 661 aattgaaata ttaggggttt taaaatgttc attaaactaa tatttagtgg gagaccataa
 721 tggcgtcgtcc accttgataa atgacagggt ggggaactgg aggttngggg gattgaaatg
 781 caagcaattt gtggatcaact gtttagggtaa gggaaatgtat gtacacatct atttttata
 841 cttttttttt taaaaaaagaa tggcgttgcgtt tattttattca aattatctca cattatgtgt
 901 tcaacatttt tatgtgttgcgtt tttcccttag acattttatg ttttttttttgcgttgcgtt agggcataat
 961 gccttggtta atgtccattc tgacgtttt ctctttccct tggaaaagag aattttatcat
 1021 tactgttaca tttgtacaaa tgacatgata ataaaagttt tattg
 //

 LOCUS HUMCTAP3 673 bp mRNA PRI 06-MAR-1995
 DEFINITION Human connective tissue activation peptide III mRNA, complete
 cds.
 ACCESSION M54995 M38441
 NID g181175
 KEYWORDS connective tissue activating peptide-III; platelet basic
 protein; thromboglobulin.
 SOURCE Human platelet, cDNA to mRNA, clone lambda-c[1,2].
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 673)
 AUTHORS Wenger, R.H., Wicki, A.N., Walz, A., Kieffer, N. and Clemetson, K.J.
 TITLE Cloning of cDNA coding for connective tissue activating peptide
 III
 JOURNAL from a human platelet-derived lambda gt11 expression library
 MEDLINE Blood 73 (6), 1498-1503 (1989)
 89229374
 FEATURES Location/Qualifiers
 source 1..673

```

        /organism="Homo sapiens"
        /db_xref="taxon:9606"
        /tissue_type="platelet"
        /clone="lambda-c1"
        /cell_type="platelet"
        /tissue_type="blood"
        /tissue_lib="lambda-gt11"
        /map="4p13-q21"
gene      67..453
        /gene="PPBP"
sig_peptide 67..168
        /gene="PPBP"
        /note="G00-127-391"
CDS       67..453
        /gene="PPBP"
        /codon_start=1
        /db_xref="GDB:G00-127-391"
        /product="connective tissue activating peptide III"
        /db_xref="PID:g181176"



|            |                                                                                                                        |         |     |     |             |
|------------|------------------------------------------------------------------------------------------------------------------------|---------|-----|-----|-------------|
| LOCUS      | HUMENA78A                                                                                                              | 2177 bp | DNA | PRI | 31-JAN-1996 |
| DEFINITION | Homo sapiens neutrophil-activating peptide 78 (ENA-78) gene, complete cds.                                             |         |     |     |             |
| ACCESSION  | L37036 Z46254                                                                                                          |         |     |     |             |
| NID        | g607030                                                                                                                |         |     |     |             |
| KEYWORDS   | ENA-78 gene; homologue; neutrophil-activating factor; neutrophil-activating peptide 78.                                |         |     |     |             |
| SOURCE     | Homo sapiens DNA.                                                                                                      |         |     |     |             |
| ORGANISM   | Homo sapiens                                                                                                           |         |     |     |             |
| REFERENCE  | Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.   |         |     |     |             |
| AUTHORS    | 1 (bases 1 to 2177) Walz,A., Burgener,R., Car,B., Baggiolini,M., Kunkel,S.L. and Strieter,R.M.                         |         |     |     |             |
| TITLE      | Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8 |         |     |     |             |
| JOURNAL    | J. Exp. Med. 174 (6), 1355-1362 (1991)                                                                                 |         |     |     |             |
| MEDLINE    | 92078844                                                                                                               |         |     |     |             |
| REFERENCE  | 2 (bases 1 to 2177)                                                                                                    |         |     |     |             |
| AUTHORS    | Walz,A.                                                                                                                |         |     |     |             |


```

TITLE Direct Submission
 JOURNAL Submitted (14-OCT-1994) A. Walz, University of Bern, Theodor
 Kocher Institute, Freiestr. 1, Bern, Switzerland 3012
 REFERENCE 3 (bases 1 to 2177)
 AUTHORS Corbett, M.S., Schmitt, I., Riess, O. and Walz, A.
 TITLE Characterization of the gene for human neutrophil-activating
 peptide 78 (ENA-78)
 JOURNAL Biochem. Biophys. Res. Commun. 205 (1), 612-617 (1994)
 MEDLINE 95091791
 FEATURES Location/Qualifiers
 source 1..2177
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /cell_type="lymphoblastoid cells"
 /clone="4H2, 178C11, 106C1"
 /chromosome="4"
 /clone_lib="Chromosome 4 cosmid library of Riess et
 al."
 gene 539..1747
 /gene="ENA-78"
 CAAT_signal 539..547
 /gene="ENA-78"
 TATA_signal 675..681
 /gene="ENA-78"
 exon <803..911
 /gene="ENA-78"
 /number=1
 CDS join(803..911, 1046..1178, 1289..1372, 1729..1747)
 /gene="ENA-78"
 /note="homologue to interleukin-8"
 /codon_start=1
 /product="neutrophil-activating peptide 78"
 /db_xref="PID:g607031"

 /translation="MSLLSSRAARVPGPSSSLCALLVLLLLTQPGPIASAGPAAVL
 RELRCVCLQTTQGVHPKMISNLQVFAIGPQCSKVEVVASLNGKEICLDPEAPFLKKV
 IQKILDGGNKEN"
 intron 912..1045
 /gene="ENA-78"
 /number=1
 exon 1046..1178
 /gene="ENA-78"
 /number=2
 intron 1179..1288
 /gene="ENA-78"
 /number=2
 exon 1289..1372
 /gene="ENA-78"
 /number=3
 intron 1373..1728
 /gene="ENA-78"
 /number=3
 exon 1729..>1747
 /gene="ENA-78"
 /number=4
 BASE COUNT 539 a 512 c 496 g 630 t
 ORIGIN
 1 gaattctcaag taagcggact taccagaatg ggtgatctgt aggggagttt aaaaaattca
 61 gtgggtttt cagggccactg acttcaagtg gcaagagaca agggctctt gttatcatgt
 121 tatctttggct tccaaaagctg ttgttgcgttcc agagatccat aaatgttcc aagaaaccta
 181 gaatggccctg cctgcaagaa gacaggaaagg actttcgtt tatacaattt caaacatgaa
 241 taacatttcc tgattaatag taataataat tagaaaggat tgactttcag aaattttct
 301 caaatcaagg ctccgttac ttgggttcca ccttttctt ctagaaggag aggaggagca
 361 tctcccagat gctgcgtgttcc ccggaaaagc cggcatccctt agcccgctctt ggcacaggcc
 421 atgaggccgtt gctgaatctt gctgaatagc tactcccttc tagctggagc cacagctccc
 481 tccacccggg aacagggtta caacgtccctt ctcggtagag gtgcacgcag ctcctcctgg
 541 ccacccccc caccaggttcc cattgtctgg cccccctccc ccaacctctt ctttccacac
 601 tgccccatga gttcaggaa ttcccccagc atcccaaagc ttgagttcc tgcgtgg
 661 gagagatgatg tgcgtataaa aggatgtcag aaggaacgag gaagccacag tgctccggat

721 cctccaatct tcgttcctcc aatctccgt cctccaccca gttcaggaac ccgcgaccgc
 781 tcgcagcgct ctcttgacca ctatgagcc cctgtccagc cgcgcggccc gtgtccccgg
 841 tccttcgagc tccttgcgc cgctgttgt gtgtctgtc ctgtgacgc agccaggggc
 901 catcgccagc ggtgagagcg catggcgccg gggacgcact cgcactcggg cacagagggt
 961 catcccgcc tctgcggggt cgctgcgtt cagggaaactc tcccaagcaac ctgcctata
 1021 aagggtgtct ctctttcttc cccagctgtt cctgcgcgt ctgtgttgag agagctgcgt
 1081 tgcgttttt tacagaccac gcaaggagtt catcccaaaa tgatcagtaa tctgcaagtg
 1141 ttgcggcatag gcccacagtg tcccaagggtt gaaatgggtt aagggtgtt ctgctgtgtc
 1201 cgctgtgacc ttggcaagag agaaatcccg cagccgggtt cttaaacattt ggtatctcat
 1261 gagttatct tctttttttt tccttcagag cctccctgaa gaaatggaa gaaatgtc
 1321 ttgtatcaga agccctttt ctaaagaaga tcatccagaa aattttggac gggtaattgt
 1381 cactttgatc ttgtgggtt taaaatctga tctaggaga ccatagactt cacaaggct
 1441 ttattttctg tacgatttaa gtaacactt tcatgtttag aattaaaagg ttgttgaatt
 1501 gggaaatgtt ttctggattt tcctggaaa atataccaat cttaatgttta attactttag
 1561 caattacaca cagcttgca ctaagttatg tttttttt accattgtt tttttttt
 1621 tttgtattct ctttttttac caaatactt aaacgcgtt gtttgcataag ggtggagtag
 1681 aaggagggtgt gaaaatgtt taaaataata taacatgtt tcaacacgtt gaaacaagga
 1741 aaactgttta agagaatgtt gcaacgtt gaaatgttcc cagttttag cagagaatgt
 1801 ttctggaggt ctctgaaacc agggaaagaca agaaggaaag atttgttgt ttgttggta
 1861 ttgtttttc cagtagttttag ctttcttcggattctca ctttgcataag gtttgcataag
 1921 acctatgtttt gcccgtttaag ctttcgttca agctaattttt gtttgcataag tagtacccct
 1981 gctatttgcgtt gttttttttt ctgtatgtt attgttgcgtt tggcaatttga ctatgttgc
 2041 agccaggaat cactggctgtt taatcttca aagtgtttt aattgttaggt gactattata
 2101 ttccaaagaa atatttttttca agatatttttttca agatatttttttca agatatttttttca
 2161 atgttttttttca agatatttttttca agatatttttttca agatatttttttca agatatttttttca

//

LOCUS HSGCP2 254 bp RNA PRI 04-MAR-1997
 DEFINITION H.sapiens mRNA for granulocyte chemotactic protein.
 ACCESSION Y08770
 NID g1769436
 KEYWORDS cell surface receptor; CXC chemokine; GCP-2 gene; granulocyte chemotactic protein.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 254)
 AUTHORS Froyen,G., Proost,P., Ronsse,I., Mitera,T., Haelens,A.,
 Wuyts,A.,
 TITLE of Opdenakker,G., Van Damme,J. and Billiau,A.
 Cloning, bacterial expression and biological characterization
 and recombinant human granulocyte chemotactic protein-2 and differential expression of granulocyte chemotactic protein-2
 JOURNAL epithelial cell-derived neutrophil activating peptide-78 mRNAs
 MEDLINE Eur. J. Biochem. 243 (3), 762-769 (1997)
 REFERENCE 97210779
 AUTHORS 2 (bases 1 to 254)
 Froyen,G.F.V.
 TITLE Direct Submission
 JOURNAL Submitted (10-OCT-1996) G.F.V. Froyen, Rega Institute,
 University of Leuven, Minderbroedersstraat 10, B-3000 Leuven, BELGIUM
 FEATURES source Location/Qualifiers
 1..254
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /haplotype="diploid"
 /tissue_type="embryonic"
 /rearranged
 /cell_type="fibroblast"
 /cell_line="E6SM (embryonic strain - skin and muscle)"
 gene 1..254
 /gene="GCP-2"
 exon <1..131
 /gene="GCP-2"
 /number=2
 <1..234
 /gene="GCP-2"
 CDS

```

/codon_start=1
/product="granulocyte chemotactic protein"
/db_xref="PID:e283124"
/db_xref="PID:g1769437"

/translation="GPVSAVLTELRCTCLRVLRVNPKTIGKLQVFPAQGPQCSKVEVV
ASLKNKGKQVCLDPEAPFLKKVIQKILDSGNKKN"
exon 132..215
/gene="GCP-2"
/number=3
exon 216..254
/gene="GCP-2"
/number=4
3' UTR 235..254
/gene="GCP-2"

BASE COUNT 66 a 64 c 70 g 54 t
ORIGIN
1 ggtctctgtct ctgctgtct cacggagctg cgttgcactt gtttacgcgt tacgctgaga
61 gtaaaaccca aaacgattgg taaactgcag gtgtccccgg caggccccca gtgctccaag
121 gtgaaagtgg tagcctccct gaagaacggg aagcaagttt gcttgacccc ggaagccct
181 tttctaaaga aagtcatcca gaaaattttt gacagtggaa acaagaaaaa ctgagtaaca
241 gtcgacccgg ccgc

//
```

LOCUS D63789 5669 bp DNA **PRI** 27-DEC-1996
DEFINITION Human DNA for SCM-1beta precursor, complete cds.
ACCESSION D63789
NID g1754608
KEYWORDS SCM-1beta; SCM-1beta precursor.
SOURCE Homo sapiens placenta DNA, clone:hg44.
ORGANISM Homo sapiens
Eukaryota; mitochondrial eukaryotes; Metazoa; Chordata;
Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
Hominidae; Homo.
REFERENCE 1 (sites)
AUTHORS Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
TITLE Molecular cloning of a novel C or gamma type chemokine, SCM-1
JOURNAL FEBS Lett. 360 (2), 155-159 (1995)
MEDLINE 95180438
REFERENCE 2 (sites)
AUTHORS Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
Yaoi,T.
TITLE and Yoshie,O.
Structure and expression of two highly related genes encoding
SCM-1/human lymphotactin
JOURNAL FEBS Lett. 395 (1), 82-88 (1996)
MEDLINE 97002294
REFERENCE 3 (bases 1 to 5669)
AUTHORS Yoshida,T.
JOURNAL Unpublished (1995)
REFERENCE 4 (bases 1 to 5669)
AUTHORS Yoshida,T.
TITLE Direct Submission
JOURNAL Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
Tetsuya Yoshida, Shionogi Institute for Medical Science; 2-5-1,
Mishima, Settsu, Osaka 566, Japan (E-
mail:teyoshid@fl.lab.shionogi.co.jp,
Tel:06-382-2612, Fax:06-382-2598)
FEATURES Location/Qualifiers
source 1..5669
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="1"
/clone="hg44"
/map="1q23"
/tissue_type="placenta"
TATA_signal 2154..2158
exon 2197..2278

```

/number=1
prim_transcript 2197..5349
gene 2218..5230
CDS /gene="SCM-1beta"
join(2218..2278,4075..4189,5062..5230)
/gene="SCM-1beta"
/codon_start=1
/product="SCM-1beta precursor"
/db_xref="PID:d1010504"
/db_xref="PID:g1754609"



```

2461 gggagaattt gattagtatc tgggctccata cttttccata ttgggtaatt tcaggttaat
 2521 tccttaacca ctcagggcct gtgcttattt atgtataaac tgaatagaat aagagacatg
 2581 atcaccttag attaagatta aataaaatatt atggtttatt taataacatc agatttcctt
 2641 acaagcagta attttttagt taatgttagc tatggattag agtgatgat tataaatgca
 2701 ttgttaggtt ttgcccattt aatatatagt ttgataaaattt atccaaatct tagagagttc
 2761 agttacaata tggggatgca ccagaggatg tatgttctgg agccaaatcaa tgtttcaat
 2821 acaaaaacctg tgtgaaggcg acagtagtgc ttgtgtgga ctggatgtcc cagtttgcc
 2881 ttccctcccc ttgataatgc aataaggac ccccatttt ggacgcaggaa caggcagaaa
 2941 gataaccgc ttgtatgggtt ccacaccatg tgcaatcaact accagcttag acttcttgg
 3001 ttccagcaag ttgggtgatga tgtaaaccct tgctcaaaaga acagggtatttccatg
 3061 gacaacccct ttgcttagcag ctttcttc agcctggcc aacagtctct gcttcttc
 3121 ttgcttgc tctggctcgt acttgttggat cagcttaatgt ggctgatgtatgat
 3181 gtctaaggct tgggtgact ggtaatggc agaaggcatt ttcatgtct tataagggat
 3241 agctttgc agcttggaaac agatatacg gggccatttc acaaaggcgt ggagggtctt
 3301 ttgggtcttgg atgtcttgc caatgcctgc ctaaaaaac ttttaggcctt tttctcac
 3361 agcggttca tcaatctt tgccttcgtc ttccctcagca cggcaggggac tggccac
 3421 tctttcttgc ggcttctt ctttcagca tcttaggcag ctgacagaga gggaaatttg
 3481 accataaa aaggggaaac cctttatattt ctcagtcata agcatgttc ctccctcac
 3541 tgaatgttgc ttgtcttgc gtaacttca cgcataactc tgcatttca cttatggtac
 3601 tgtaacatgt tgacttattt gaaatgtatc tttcttgcctt cttgtctgtgc
 3661 ctcatgagaa gatatgtct atgaaacacag ggataatgtc tgcatttataaaatgtgg
 3721 gacacaacag gcaccattgt ataaatgtatc gatgtgttgc cactggggca tttgctagg
 3781 gtcccaatgt tctaagtggaa aataatcaca gagacgggat aacatcttgc
 3841 cagcatgaaa ttcttgc aatttctgtt attgttgcattt taaatgttgc
 3901 taagaatctg tgacgggca gaggatcggg atgcatttca gtccttctt cccccaaaa
 3961 gcaaattggcc ttatatttca acaacatttca cagatgttcaaaatgttgc
 4021 gatctgggat attgttttca ttttatttgc ttttgcattt ttttcttca tcaagggttag
 4081 ggagtgaagt ctcacatagg aggacctgtg tgagcttcaac taccaggcga ctgccc
 4141 gcagaatcaa gacccatcacc atcacggaa gtccttgc gaggatgttgc
 4201 ttccctcagaag ttgggctggg tgggttactt gaggatgttgc aataacttct atagaaatgc
 4261 tgccatcctc agggaaatgtt ggtcagcata gaggaaacacc tcaacttca
 4321 tttagtttgc ttatatttcaatgttttgc ttttgcatttgc ttttcttca
 4381 aatttggctg ccaaaaggaaatgttgc aataatgttgc ttttgcatttgc
 4441 ttgaatactg tgacatgttgc ttttgcatttgc ttttgcatttgc
 4501 tccctcagaag cctcaactggg gttggggat ctttgcatttgc ttttgcatttgc
 4561 ttatatttgc ttatatttcaatgttgc aataatgttgc ttttgcatttgc
 4621 tctaccagaa tcttgcatttgc ttttgcatttgc ttttgcatttgc
 4681 tctaaggat aataatgttgc ttttgcatttgc ttttgcatttgc
 4741 tttagggat aagatgttgc ttttgcatttgc ttttgcatttgc
 4801 caacatgttgc tgacatgttgc ttttgcatttgc ttttgcatttgc
 4861 gataacttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 4921 ttatatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 4981 catgtcttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5041 ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5101 acaaggccacg tgggttgc ttttgcatttgc ttttgcatttgc
 5161 taatcatgttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5221 gactggcttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5281 caccctcatg gactggat ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5341 ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5401 ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5461 ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5521 ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc
 5581 aatgggttctt tacacatgttgc ttttgcatttgc ttttgcatttgc
 5641 ttttgcatttgc ttttgcatttgc ttttgcatttgc ttttgcatttgc

//

LOCUS D63790 5660 bp DNA PRI 27-DEC-1996
 DEFINITION Human DNA for SCM-1alpha precursor, complete cds.
 ACCESSION D63790
 NID g1754610
 KEYWORDS SCM-1alpha precursor; SCM-1 alpha.
 SOURCE Homo sapiens placenta DNA, clone:hg40.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Mammalia; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (sites)
 AUTHORS Yoshida,T., Imai,T., Kakizaki,M., Nishimura,M. and Yoshie,O.
 TITLE Molecular cloning of a novel C or gamma type chemokine, SCM-1
 JOURNAL FEBS Lett. 360 (2), 155-159 (1995)

MEDLINE 95180438
 REFERENCE 2 (sites)
 AUTHORS Yoshida,T., Imai,T., Takagi,S., Nishimura,M., Ishikawa,I.,
 Yaoi,T.
 and Yoshie,O.
 TITLE Structure and expression of two highly related genes encoding
 SCM-1/human lymphotactin
 JOURNAL FEBS Lett. 395 (1), 82-88 (1996)
 MEDLINE 97002294
 REFERENCE 3 (bases 1 to 5660)
 AUTHORS Yoshida,T.
 JOURNAL Unpublished (1995)
 REFERENCE 4 (bases 1 to 5660)
 AUTHORS Yoshida,T.
 TITLE Direct Submission
 JOURNAL Submitted (07-AUG-1995) to the DDBJ/EMBL/GenBank databases.
 Tetsuya
 Yoshida, Shionogi Institute for Medical Science; 2-5-1,
 Mishima,
 Settsu, Osaka 566, Japan (E-
 mail:teyoshid@f1.lab.shionogi.co.jp,
 Tel:06-382-2612, Fax:06-382-2598)
 FEATURES Location/Qualifiers
 source 1..5660
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="1"
 /clone="hg40"
 /map="1q23"
 /tissue_type="placenta"
 TATA_signal 640..644
 exon 683..764
 /number=1
 prim_transcript 683..5340
 CDS join(704..764,4064..4178,5053..5221)
 /codon_start=1
 /product="SCM-1alpha precursor"
 /db_xref="PID:d1010505"
 /db_xref="PID:g1754611"

 /translation="MRLLILALLGICSLTAYIVEVGVGSEVSDKRTCVSLTTQRLPVSR
 IKTYTITEGSLRAVIFITKRLGLKVCADPQATWVRDVVRSMDRKSNTNNMIQTKPTGT
 QQSTNTAVTLTG"
 intron 765..4063
 /number=1
 exon 4064..4178
 /number=2
 mat_peptide join(4066..4178,5053..5218)
 /note="SCM-1alpha mature peptide"
 intron 4179..5052
 /number=2
 exon 5053..5340
 /number=3
 BASE COUNT 1623 a 1139 c 1175 g 1723 t
 ORIGIN
 1 aagcttctat aaatgtgtat gttaaaggta aataaaagca acacatgcat gtagacatgc
 61 ttaaacagtt atttaaattgt ttcttgggtt cctggggaga tggggtaag aaagggggggt
 121 gacttgaatg aagggtggagg agaaaaatga gaaccaagaa agcaaaggat cgagaagctc
 181 agtgtggcag cagctctttt cccctcttga gagatcggaa gggtggcatc agggactcat
 241 gatccatgtt tggaaagcc tcatgtcaca ctggatgtca catggatgtt gatggaaacac
 301 agtggaccacc ccacccattt tcctttacag ctggatgtt gatggaaacac
 361 ttcaggcatg tctacggcgg aatatctgaa ttccatgtt gatggaaacac
 421 acgtttttttt ttatgtatgc attgttttta attgacacat taaccacaga caaagggtt
 481 aaggccacaa ggcgttaggt tagatgaaac agggaaaagg gactttttttt ttttttttta
 541 agaaaaataa aagcatcgtt attcacaaatg ctttccatgtt tccatgtt acctcgaaag
 601 cccctcttca ccacaggaaatg tgcaactgacc actggaggca taaaagatgtt cctcaagat
 661 cccgatcttc actcttcttgc cacagctcgat caggacatca gccatgtatgc ttctcatct
 721 ggcctcttca ggcatctgtt ctctactgtt atacattgtt gatggtaatgtt ggagaagctg
 781 tctgttagat aaaaacagg gaggcaaggc aggtgggcac acatgggggggggggggggggggg
 841 gttatgtactg gactaatctg ctttccccat gggagccat aacttccat gttcaagaaa

901 ggaatgatga ttttgcgtgt agagggcttc gtaaacttcc aaaaacaggga gaatttgatt
 961 agtatctggg ctctactttt tcctaattgg gtaatttcag gtaaatttcct taaccactca
 1021 gggcctgtgc ttatattatgt ataactgaat agtataacag acttgatcac ctgagattaa
 1081 gattaaataa atattatggt ttatattataa acatcagatt tccttacaag cagtaatttt
 1141 ttgatataatg ttagctatgg attagagggt atgattataa atgcattttgt aggtttgcc
 1201 catttaatataatgat aaattatcaa aatcttagag agttcagttt cgtatgtgggg
 1261 atgcaccatt ggtatgtgt tctggagtaa atcaatgtt tcaatacacaactaagcccc
 1321 aatgactgg aagttcaaaac cttatgttca agaaatca tattacccctt aagtacgtgg
 1381 gggactctgt tagtaatgcc atgacttata ctattatga gaaattttctt gttttgttaa
 1441 gagaacatac aataaataact actaccaat agatcagcac ctatatacaca gttcaataaaa
 1501 cctgcagac acatccaggta aagatcaga tataccggc ctttacccgt gcatatcagta
 1561 ggtatcttctt aaggattgtt tttccatgt actggagggtt aatctgtcga cttatgttgc
 1621 ttcttagttgg taggcttattt acttagacta tgatattata acttaataat gggccccca
 1681 ggggttccat gaataaaagggt ggctaaatgtt ggaaggccctt gaaattatggg ataaaacaaa
 1741 aaaaatactga tggaaaaaaa gatgtttgattt actacattag gccacatgtt gctacctggc
 1801 tggcattttt ctgagacaat gggcatacca ttttgcggg actcagatctt ggttgggg
 1861 aaggagctctt ataaatgttccca ctgttgcata gtttccatgttatacataaaaaatg agggaaaacg
 1921 gtctctgtttt tgactcaattt ttgcacccctt agtgaagggtt atatttttttt aataaacaca
 1981 gacactcaaa cattgctgac aataaggaaa aggctttgtt gtttcaagca taacaggatt
 2041 ccctgagtct taggatgttca ctccatgttccatc ttcacagaga gaaatattgtt ttcttaata
 2101 tgagaaaaac agagaaaaaa cccagattttt ttccttccatc ttggcttccatc aacaatcca
 2161 ccactaaaaaa taatattggca aaggtagggg atagcaatgtt gcaactggc attgagatgt
 2221 aagaatgtt gaaagaaaagc acacaatggaa cacttccatc tttagtccctt gttttttttt
 2281 atgccttccat atatttagca cactacagac caatgttgc cattatcagt gtttacttta
 2341 gatgtttttt agtgccttccat ttccttgggaa agcaaaagggc agtgccttaca gctaaggaga
 2401 aatcagcac ttagaaactt gatgtttttt tcaatccatc cttaaatgtt gttttttttt
 2461 caagtttattt ttccatgttca aatgtttttt tgatcttca cttaaatgtt gttttttttt
 2521 ttggcccttactatgggg atgcataat ttttggggatgtt aagggttgc ttcctttttt
 2581 ccttttacca ttatattttt ttttggggatgtt ttttattttt tttttttttt tttttttttt
 2641 acatgttaca ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 2701 gcatttttgc ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 2761 taattttgttcc ttatgttcc ttttggggatgtt ttttggggatgtt ttttggggatgtt
 2821 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 2881 ctttttttttacca ttatattttt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 2941 agcttggatgg ggttccacacc atgttcaaaatgtt ttttggggatgtt ttttggggatgtt
 3001 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3061 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3121 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3181 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3241 gtttttttttacca ttatattttt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3301 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3361 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3421 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3481 aaggagaaca ctttttttttacca ttatattttt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3541 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3601 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3661 gatgttccatc ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3721 ctttttttttacca ttatattttt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3781 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3841 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3901 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 3961 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4021 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4081 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4141 accttccatc ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4201 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4261 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4321 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4381 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4441 gtttttttttacca ttatattttt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4501 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4561 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4621 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4681 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4741 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4801 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4861 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4921 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 4981 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 5041 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt
 5101 ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt ttttggggatgtt

5161 ccagaccaag ccaacaggaa cccagcaatc gaccaataca gctgtgactc tgactggcta
 5221 gtagtctctg gcacccgtc cgtctccagc cagccagtc atttacttt acacgctcat
 5281 ggactgagtt tatactcacc ttttatgaaa gcactgcatt aataaaatta ttcctttgtat
 5341 ttttacttt taaatgtctt ctgtattcac ttatatgttc taattaaataa attattttatt
 5401 attaagaata gttccctagt ctattcatta tatttagga aaggtagtgt atcattgttg
 5461 tttgatttct gacctgtac ctcttttga tggtaaccat aatgaaagat attctggctat
 5521 gtagtctatca gaggtgaaag ctatatcaat ctcttttga gtccagcttga taatgggttct
 5581 ttacacatca gtcacaaatc acagctgtga caatggcaac aatttggat gtagtcttcaac
 5641 ttgtcttat aatagaattc
 //

LOCUS HSU91835 **1635 bp** **mRNA**
DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced, complete cds.
ACCESSION U91835
NID g1899258
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1635)
AUTHORS Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D.R., Zlotnik, A. and Schall, T.J.
TITLE A new class of membrane-bound chemokine with a CX3C motif
JOURNAL Nature 385 (6617), 640-644 (1997)
MEDLINE 97177111
REFERENCE 2 (bases 1 to 1635)
AUTHORS Bazan, J.F., Bacon, K.B., Hardiman, G., Wang, W., Rossi, D., Greaves, D.R., Zlotnik, A. and Schall, T.J.
TITLE Direct Submission
JOURNAL Submitted (03-MAR-1997) Molecular Biology, DNAX Research Institute,
FEATURES 901 California Ave., Palo Alto, CA 94304-1104, USA
source Location/Qualifiers
 1..1635
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 80..1273
 /note="membrane-tethered chemokine module"
 /codon_start=1
 /product="CX3C chemokine precursor"
 /db_xref="PID:g1899259"

 /translation="MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIP
 VALLIHYQQNQASC GKRAILETRQHRLFCADPKEQWVKDAMQHLD RQAAALTRNGGT
 FEKQIGEVKPRTPAAGGMDES VVLEPEATGESSLEPTPSSQEAQR ALG TSPELPTG
 VTGSSGTRLPPTPKAQDCGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA
 PSTQDPSTQASTASSPAPEENAPSEGQRVWGGQSPR PENS LEREEMGPVPAHTDAFQ
 DWGPGSMAHVSVVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDA
 QAA TRRQAVGLLAFLGLLFC LGVAMFTYQSLQGC PRK MAGE MAEGLRYI PRSCGSNSY
 VLVPV"
 sig_peptide 80..151
 mat_peptide 152..1270
 /product="CX3C chemokine"
 misc_feature 152..379
 /note="encodes chemokine module"
 misc_feature 380..1102
 /note="encodes glycosylation stalk"
 misc_feature 1103..1159
 /note="encodes transmembrane helix"
 misc_feature 1160..1270
 /note="encodes intracellular domain"
 3'UTR 1274..1635
 /note="alternatively spliced; long transcript can be"

found

in GenBank Accession Number U84487*

BASE COUNT 338 a 544 c 464 g 289 t
ORIGIN

```

1 ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgcctggcc cccgcgggaa
61 ctcttgcrrca ccctcagcca tggctccgat atctctgtcg tggctgtcc gcttggccac
121 cttctggcat ctgactgtcc tgctggctgg acagcacac ggtgtgacga aatgcaacat
181 cacgtgcagc aagatgacat caaagatacc tctatccact atcaacagaa
241 ccaggcatca tgcggcaaac gcgcataatcat cttggagacg agacagcaca ggctgttctg
301 tgcgcaccccg aaggagcaat gggtaagggaa cgcgatgcag catctggacc gccagggctgc
361 tgccttaact cgaatggcg gcacccctcgaa gaagcagatc ggcgaggtga agccaggac
421 caccctgcgc gcccggggaa tggacgagtc tggctgtcc gaggccaaag ccacaggcga
481 aaggcgttagc ctggagccga ctcccttcttc ccaggaaagca cagagggccc tggggaccc
541 cccagagctg ccgcacggcg tgactggttc ctcaggacc agggcccccc cgacgcacaa
601 ggctcaggat ggaggccctg tgggcacgga gctttccga gtgcctcccg tctccactgc
661 cgccacgtgg cagatgtcc ctcccccacca acctggccca agccctctggg ctgaggcaaa
721 gacctcttag cgcggctcca ccaggacc ctcacccag gcctccactg ctgcctccccc
781 agccccagag gagaatgctc cgtctgaaagg ccagcgtgtg tgggtcagg gacagagccc
841 caggccagag aactctctgg agcggggagga gatgggtccc gtgcctccgc acacggatgc
901 cttccaggac tggggccctg gcagcatggc ccacgtctct gtggccctg tctccctcaga
961 agggacccccc agcaggagc cagtggcttcc aggcagctgg accccctaaagg ctgaggaacc
1021 catccatgcc accatggacc cccagggactt gggcgttcc atcactctg tccctgacgc
1081 ccaggctgcc accccggaggc aggcgggtggg gctgtggcc ttccctggcc ttcttttctg
1141 cctgggggtg gccatgttca cttaccagag cctccaggcc tgccctcgaa agatggcagg
1201 agagatggcg gaggcccttc gctacatccc ccggagctgt ggtagtaatt catatgtct
1261 ggtgcctgtg tgaactctc tggctgtgt ctatgtttt gattcagaca gctgcctggg
1321 atccctcatc ctcataccca ccccccacca agggcgtgg ctgagctggg atgattggag
1381 gggggaggtg ggatcttcca ggtgcacaag ctccaaagtc ccaggcattc cccaggagggc
1441 cagcccttgc cattctccac cttccaggga cagaggggtt ggcctcccaa ctcacccca
1501 ccccaaaact ctcctctgt gctggctgtt tagaggttcc ctggacgccc atcccagccc
1561 caatgaaaca ttatattat aatggccacg cccttctgaa aaaaaaaaaa aaaaaaaaaa
1621 aaaaaaaaaa aaaaa
//
```

LOCUS HSU84487 3310 bp mRNA PRI 15-MAR-1997
 DEFINITION Human CX3C chemokine precursor, mRNA, alternatively spliced, complete cds.
 ACCESSION U84487
 NID g1888522
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 3310)
 AUTHORS Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Soo,K., Rossi,D., Greaves,D.R., Zlotnik,A. and Schall,T.J.
 TITLE A new class of membrane-bound chemokine with a CX3C motif
 JOURNAL Nature 385 (6617), 640-644 (1997)
 MEDLINE 97177111
 REFERENCE 2 (bases 1 to 3310)
 AUTHORS Bazan,J.F., Bacon,K.B., Hardiman,G., Wang,W., Rossi,D., Greaves,D.R., Zlotnik,A. and Schall,T.J.
 TITLE Direct Submission
 JOURNAL Submitted (07-JAN-1997) Molecular Biology, DNAX Research Institute,
 FEATURES 901 California Ave., Palo Alto, CA 94304-1104, USA
 source Location/Qualifiers
 source 1..3310
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS 80..1273
 /note="membrane-tethered chemokine module"
 /codon_start=1
 /product="CX3C chemokine precursor"
 /db_xref="PID:g1888523"
 /translation="MAPISLSWLLRLATFCHLTVLLAGQHHGVTKCNITCSKMTSKIP
 VALLIHYQQNQASCCKRAIILETRQHRLFCADPKEQWVKDAMQHLDRAAALTRNGGT

FEKQIGEVKPRTPAAGGMDESVVLEPEATGESSSLEPTPSSQEAQRALGTSPELPTG
 VTGSSGTRLPPTPKAQDGGPVGTELFRVPPVSTAATWQSSAPHQPGPSLWAEAKTSEA
 PSTQDPSTQASTASSPAPEENAPSEGQRVWQGQSPRPNLEREEMGPVPAHTDAFQ
 DWGPGSMAHVSVPVSSEGTPSREPVASGSWTPKAEEPIHATMDPQRLGVLITPVPDA
 QAATRRQAVGLAFLGLFCLGVAMFTYQSLQGCPRKMAGEMAEGLRYIPRSCGSNSY
 VLVPV"
 sig_peptide 80..151
 mat_peptide 152..1270
 /product="CX3C chemokine"
 misc_feature 152..379
 /note="encodes chemokine module"
 misc_feature 380..1102
 /note="encodes glycosylation stalk"
 misc_feature 1103..1159
 /note="encodes transmembrane helix"
 misc_feature 1160..1270
 /note="encodes intracellular domain"
 3'UTR 1274..3310
 /note="alternatively spliced; short transcript
 deposited as GenBank Accession Number U91835"
 BASE COUNT 659 a 1051 c 916 g 682 t 2 others
 ORIGIN

```

  1 ggcacgaggg cactgagctc tgccgcctgg ctctagccgc ctgcctggcc cccgggggaa
  61 ctcttgccca ccctcagcca tggctccat atctctgtcg tggctgctcc gcttggccac
  121 cttctgcct ctgactgtcc tgcggctgg acagcaccac ggtgtgacga aatgcaacat
  181 cacgtgcagc aagatgacat caaagatacc tgcgttgc tgcgttgc atcaacagaa
  241 ccaggcatca tgcggcaaaac ggcgaatcat ctggagacg agacagcaca ggctgttctg
  301 tgccgacccg aaggagcaat gggtaagga cgcgtatcgat catctggacc gccaggctgc
  361 tgccctaact cggaaatggcg gcaacccatcgaa gaagcagatc ggcgagggtga agccaggac
  421 caccctgcgc gccgggggaa tggtggatc tgcgttgc tgcgttgc gggccggaa acacaggcg
  481 aagcgttgc ctggagccgc ctgcgttgc ccaggaaatc cagaggggcc tggggacccctc
  541 cccagagctg ccgcacggcg tgcgttgc tgcgttgc aggtttccccc cgcacgcacaaa
  601 ggctcaggat ggaggccctg tgggcacggaa gctttcccgat gtgccttcccg ttcactgc
  661 cggccacgtgg cagatgtcg ctcccccacca acctggggggaa acgccttgcggg ctgaggcaaa
  721 gacccctgcgc gccccatcgatcc cccaggaccc ctccacccatc gcttccactg ctgcgttccccc
  781 agcccccacag gagaatgtcg ctgcgttgc ccaggatcg tggggtcagg gacagagcc
  841 caggccacag aactctctgg agcggggagga gatgggtccc gtgcacgc acacggatgc
  901 cttccaggac tggggccctg gcaatgtcg ccacgttgc tgcgttgc ttcacttcaga
  961 agggacccccc agcaggggacg cttgcgttgc aggcgttgc acccctaagg ctgaggaacc
  1021 catccatgtcc accatggacc cccaggatcg gggcgttgc ttcacttcgc tccctgacgc
  1081 ccaggctgtcc accccggggc agggcgttgc gtcgttgc ttccttgc tcccttgc
  1141 cttccgggttgc gccatgttca ctccatcgatcc cccaggatcg tgcgttgc agatggcagg
  1201 agagatgtcg gaggccctg gcaatgtcg ccacgttgc tgcgttgc ttcacttcgc
  1261 ggtggccctg tgcgttgc tgcgttgc tgcgttgc ttcacttcgc tcccttgc
  1321 atccctcatc ctatccatcc ccccccacca agggcgttgc tgcgttgc atggggatgg
  1381 gggggaggtg gatgttgc ggtgcacaatg ctccaaatcg ccaggatcc cccaggaggc
  1441 caggccatcg cttccatccatcc ctccatccatcc cccaggatcg tgcgttgc acacggatcc
  1501 ccccaaaact ctccatccatcc ctccatccatcc cccaggatcg tgcgttgc atcccaatcc
  1561 caatgttgc tttttttttt aatgtccatcc cccttgc tgcgttgc tgcgttgc
  1621 tacatgttgc cccatccatcc catgttgc tgcgttgc tgcgttgc tccctgacgc
  1681 ctgttgc tgcgttgc tgcgttgc tgcgttgc tgcgttgc tcccttgc
  1741 ctcccccacg cccatccatcc tgcgttgc tgcgttgc tgcgttgc tcccttgc
  1801 gcatgttgc tgcgttgc tgcgttgc tgcgttgc tgcgttgc tcccttgc
  1861 ggsattgtgg gaaaggggaaa taagggttgc tgcgttgc tgcgttgc tcccttgc
  1921 ctgttgc tgcgttgc tgcgttgc tgcgttgc tgcgttgc tcccttgc
  1981 tctgtgaaat gaaaggggaaa ggttggatc acctgttgc tgcgttgc tcccttgc
  2041 gaggcccttc tccatccatcc tgcgttgc tgcgttgc tgcgttgc tcccttgc
  2101 gacatgttgc tccatccatcc tgcgttgc tgcgttgc tgcgttgc tcccttgc
  2161 ggaggatcg tttttttttt aatgttgc tgcgttgc tgcgttgc tcccttgc
  2221 gagaccatcc ctggggggcc cccaggatcg tttttttttt aatgttgc tgcgttgc tcccttgc
  2281 cccatccatcc tttttttttt aatgttgc tgcgttgc tgcgttgc tcccttgc
  2341 ctccatccatcc tttttttttt aatgttgc tgcgttgc tgcgttgc tcccttgc
  2401 aagaccatcc tttttttttt aatgttgc tgcgttgc tgcgttgc tcccttgc
  2461 ccacatgttgc tttttttttt aatgttgc tgcgttgc tgcgttgc tcccttgc
  2521 ttgtccatcc tttttttttt aatgttgc tgcgttgc tgcgttgc tcccttgc
  2581 tttttttttt aatgttgc tgcgttgc tgcgttgc tgcgttgc tcccttgc
  
```

2641 ggcataaaagt caggggttcc cttttttggc tgctgaaggc tcgagcatgc ctggatgggg
 2701 ctgcaccggc tggcctggcc cctcagggtc cctgggtggca gtcacatctt cccttggatt
 2761 gtcggcggacc cttggccgtt acctggggg cttttatgg gctgggttctt acccagggtgc
 2821 taggaacact ctttcacaga tgggtgttgg gaggaaaggaa acccagctt ggtccataga
 2881 gagcaaaaacg ctgtgtgtcc ctgtccaccc tggcttgc actccctgc tgggtgtgg
 2941 gcagcatatt caggaagtc agggccctgg ctcagggtgg gtcaactctgg cagctcag
 3001 aggggtggag tgggtccat gcaacttgc ttggcttcc caggctggaa gagccttca
 3061 ggggtgggac accctgtat gggggccctgc ctcccttgc aggaagccgc tggggccagt
 3121 tggtccccc tccatggact ttgttagttt tcacaaggag gacatggaca aggtatgt
 3181 aggaagactt tggaaagagt aggaagactt tggaaagact tttccaaacc tcataccaa
 3241 cgtctgtgtcc attttgtatt ttactataaa aatttaaaag tcttgtgaaa aaaaaaaaaa
 3301 aaaaaaaaaa

//

LOCUS HSU91746 1430 bp mRNA PRI 12-MAR-1998
 DEFINITION Homo sapiens IL-10-inducible chemokine (HCC-4) mRNA, complete
 cds.
 ACCESSION U91746
 NID g2581780
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata;
 Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 1430)
 AUTHORS Hedrick, J.A., Helms, A., Gorman, D. and Zlotnik, A.
 TITLE Identification of a novel human CC chemokine upregulated by IL-
 10
 JOURNAL Blood (1998) In press
 REFERENCE 2 (bases 1 to 1430)
 AUTHORS Hedrick, J.A., Helms, A., Gorman, D. and Zlotnik, A.
 TITLE Direct Submission
 JOURNAL Submitted (02-MAR-1997) Immunology, DNAX Research Institute,
 901 California Ave, Palo Alto, CA 94304, USA
 FEATURES Location/Qualifiers
 source 1..1430
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /chromosome="17"
 gene 1..1430
 /gene="HCC-4"
 CDS 1..363
 /gene="HCC-4"
 /note="CC or beta chemokine family member"
 /codon_start=1
 /product="IL-10-inducible chemokine"
 /db_xref="PID:g2581781"

/translation="MKVSEAAALSLLVLILIIITSASRSQPKVPEWVNTPSTCCLKYEEK
 VLPRLVVGYRKALNCHLPAIIFVTKRNREVCTNPNDWVQEYIKDPNLPLLPTRNLS
 TVKIIITAKNGQPQLLNSQ"
 BASE COUNT 401 a 351 c 293 g 385 t
 ORIGIN

1 atgaagggtct ccgaggctgc cctgtctctc cttgtccctca tccttatcat tacttcggct
 61 tctcgcagcc agccaaaagt tccctgggttgg gtgaacaccc catccacctg ctgcctgaag
 121 tattatgaga aagtgttggc aaggagacta gtgggtggat acagaaggc cctcaactgt
 181 cacctggccag caatcatttt cgtcaccaag aggaaccggc aagtgtgcac caaccccaat
 241 gacgactggg tccaaagatca catcaaggat cccaaacctac ctttgcgtcc taccaggaac
 301 ttgtccacgg ttaaaattat tacagcaaag aatggtaaac cccagcttctt caactcccg
 361 tgatgaccag gcttttaggg aaggcttgc ttacagaaga gagggtaaa cctatgaaaa
 421 caggggaaacg ctatttaggc tggaaatggc cagtcacattt gagagaagca gaacatgt
 481 caaaataaaag gagaagtatt tcaatattt tctcaatctt aggaggaaat accaaaggta
 541 agggacgtgg gcagaggatc gctttttat ttttatattt atattttat tttttgaga
 601 taggtcttac tctgtcaccc aggtgtggat gcaatgggtt gatcttggct cacttgatct
 661 tggctcaactg taacccatcc ac cttccaggat caagtgtatcc tcccaacccca gcctccccag
 721 tagctggac tacaggcttgc cgccacccca cttggctaat ttttgatattt ttggtagaga
 781 cgggattcta ccatgttgc caggctggc tcaaaactctgt gtgcaccaagc aatccacctg
 841 cctcagcctt cccaaagtgc tggattaca ggcgtgagcc accacatccg gccagtgcac
 901 tcttaataca cagaaaaata tatttcacat ctttctctgt ctctttca attcctcaact

961 tcacaccagt acacaagcca ttctaaatac ttagccagtt tccagccttc cagatgatct
1021 ttgcctctg ggttttgacc cattaagagc cccatagaac tcttgatttt tcctgtccat
1081 ctttatggat tttctggat ctatatttc ttcaattatt ctttcatttt ataatgcaac
1141 tttttcatag gaagtcggta tggaaatatt cacattaatc attttgcag agactttgct
1201 agatctctc atattttgtc ttccctcaggg tggcagggtt acagagagtg cctgatttgg
1261 aaaaaaaaaaa aaagagagag agagagaaga agaagaagaa gagacacaaa tctctacctc
1321 ccatgttaag ctttgcagga cagggaaaga aagggtatga gacacggcta ggggtaaact
1381 ctttagtccaa aacccaagca tgcaataataaaactccct tatttgacaa

//

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,141, 867 A (IVANOFF et al.) 25 August 1992, see entire document.	22-32, 45-55
A	ENG et al. The Stimulatory Effects of Interleukin (IL)-12 On Hematopoiesis Are Antagonized by IL-12-induced Interferon γ In Vivo. J. Exp. Med. May 1995, Vol.181, pages 1893-1898, see entire document.	1-21, 33-44
A	ORANGE et al. Mechanism of Interleukin 12-mediated Toxicities during Experimental Viral Infections: Role of Tumor Necrosis Factor and Glucocorticoids. J. Exp. Med. March 1995, Vol.181, pages 901-914, see entire document.	1-21, 33-44

 Further documents are listed in the continuation of Box C. See patent family annex.

• Special categories of cited documents	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance		
E earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O document referring to an oral disclosure, use, exhibition or other means	*&*	document member of the same patent family
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
25 MARCH 1999Date of mailing of the international search report
15 APR 1999Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

PREMA MERTZ

Telephone No. (703) 308-0196



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WU et al. Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System. The Journal of Biological Chemistry. 05 April 1987, Vol.252, No. 10, pages 4429-4432, see entire document.	22-32, 45-55

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US98/26291

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/26291

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

C07K 14/47, 14/52; C12N 15/12, 15/19, 15/63; A61K 38/16, 38/19, 48/00

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

424/84, 85.1, 184.1, 186.1, 188.1, 278.1; 514/2, 8, 12, 44; 530/300, 324

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, CAN ONLINE, MEDLINE, CAPLUS

search terms: chemokine, vaccination, immunogenic, antigen, HIV, efficacy, macrophage-derived chemokine, stromal cell-derived factor, monocyte chemotactic protein, composition, administration

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-21, 33-44, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto.

Group II, claims 22-32, 45-55, drawn to a method to enhance the efficacy of a vaccine in a subject comprising administering nucleic acid sequences encoding one or more antigens and nucleic acid sequences encoding one or more chemokines.

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The inventions listed as Groups I-II do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Pursuant to 37 C.F.R. § 1.475 (d), the ISA/US considers that where multiple products and processes are claimed, the main invention shall consist of the first invention of the category first mentioned in the claims and the first recited invention of each of the other categories related thereto. Accordingly, the main invention (Group I) comprises the first-recited product and method, a method to enhance the efficacy of a vaccine in a subject comprising administering an antigen and one or more chemokines and a composition thereto. Further pursuant to 37

C.F.R. § 1.475 (d), the ISA/US considers that any feature which the subsequently recited products and methods share with the main invention does not constitute a special technical feature within the meaning of PCT Rule 13.2 and that each of such products and methods accordingly defines a separate invention.